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Melanoma skin cancer is currently the sixth most common cancer in the US and is responsible for 
80% of skin cancer related deaths. Although its worldwide incidence rates have doubled over the past 
years, the mortality rates have remained constant, possibly due to higher public awareness and early 
detection. Surgical removal of early lesions remains the most effective treatment, and about 80% of 
melanoma patients can be cured this way. However, in approximately 20% of patients, disseminated 
disease develops, which results in a poor prognosis with nearly all stage IV melanoma patients dying 
from their disease within 5 years. Over the last decade, important steps in stage IV melanoma 
treatment have been made, with immunotherapy and MAPK targeted therapies showing an overall 
survival benefit for the first time in the history of melanoma clinical research. 
MAPK targeted therapies are used in patients with a constitutively active MAPK pathway due to 
activating BRAF or NRAS mutations. Despite a fast response and relatively little adverse effects in a 
large proportion of patients, the majority of patients will develop therapeutic resistance after 
approximately 9 months of treatment, resulting in a relapse of tumor growth. Thus, a better 
understanding the molecular basis of the resistance mechanisms that develop during MAPK targeted 
therapy is mandatory.  
The overall aim of this PhD thesis was therefore to gain insight into the evolution of targeted therapy 
resistance in BRAF and NRAS mutated patients treated with BRAF and MEK inhibitors, respectively, 
as well as to identify new resistance mechanisms and their origin. 
First, to recapitulate in vivo tumor heterogeneity in vitro, we developed new protocols for the 
generation of cell cultures from surplus material we obtained from MAPK pathway inhibitor resistant 
patients who had been treated for melanoma in our clinic. We hypothesized that disease 
heterogeneity plays an important role in the development of resistance, and unlike other studies, we  
wished to work with cells that were derived from patients who became resistant to targeted inhibitors, 
rather than cell lines that derived resistance in vitro. These efforts resulted in newly developed, more 
efficient cell culturing protocols that are currently successfully used for our melanoma cell biobanking 
project (Raaijmakers et al., 2015).  
Next, by whole exome sequencing of different tumors from multiple sites from single patients, we 
studied the evolution of targeted therapy resistance in a BRAF mutated patient treated with a BRAF 
inhibitor, an NRAS mutated patient treated with a MEK inhibitor and, as a control, a BRAF and NRAS 
wildtype patient who did not receive a specific targeted therapy but a multi-tyrosine kinase inhibitor. 
Through phylogenetic analysis we observed a monophyletic evolution of the different tumors from the 
patients treated with targeted therapy which was not observed in the patient not treated with targeted 
therapy. Furthermore, we identified a secondary NRAS mutation in several single cell clones 
generated from one particular metastasis isolated from the BRAF mutated patient, confirming that 
activating BRAF and NRAS mutations can co-occur in a single cell, something which was in contrast 
to the general belief at that time. We subsequently confirmed this finding in 5 other BRAF mutated 
patients treated with BRAF inhibitors. For all patients, we could find the secondary NRAS mutation 
only in the after-treatment samples, suggesting that this mutation either arose during treatment, or that 
a small amount of NRAS mutated cells was already present before treatment which did have a survival 
disadvantage in the non-treatment setting and therefore remained undetectable. All of the double 
mutated cell cultures we subsequently tested for sensitivity to different MAPK and PI3K pathway 
inhibitors, and a very heterogeneous response was found, indicating that the sole finding of a double 
mutation in a given patient cannot predict follow up therapy, but rather that additional mechanisms of 
resistance must also play an important role. This work was recently published in Oncotarget 
(Raaijmakers et al. 2016). 
To further elucidate additional resistance mechanisms, in the final part of this thesis we characterized 
NRAS mutated, MEK inhibitor resistant cell cultures. We found that MEK162 resistance was 
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associated  high IRS1 expression; however, it was not a cause of resistance. Nevertheless, some of 
the MEK resistant cells were sensitive to NT157, an IRS1 inhibitor. The exact mechanism by which 
NT157 acts to reduce viability in these cells will require further investigation. We also found that 
NT157 and MEK inhibition work antagonistically, underscoring the notion that knowing the exact 
working mechanism of a drug, in addition to potential interactions, is essential before rational 
combinations of drugs can be suggested.  
In conclusion, targeted therapy is a treatment modality that provides great benefit for the survival of 
melanoma patients; however, further improvements must be made in alternative administration 
schemes and in optimal drug combinations. Because cancer in general, and melanoma in particular, is 
such a heterogeneous disease, resistance to targeted therapies almost seem inevitable, but 
understanding the exact causes of these resistance mechanisms will allow us to design better 




2. Zusammenfassung  
Der schwarze Hautkrebs oder das Melanom ist die derzeit sechst-häufigste Krebsart in den USA und 
ist für 80% der Hautkrebs–Todesfälle verantwortlich. Obwohl sich die weltweiten Inzidenzraten in den 
vergangenen Jahren verdoppelt haben, sind die Sterblichkeitsraten konstant geblieben, 
möglicherweise aufgrund des höheren öffentlichen Bewusstseins und der besseren Früherkennung. 
Die chirurgische Entfernung der frühen Läsionen bleibt die effektivste Behandlung, und etwa 80% der 
Melanom Patienten können auf diese Weise geheilt werden. Bei etwa 20% der Patienten entwickelt 
sich jedoch eine disseminierte Erkrankung, welche eine schlechte Prognose hat, da fast alle Stadium 
IV Melanom-Patienten innerhalb von 5 Jahren an ihrer Krankheit sterben. Im Laufe des letzten 
Jahrzehnts wurden wichtige Fortschritte in der Melanom-Behandlung erzielt. Immuntherapien und 
MAPK-gezielte Therapien haben zum ersten Mal in der Geschichte der klinischen Melanom-
Forschung einen Gesamtüberlebensvorteil gezeigt. 
MAPK-gezielte Therapien werden bei Patienten eingesetzt, deren Tumoren aufgrund der aktivierende 
Mutationen von BRAF oder NRAS einen konstitutiv aktiven MAPK-Signalweg haben. Trotz eines 
schnellen Ansprechens und relativ geringen Nebenwirkungen bei einem Grossteil der Patienten, 
entwickelt die Mehrheit der Patienten nach einer Behandlung von etwa 9 Monaten therapeutische 
Resistenz, mit erneutem Tumorwachstum. Daher interessieren wir uns für ein besseres Verständnis 
der molekularen Basis der Resistenzmechanismen, welche sich während der MAPK-zielgerichteten 
Therapie entwickeln. 
Ziel dieser Doktorarbeit war es, Einblicke in die Evolution der zielgerichteten Therapie-Resistenz bei 
BRAF- und NRAS-mutierten Patienten zu gewinnen, welche mit BRAF- bzw. MEK-Inhibitoren 
behandelt wurden, sowie neue Resistenzmechanismen und deren Ursprung zu identifizieren. 
Um die in vivo Tumor-Heterogenität in vitro zu erhalten, haben wir neue Protokolle entwickelt für die 
Erzeugung von Zellkulturen aus überschüssigem Material von MAPK-Inhibitor-resistenten Melanom 
Patienten, welche an unserer Klinik behandelt wurden. Wir vermuteten, dass die Heterogenität der 
Krankheit eine wichtige Rolle bei der Entwicklung der Resistenz spielt. Im Gegensatz zu anderen 
Studien wollten wir an Zellen arbeiten welche von Patienten stammen, die gegen gezielte Inhibitoren 
resistent wurden, anstatt Zelllinien welche in vitro resistent wurden. Diese effizienteren 
Kultivierungsprotokolle wurden als neue Methode für das Melanomzell -Biobanking publiziert 
(Raaijmakers et al., 2015). 
Als nächstes untersuchten wir mittels whole exome Sequenzierung verschiedener 
Tumorlokalisationen von einzelnen Patienten die Evolution der gezielten Therapieresistenz. Dies in 
einem mit BRAF-Inhibitor behandelten BRAF-mutierten Patienten, einem mit MEK-Inhibitor 
behandelten NRAS-mutierten Patienten und als Kontrolle, in einem BRAF- und NRAS-Wildtyp-Patient, 
welcher keine gezielte Therapie erhielt. Durch phylogenetische Analyse beobachteten wir eine 
monophyletische Evolution der verschiedenen Tumoren von den Patienten, welche mit einer gezielten 
Therapie behandelt wurden. Dies war bei dem Patienten welcher nicht mit einer gezielten Therapie 
behandelt wurde nicht zu beobachten. Des Weiteren haben wir eine sekundäre NRAS-Mutation in 
ceiner Metastase aus dem BRAF-mutierten Patienten identifiziert, und über die Analyse einzelner 
Zellklone aus dieser Metastase fanden wir, im Gegensatz zu der damaligen vorherrschenden 
Meinung, dass die aktivierenden Mutationen von BRAF und NRAS in einer Zelle zusammen auftreten 
können. Wir konnten anschliessend die Existenz von aktivierende BRAF- und NRAS- 
Doppelmutationen in einer einzigen Zelle in 5 anderen BRAF-mutierten Patienten, die mit BRAF-
Inhibitoren behandelt wurden, bestätigen. Für alle Patienten konnten wir die sekundäre NRAS-
Mutation nur in den Proben nach Therapie finden, was darauf hindeutet, dass diese Mutation 
entweder während der Behandlung entstanden ist oder dass ein kleiner Subklon vor der Behandlung 
vorhanden war, welcher ohne Behandlung einen Überlebensnachteil hatte und daher klein blieb. Alle 
doppelt mutierten Zellkulturen haben wir anschließend auf Sensitivität gegenüber verschiedenen 
MAPK- und PI3K-Pathway-Inhibitoren getestet, und wir fanden ein sehr heterogenes 
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Therapieansprechen. Diese zeigt, dass die alleinige Entdeckung einer doppelten Mutation bei einem 
Patienten nicht prädiktiv für die Folgetherapie ist. Diese Arbeit wurde vor kurzem in Oncotarget 
publiziert (Raaijmakers et al., 2016). 
Drittens wollten wir Resistenzmechanismen in NRAS-mutierten MEK-Inhibitor resistenten Zellkulturen 
identifizieren. Wir fanden, dass eine hohe IRS1-Expression mit der MEK162-Resistenz assoziiert war, 
allerdings war diese nicht die Ursache der Therapie-Resistenz. Nichtsdestotrotz waren einige der 
MEK-resistenten Zellen sensitiv gegenüber NT157, einem IRS1-Inhibitor. Der genaue Mechanismus 
mit dem NT157 wirkt, um die Viabilität dieser Zellen zu reduzieren, bedarf weiterer Untersuchungen. 
Wir fanden weiter, dass NT157 und MEK-Hemmung antagonistisch wirken, was wiederum zeigt, dass 
die Kenntnis des genauen Wirkungsmechanismus eines Medikaments essentiell ist, um rationale 
Kombinationen von Arzneimitteln vorgeschlagen zu können. Diese Arbeit ist derzeit in Vorbereitung für 
die Publikationseinreichung. 
Zusammenfassend ist die gezielte Therapie eine Behandlungsmethode, welche sich bei Melanom 
Patienten als sehr wirksam erwiesen hat. Allerdings müssen Verbesserungen vorgenommen werden, 
wie gezielte Therapien verabreicht werden und in welchen rationalen Kombinationen sie verwendet 
werden. Weil Krebs und das Melanom insbesondere so heterogen sind, scheint die Entwicklung von 
Resistenzgegen gezielte Therapien fast unvermeidlich zu sein. jDas Verständnis des Ursprungs und 
der Natur der Resistenzmechanismen wird es uns ermöglichen, sie in zukünftigen therapeutischen 




3.1 The development and function of normal melanocytes 
Early in the second month of human embryologic development, melanoblasts, which differentiate from 
pluripotent neural crest cells, migrate into the embryonic dermis [1]. A few weeks later, the 
melanoblasts migrate further into the epidermis, however, it takes until mid-pregnancy before they 
start producing pigment and differentiate into melanocytes [1].  
Melanocytes are long-lived, dendritic cells that live for decades in the epidermis. Their function is to 
protect the other skin cells from UV damage by producing melanosomes containing melanin, which 
are taken up by adjacent keratinocytes to form a protective cap over their nucleus. Melanin in the 
epidermis also protects the fibroblasts in the underlying dermis. In response to UV light, keratinocytes 
and fibroblasts generate factors that stimulate the proliferation and synthesis of melanin by 
melanocytes, indicating the presence of a paracrine/autocrine communication system between the 
different skin cells.    
3.2 The development of melanoma skin cancer 
 
Due to their longevity, it is thought that melanocytes are prone to accumulate genomic mutations that 
may lead to their malignant transformation as melanoma skin cancer. Solar UV-exposure is the most 
important mutagen, and hence, factors related to increased susceptibility of accumulated UV damage, 
such as age, fair skin, solar or tanning bed UV exposure, family history (genetic predisposition, e.g. 
mutations in DNA repair mechanisms) and number of pigmented nevi are important risk-factors.  
 
3.2.1 Melanoma incidence 
 
Over the past two decades, the worldwide incidence of melanoma has doubled, making it the 5th most 
common cancer in men and 7th in women of the United States [2], in Switzerland it is the 4th most 
common cancer for both men and women [3]. Even though the incidence has doubled, the mortality 
rates have remained constant [4], possibly because of the higher awareness of the general public and 
a rise in screenings programs, leading to a higher detection of early melanomas which can be 
removed completely. In about 80% of the patients the melanoma is detected in an early enough state 
to be cured by surgery. However, for the remaining 20% (annually more than 60.000 people worldwide 
[4]) who present with advanced disease, the prognosis is poor, and the vast majority of patients will die 
from their disease. Unfortunately, without preventive measures, predictions estimate that the trend of 
increasing incidence will continue over the next 15 years, with consequential increases in health care 
costs [4]. 
 
3.2.2 Melanoma genetics 
 
The availability of Whole Genome Sequencing or Whole Exome Sequencing (WGS and WES, 
respectively), allowed for the identification of novel genetic drivers of melanoma formation. Melanomas 
derived from sun-exposed skin sites were found to have one of the highest somatic mutation burdens 
compared to other malignancies, mainly due to mutations that are associated with UV radiation [5]. 
Due to this high mutational load, it is difficult to distinguish between driver- and bystander mutations. In 
a given number of melanoma samples, it is expected that driver genes contain mutations in a larger 
number of samples than expected by chance, however to apply this criterion in a mutational 
heterogeneous cancer, large sample sizes and sophisticated bioinformatic analysis are needed. 
Several WGS and WES studies have been performed on melanoma samples, each identifying a set of 
similar, prevalent mutated genes, such as BRAF, NRAS and CDKN2 and also  some different genes in 
different mutation frequencies, depending on the analysis method used. In The Cancer Genome Atlas 
(TCGA), which was initiated by the National Institute of Health (NIH), melanoma samples were 
analyzed with 3 different methods and 13 genes were found to be significantly mutated in all three 
methods used, these were: BRAF (52% of 345 samples analyzed), NRAS (28%), CDKN2A (13% 
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mutated, 31% deleted), TP53 (5%), ARID2 (14%), IDH1 (5.7%), PPP6C (7%), PTEN (8.5%), DDX3X 
(6.3%), RAC1 (6.3%), MAP2K1 (5.1%), NF1 (4%) and RB1 (3.8%) (Watson et al 2015). These genes 
were also found at roughly the same mutation frequencies in the Broad and Yale datasets [5, 6]. 
 
BRAF, NRAS, NF1, and MAP2K1  
In the majority of melanoma patients, two signal transduction pathways are often altered and 
activated: the MAPK (BRAF, NRAS, NF1 and MAP2K1) and/or PI3K/AKT (NRAS, NF1 and PTEN) 
pathways (Figure 1).  
The MAPK pathway is involved in cell proliferation, differentiation and transcriptional regulation. In the 
MAPK pathway, BRAF is a serine-threonine protein kinase that exerts its effect mainly through the 
phosphorylation of MAP2K1 (MEK), which in turn exerts its effect by phosphorylating ERK. The high 
prevalence (approximately 50%) of BRAF mutations in all types of melanoma skin cancer, but mostly 
in melanomas from non-chronically sun exposed skin [7, 8], was discovered in 2002 [9]. Most 
mutations have consequences for the amino acid on position 600, which leads to the substitution of 
the amino acid valine to either glutamic acid (V600E, approximately 80-90% of cases) or lysine 
(V600K, approximately 5-12%) or arginine or aspartic Acid (V600R and V600D respectively, both in 
5% or less of the cases) [10, 11]. All these changes result in a constitutively active BRAF and a 
subsequent increased phosphorylation of MEK and ERK. Under normal circumstances, a constitutively 
active MAPK pathway induces cellular senescence, hence a second hit is necessary and a BRAF 
mutation alone is not sufficient to induce malignant transformation, underscored by the observation 
that a BRAF mutation can also be found in benign nevi. 
NRAS is a small GTP-ase that cycles between an inactive GDP bound and an active GTP bound 
state. NRAS mediates signals from growth factor receptors directly to downstream targets of both the 
MAPK and the PI3K/AKT pathways. Certain mutations in NRAS lead to a constitutively active GTPase, 
capable of activating downstream mediators in the absence of growth factor receptor activation. 
Approximately 25% of melanoma’s harbor an NRAS mutation, most commonly in the form of a 
missense mutation that introduces an amino acid substitution at position 12, 13 or 61 [7, 12, 13]. The 
mutation has a slightly higher prevalence in melanomas derived from chronically sun exposed skin.  
MAP2K1 or MEK1 is a serine-threonine protein kinase that is a central mediator in the MAPK pathway. 
Mutations often involve C>T and G>A changes, typical for UV-induced mutagenesis [14, 15]. MEK1 
mutations often co-occur with BRAF or NRAS mutations [14-16].  
NF1 is a tumor suppressor gene that inhibits RAS, thereby regulating the activity of both the MAPK 
and PI3K-AKT pathways [17, 18]. Somatic mutations within this gene have been identified in many 
different cancer types and germline mutations of NF1 predispose patients to several malignancies, 
including melanoma [18]. All described NF1 mutations [19-21], are protein-inactivating or resulting in 
loss of NF1 expression. In pre-clinical studies, melanoma cells with NF1 mutations were found to be 
resistant to BRAF inhibitors but sensitive to MEK inhibitors [22, 23]. 
 
CDKN2A and p16 loss 
Somatic, as well as germline mutations, in the p16/CDK4/cyclin D1/Rb pathway can contribute to 
melanoma formation (Figure 1). Germline mutations in CDKN2A have been found in 35-40% of familial 
melanoma cases [24]. 
The CDKN2A locus encodes for 2 genes (p16 and p14arf) which both act as tumor suppressor genes. 
P16 inhibits CDK4 and CDK6 and activates the RB protein family, which results in blockage of cell 
cycle progression of G1 to S-phase. P14arf activates the tumor suppressor TP53.  
In the TCGA melanoma dataset, CDKN2A was altered in 44% of the melanomas, 13% harboring an 
inactivating mutation and 31% a deletion, however some studies suggest that this is an overestimation 
in thin melanoma lesions, as the prevalence of CDKN2A alterations is higher in advanced melanoma 
tumors [25].  
   
Surprisingly, the TCGA analysis did not identify some already well known driver mutations of 
melanoma, underscoring that each individual study is limited in the capability to inform completely 
about all the genes important in melanoma development, which is probably due to the relatively small 
sample size of each study for a heterogenous disease such as melanoma. Melanoma driver genes 
identified in other studies include PREX2 [26], GRIN2A [27], ERBB4 [28], BCL2L12 [29], SOX10 [30], 
MITF [30] and KIT [31].  
 
Besides mutations in the coding region of genes, mutations in non-coding regions identified by WGS 
can also function as driver mutations. For example, mutations in the TERT promotor resulting in a 2 to 
4 fold increase in TERT expression [32] were found to occur in 33% of primary melanomas and in 85% 
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of metastases [33]. Mutations in the 5’UTR region have been analyzed to a lesser extent, and until 





Figure 1: Signaling pathways often altered in melanoma 
Green arrows indicate stimulation, red arrows indicate inhibition. 
Orange box: PI3K-AKT pathway. This pathway is often hyperactivated as an escape pathway when tumors become resistant for 
MAPK inhibition. 
Green box: MAPK pathway. Approximately 50% of melanomas harbor mutations in BRAF, 25% in NRAS and 15% in NF1 
resulting in hyperactivation of the MAPK pathway, making the MAPK pathway the most altered pathway in melanoma. 
Figure adapted from Wiesner et al, Pathology 2016, p113 
3.3 Diagnosis of melanoma  
 
Melanoma lesions can sometimes be very hard to distinguish from benign moles or nevi. To 
differentiate malignant from benign, the so-called ‘ABCDE rule’ [34] can be used: 
 
A = Asymmetry 
B = Border 
C = Color 
D = Diameter 
E = Evolution 
 
An asymmetric skin lesion with an irregular border, variegated color and a diameter of more than 6 
mm is suspicious for melanoma.  Additional early signs include a recent change in or development of a 
lesion and an "ugly duckling" sign, meaning a lesion that looks different than surrounding lesions in 
that patient. In a retrospective study analyzing the sensitivity and specificity of the ABCDE rule [35], 
the authors found that the sensitivity of the test was 97% when using one criterion and 43% when 
using all five criteria, indicating that not all 5 criteria must be present for the lesion to be a melanoma. 
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The specificity of the test is 36% when using one criterion and 100% when all 5 criteria were used, 
indicating that if all 5 criteria are present, it is almost certainly a melanoma.  
 
When a melanoma is suspected, a total surgical excision is warranted with 1 to 3 mm of normal skin at 
the resection border whenever possible. Incisional biopsies are only indicated for large tumors or for 
tumors present on certain anatomical locations such as the face and ear.  
 
A histopathologic examination is essential to confirm the diagnosis. In order for a dermatopathologist 
to diagnose melanoma, he or she will analyze the lesion for typical signs of cancerous uncontrolled 
proliferation, such as variability and abnormality in size and shape from the cells and their nuclei, 
prominent nucleoli and an increased amount of mitosis per phase field. The mitotic rate is the third 
most important prognostic factor on multivariate analysis, after the thickness of the primary tumor and 
ulceration (see later) [36]. Also, when melanoma is present, the melanoma cells move in all of the 
layers of the epidermis and in the epithelial adnexstructures. Some nests of melanoma cells will form 
with different shapes and sizes and with different distances to each other.  
When the melanoma becomes invasive, melanoma cells can be found below the basal layer in the 
dermis. An important criteria is that the melanoma cells in the deeper dermis are as big and atypical as 
the melanoma cells on the surface. 
 
The pathologists will also evaluate the additional prognostic factors: 
 tumor thickness according to Breslow: Tumor thickness is the most important prognostic factor 
found by two large studies [37, 38]. The tumor thickness is measured from the surface of the 
skin over the tumor mass to the deepest point of invasion. Because it should be measured 
over the thickest part of the tumor, it is safer to evaluate it from an excisional biopsy rather 
than a punch biopsy as then the thickest part may be missed. 
 histologic ulceration: ulceration means the absence of an intact epithelium over the melanoma 
lesion. In patients with tumors of the same thickness, those with ulceration have worse 
outcome. 
 margin status 
 lymphocyte infiltrates: Lymphocytes infiltrating the tumor have been associated with a better 
prognosis [39], however, multivariate analysis of many studies has not found a clear 
relationship [40].  
 microsatellites: satellite lesions are considered cutaneous melanoma metastasis within a 2 cm 
radius of the primary tumor. Generally, they are located between the primary tumor and the 
draining lymph node. Macrosatellites are visible by eye, whereas microsatellites are only 
visible with microscopy. If the tumor is more than 3 mm thick, microsatellites are present in 
30% of cases, whereas in smaller lesions this is only 5% [41]. 
 neural or vascular invasion 
 
The diagnostic and prognostic information on the pathology report of the excised lesion determines 
clinical assessment and follow-up treatment. 
 
3.4 Melanoma staging systems 
 
3.4.1 TNM staging  
 
The TNM (tumor, nodes, metastasis) staging system from the American Joint Committee on Cancer 
(AJCC, 7th edition) stages melanoma disease based on the most important prognostic factors. 
 
T: primary tumor. Increased tumor thickness, increased number of mitotic figures and ulceration are 
associated with higher risk of relapse. 
N: Presence of lymph node metastasis.  Lymph node metastasis are associated with higher risk of 
relapse, and this is also dependent on the number and the extend of lymph node disease 
M: Presence of distant metastasis. 
 
Based on the TNM classification, patients can be divided into four stages which have shown to have 
prognostic value for the survival of melanoma patients: 
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 Stage I: These are low risk melanoma patients without regional or lymph node metastasis. 
Stage I is further subdivided into stage IA and stage IB, depending on tumor thickness, mitotic 
rate and the presence or absence of ulceration;  
 Stage II: These patients also have no evidence of metastasis, however, they have a higher 
risk of recurrence. This stage is divided into stage IIA, stage IIB and stage IIC, depending on 
tumor thickness and the presence or absence of ulceration; 
 Stage III: Patients have regional lymph node metastases or satellite metastases. This stage is 
divided into stage IIIA, stage IIIB and stage IIIC, depending on the extent of lymph node 
metastasis. 




3.4.2 Genetic staging 
 
Based on genetic mutations, melanomas can be categorized into BRAF mutant (52%), RAS mutant 
(28%), NF1 mutant (14%) and Triple-wild type subtypes (6%) [42]. In the latter, an enrichment of KIT 
mutation and focal amplifications and complex structural rearrangements can be observed. Depending 
on the mutations present, specific targeted therapies are possible.   
 
Genetic screens, such as the DecisionDx-Melanoma, claim to accurately predict the presence of micro 
metastasis, independent of other prognostic factors, in patients who have been recently diagnosed 
with melanoma and have no visible metastatic disease yet [43]. By measuring the expression of 31 
genes in a primary tumor, it can classify patients in high-risk or low-risk categories. Combined use of 








Surgical intervention is important in the initial removal of the melanoma (Figure 2). Luckily, the majority 
of melanoma patients are diagnosed in the low risk category, i.e. patients with TI or IIA (and N0 M0) 
disease (tumor thickness below 2 mm with ulceration or below 4 mm without ulceration), and in this 
category surgical excision is usually curative.  
However, surgery also has a place in: 
 Regional lymph nodes  
If there is a risk of regional lymph node metastasis, lymphatic mapping (based on the observation that 
melanomas on specific body sites have specific patterns of lymphatic spread) and sentinel lymph node 
biopsy are performed. When positive nodes are found, this is followed by complete lymphadenectomy. 
However, the effect on survival is uncertain [45-50].    
 Local recurrences 
 Satellite metastases 
 Distant metastatic disease 
 
3.5.2 Chemotherapeutic drugs 
 
As chemotherapeutics have not improved overall survival and the response rates are low (less than 
20%) [51], these drugs are limited to patients who cannot be treated with immunotherapy checkpoint 





3.5.3 Radiation therapy 
 
Radiation therapy is mainly restricted to palliative care for localized symptomatic disease. Caution 
should be paid with radiation in combination with BRAF inhibitors (see below). Significant toxicity can 
be prevented if treatment with BRAF inhibitor is interrupted at least three days before and after 




Figure 2: Clinical Decision Making Algorithm Melanoma 
Clinical assesment after excision of a suspected melanoma is guided via prognostic factors on which the TNM classification is 
based.  
Blue box: Systemic therapy. When a targetable mutation (e.g. BRAF, NRAS, KIT) is present, no data are available whether 
immunotherapy or targeted therapy as the initial therapy should be given (clinical trial EA6134). When a patient has progressive 
disease on the initial therapy, the other treatment (targeted therapy or immunotherapy) can be given. For immunotherapy 
combination therapy with anti-PD1 and anti-CTLA4 is preferred in healthy patients with no comorbidities.  
Orange box: Adjuvant therapy. Clinical trials with adjuvant anti-PD1 immunotherapy are currently undertaken, alternatively anti-
CTLA4 has been approved in patients with node positive disease. For patients with node negative disease, no data on the 
benefit of adjuvant immunotherapy are available; however adjuvant IFN has been demonstrated beneficial.  




Immunotherapy is based on the notion of using the immune system’s ability to destroy “non-self” 
invaders for the eradication of “self” cancer cells. Although these “self” cancer cells originate from the 
patient, they are likely to express cancer-specific antigens, such as products from mutated genes or 
products from genes expressed specifically in cancer cells (e.g. cancer-testis-antigens, these genes 
are normally only expressed in the testis, where the blood-testis barrier prevents the entrance of 
immune cells [53], but can be re-expressed in tumor cells, including melanoma, upon dedifferentiation 
of the tumor cells), or differentiation antigens from the tumors tissue of origin (e.g. melanocytic 
differentiation antigens) [54], which can all serve as antigens which the immune cells can use to 
recognize tumor cells.  
13 
 
Anti-PD1 and anti-CTLA4 inihibitors both work by blocking an inhibitory interaction (CTLA4 on T-cells 
with B7 on dendritic cells in the activation phase of the immune response, and PD-1 on T-cells with 
PD-1 ligand on tumor cells in the effector phase of the immune response, respectively) which normally 
functions to stop T-cell activation, as a safety mechanism to prevent the destruction of “self” tissue. 
However, by blocking this inhibitory interaction, T-cells are stimulated to eradicate tumor cells.   
In patients with metastatic disease who receive immunotherapy, a combination with anti-PD1 
antibodies (pembrolizumab, nivolumab) with anti-CTLA4 antibodies (ipilimumab) is preferred, as this 
increases response rate and tumor shrinkage compared to either treatment alone [55]. However, 
serious adverse effects with required discontinuation of treatment were more frequent in the 
combination therapy than in anti-CTLA4 or anti-PD1 monotherapy. 
In the phase III KEYNOTE-006 trial, anti-CTLA4 monotherapy was directly compared to anti-PD1 
monotherapy, showing an increased progression free survival and overall survival in the anti-PD1 
treated patients in all patients subsets (with and without BRAF mutation, with and without prior 
targeted therapy), except for patients without expression of PD-L1 on their tumors, in which no 
difference between anti-PD1 and anti-CTLA4 treatment was found [56].  
Patients who have been treated before with ipilimumab without benefit from treatment or, in case of a 
BRAF mutant tumor, with BRAF inhibitors and progressed under these inhibitors, can still benefit from 
anti-PD1 treatment, independent of prior treatment response [57]. Considering the results from 4 
independent clinical trials, BRAF WT and BRAF mutated patients had the same response rate 
(approximately 33%) and same response duration (approximately 12 months) on anti-PD1 therapy [58] 
After 3 years of treatment, a plateau is observed in the survival curves of anti-CTLA4 treated patients, 
resulting in a durable response in  approximately 20% of patients, even after stopping treatment [59]. 
In the case of a BRAF mutated patient for whom both the option of targeted therapy or immunotherapy 
is available, choice is dependent on performance status of the patient, due to lack of available data yet 
(randomized clinical trial EA6134 currently taking place). Patients with worse performance status are 
suggested to start with targeted therapy, due to the faster response (rapid tumor regression) and 
higher response rate and as it is relative well-tolerated by patients. 
Adjuvant immunotherapy is available for patients who do not have clinical evidence of distant 
metastases, but do have a high risk tumor, based on prognostic factors such as tumor thickness, 
presence of ulceration and presence of lymph node metastases. Interferons (IFNs) are pleiotropic 
cytokines which induce the synthesis of hundreds of different proteins by activating the JAK-STAT 
pathway, they have an important role in inflammation and immune activation, and they have been 
shown to have anti-proliferative activities [60]. Adjuvant therapy with IFN alpha has been 
demonstrated to significantly increase disease-free survival (DFS) [61-64] and in some studies overall 
survival (OS) [65-67]. Therefore, high risk, node negative (TIIB or IIC) patients (tumor thickness higher 
than 4 mm or higher than 2 mm with ulceration), who are at increased risk for disease recurrence, as 
well as patients with microscopic disease smaller than 1 mm in a single lymph node will be monitored 
and might benefit from adjuvant high-dose IFN alpha. As these patients were excluded from the 
EORTC 18071 trial, no data on anti-CTLA4 in the adjuvant setting in these patients is available. 
In the case of macroscopic lymph node involvement, multiple lymph nodes or a single lymph node with 
more than 1 mm of microscopic disease, patients can be enrolled in a clinical trial which evaluates the 
effect of anti-PD1 treatment in the adjuvant setting, or when clinical trial participation is not possible, 
adjuvant high dose anti-CTLA4 treatment (10 mg/kg) has been approved for this patient group. 
Participation in the clinical trial setting with anti-PD1 is preferred, although no data are yet available in 
the adjuvant setting, in the metastatic setting these drugs (alone or in combination with anti-CTLA4 
treatment) are more effective than single-agent anti-CTLA4 treatment. Trial Eastern Cooperative 
Oncology Group [ECOG] E1609, NCT01274338 is currently directly comparing high dose CTLA4, 
normal dose CTLA4 or IFNa in this patient group, for which the results are expected in 2018, however, 
based on the magnitude of overall survival benefit of anti-CTLA4 vs placebo, anti-CTLA4 treatment is 
preferred until then [68].  
Compared to cytotoxic or targeted therapy (see next session), there are some differences in the 
pattern of response with immunotherapy. The response on treatment may be delayed, and the disease 
may even worsen at onset, before stabilizing or regressing. Furthermore, patients who do not respond 
on first sight may have clinically relevant periods of stable disease [69].  
Last but not least, toxicities with immunotherapy are significant, with the most common serious 
adverse events being enterocolitis, hepatitis, dermatitis and endocrinopathies, but side-effects in other 
organs also have been described . For a more detailed review of the various immunotherapy options 
available to melanoma patients, please see a review that we published a few years ago (Raaijmakers 




3.5.5 Targeted therapy 
 
 
Targeted therapy aims to specifically target cancer cells, usually by inhibiting one of the pro-survival 
pathways on which the cancer cells have shown to be reliant. Approximately 90% of melanomas 
(BRAF, NRAS or NF1 mutated) are dependent on an overactive MAPK pathway. Specific BRAF 
inhibitors (only targeting mutated BRAF), general MEK inhibitors and, recently, general ERK inhibitors 
have been shown to be beneficial in melanoma patients with metastatic disease .    
Because in approximately 40 to 60% of melanoma patients the presence of an activating BRAF 
mutation is found,  tumors of patients with advanced melanoma should be tested for such mutations 
[70-72]. In such cases,  treatment with a BRAF inhibitor, preferably in combination with a MEK 
inhibitor, (dabrafenib with trametinib, or vemurafenib with cobimetinib) are preferred as they show 
improved progression free and overall survival compared to BRAF inhibition alone [73]. Currently, for 
patients with BRAF mutated melanoma without metastases but with high metastases risk, trials are 
performed to evaluate targeted (combination) therapy in the adjuvant setting (vemurafenib; trial 
NCT01667419, dabrafenib plus trametinib; trial NCT01682083). 
The median survival for patients receiving the BRAF and MEK inhibitor combination is approximately 
two years. However, 9 to 12 months after initiation of treatment, patients may develop progressive 
disease due to resistance of the tumor cells to therapy. 
Common toxicities associated with BRAF inhibition (reported in 15% or more of patients) include 
cutaneous side effects (squamous cell carcinomas, photosensitivity, skin rash, alopecia), arthralgia’s, 
headache, weakness and/or fatigue. 
When a BRAF inhibitor is given in combination with a MEK inhibitor, the development of squamous 
cell carcinoma is reduced [74]. Studies indicated that the development of squamous cell carcinomas is 
due to a paradoxical activation of the MAPK pathway in non-mutated cells upon treatment with BRAF 
inhibitor alone [75], and that the addition of a MEK inhibitor can block this paradoxical activation [74]. 
Single agent MEK inhibitor treatment may have a role in BRAF wildtype but NRAS mutated melanoma 
patients, where it was shown in a phase III (comparing binimetinib with dacarbazine in NRAS mutant 
melanoma) trial to significantly increase progression free survival but with no difference in overall 
survival at interim analysis [76]. If NRAS mutated patients also have a p16 loss, combination therapy 
of a MEK inhibitor together with a CDK4/6 inhibitor has been found to have significant anti-tumor 
responses in two thirds of patients [77]. 
KIT mutations are present in 25% of mucosal and acral melanomas, approximately 30% of these 
patients respond to several KIT inhibitors, such as imatinib [78-80],  sunitinib [81], sorafenib [82] and 
nilotinib [83].  
 
3.6 The development of targeted therapy resistance 
 
Unfortunately, most patients receiving targeted therapy will develop therapeutic resistance after some 
months of successful treatment. Over the past years, research has focused on tumor cell resistance 
mechanisms mainly in BRAF mutant patients treated with a BRAF inhibitor such as vemurafenib. 
Reactivation of the MAPK pathway is an important resistance mechanism that was seen in nearly all 
BRAF inhibitor resistant tumors from the BRIM-2 vemurafenib phase II trial [84]. The same was found 
by Shi et al, in a study where they sequenced the genomes of 71 resistant post-treatment samples 
and found in 70% of the cases MAPK reactivation as a mechanism of resistance, either by an 
additional NRAS or KRAS mutation, mutant BRAF amplification or BRAF alternative splicing, or by 
CDKN2A loss [16]. In 22% of the cases they found several genetic alterations in regulators of the 
PI3K-AKT pathway, which were proven to be functional in inducing resistance by overexpression and 
knockdown studies. Furthermore, by analyzing several metastases from the same patient, they could 
identify at least 5 different resistance mechanisms in that patient, indicating that the selection of follow-
up therapy should not be planned on one post-treatment biopsy only.   
 
The finding that multiple resistance mechanisms co-exist in different metastases from the same 
patient, raises the question whether small populations of different resistant subclones were already 
present before treatment which become selected during treatment due to the survival advantage they 
have over sensitive tumor cells, or whether resistant tumors result from prior sensitive cells which have 
adapted to the treatment. A recent study in EGFR inhibitor resistance in lung cancer found that both 
processes can happen and that these different processes might provide an explanation as to why 
some patients progress quickly under treatment whereas others have a much longer response 
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duration [85]. Furthermore, they noticed that, prior to the appearance of a resistant mutation in their 
cell line under EGFR inhibitor treatment, a state of drug tolerance was present which was 
characterized by the ability to evade drug-induced apoptosis and by a mesenchymal transcription 
profile and that these molecular features of the drug-tolerant state - which impact general drug 
sensitivity - may be maintained even after acquisition of the resistant mutation for a specific drug [85]. 
    
Also in melanoma it has been acknowledged for some years that besides the permanent genetic 
changes that lead to drug resistance, also possibly transient or reversible non-genetic stages of 
resistance can be found. A drug tolerant state in melanoma [86], characterized by a reduced 
expression of melanocytic lineage specific markers and an increased expression of stemness and 
Epithelial-To-Mesenchymal (EMT) markers and of genes involved in epigenetic remodeling can be 
found after a relatively short exposure to targeted therapy. For instance, the enzyme KDM5B, which is 
a marker for a slow cycling phenotype with increased drug tolerance [87, 88], was upregulated in the 
stress response after the initiation of therapy. An early adaptive response upon BRAF inhibitor therapy 
can occur as soon as 24 hours after initiation of therapy [89]. Upon treatment, cells change 
morphology to a flattened and enlarged phenotype and increased senescence associated SA-β-Gal 
activity, H3K9me3-positive heterochromatic foci and PML bodies [90]. Also other stressors, such as 
hypoxia or low glucose can induce a similar stress response. Interestingly, when cells that exhibit such 
a stress response are exposed to various drugs, they are more resistant than their non-stressed 
equivalents, pointing towards a general drug tolerant state.  
 
Besides cell autonomous processes that generate resistance, such as genetic mutations or epigenetic 
alterations that come from the cell itself, processes outside the cell (cell non-autonomous processes) 
can also contribute to resistance. Different tumor subclones can collaborate with each other or with 
other cells in their tumor micro-environment in order to withstand treatment. For instance, treatment 
with a MAPK pathway inhibitor induces sensitive cells to secrete a treatment induced secretome (TIS), 
which components have the ability to directly or indirectly activate the PI3K-AKT pathway in resistant 
cells, which thereby can overcome their semi-quiescent state and become more proliferative while 
staying resistant [91]. Combination therapy of MAPK inhibitors with PI3K-AKT pathway inhibitors could 
prevent the therapy induced accelerated expansion of resistant cells in mice [91]. On the opposite, 
MAPK pathway inhibitor treatment also induces sensitive cells to express danger signals which incite 
an immune response, here the resistant cells have a dampening effect on that, thereby preventing an 
immune attack on the sensitive cells [92].  
Tumor cells can also collaborate with non-tumor cells in their micro-environment, such as fibroblasts. 
Hirata et al showed that fibroblasts increase their expression of PDGFRa in response to treatment with 
BRAF inhibitors, due to the paradoxical activation of the MAPK pathway in non-mutated cells from 
BRAF inhibitors. This results in the production of a denser collagen fibril matrix, with alterations in 
integrin organization and FAK signaling, which directly provides a safe haven for melanoma cells to 
withstand BRAF inhibitor therapy [93]. Interestingly, when these melanoma cells are taken out of the 
altered matrix, they are sensitive again to BRAF inhibition. 
 
In order to find new therapeutic strategies to overcome melanoma drug resistance, it is important to 
have a good overview of all the strategies melanoma cells use to overcome drug treatment. In the past 
years, we have tried to contribute a little piece of knowledge and insight in the huge melanoma puzzle, 
with the hopes that in the future, metastatic melanoma can be cured or can become a chronic disease 
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4. Aims of the Thesis 
 
The general aim of this thesis was to gain insight into the development of MAPK pathway inhibitor 
resistance in advanced melanoma.  
 
 
 Finding new biobanking methods in order to improve the successrate of establishing cell 
cultures and to recapitulate the in vivo tumor heterogeneity in an in vitro setting  
 
 Investigate how therapeutic resistance develops within single patients 
 
 Identify (new) resistance mechanism and investigate alternative strategies to target MAPK-






5. Contribution to the different manuscripts 
and reviews 
Papers covered in this thesis 
Paper 1: A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from 
native biopsies 
For this paper I developed and experimentally validated the different culture techniques for efficient 
retrieval and generation of in vitro melanoma cell cultures out of native patient biopsies. I described 
our findings in this paper for which I am first author. 
Paper 2: Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in 
heterogeneity of targeted therapy resistance 
For this paper I performed all the in vitro melanoma experiments, as well as Sanger sequencing of cell 
cultures and histology blocks and preparation of the cell and/or tumor DNA for the whole exome 
sequencing, ultra-deep seqencing and digital PCR part. I described our findings in this paper for which 
I am first author.  
Manuscript 1 in preparation: IRS1 expression is correlated with, but it is not a direct mechanism of 
MEK162 resistance in NRAS mutated melanoma 
For this manuscript I assisted the pathology with the patients’ autopsy, selected the tumors and 
generated the cell cultures from these tumors, performed all the subsequent in vitro experiments and 
generated the DNA and RNA for the whole exome sequencing and RNA sequencing experiments. I 
described our findings in this paper for which I am first author. 
Review 1: Melanoma immunotherapy: historical precedents, recent successes and future prospects 
For this review I wrote most of the sections and I coordinated the overall process. I am first author of 
this review.  
Review 2: Metastatic melanoma moves on: translational science in the era of personalized medicine 
For this review I wrote the sections on melanoma resistance (genomic, transcriptional and non-cell 
autonomous) for targeted MAPK inhibitors. For this review I am a co-author.   
Papers not covered in this thesis 
 
Paper 3: Hypoxia contributes to melanoma heterogeneity by triggering HIF1a-dependent phenotype 
switching 
For this paper I performed in vitro growth assays for different cell cultures. For this manuscript I am a 
co-author. 
Paper 4: Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is 
a negative prognostic factor in advanced melanoma 





6. Paper 1:  A new live-cell biobank workflow 
efficiently recovers heterogeneous melanoma 







A new live-cell biobank workflow efficiently recovers 
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Abstract: Fibroblast  contamination  can  make  establishing 
primary melanoma cell cultures from native biopsies a major 
challenge, due to fibroblasts overgrowing the melanoma cells. 
Standard protocols therefore enrich for highly proliferative 
melanoma cells that grow well in vitro but may not represent 
the full range of in vivo tumor heterogeneity. Here we apply 
conditional methods that more effectively retrieve melanoma 
cells by differential trypsinization or by inducing fibroblast 
senescence through contact inhibition, serum starvation or 
deprivation of adhesion. Simple mixing experiments of 
melanoma and fibroblast cells demonstrated the efficacy of the 
new protocols in retrieving slow-growing melanoma cells. 
Applying our protocols to 20 cultures that had failed to grow 
by conventional methods, we could retrieve 12 (60%) validated 
melanoma cell cultures. Further application of the protocols in 
the live-cell biobank of 124 early passage cultures significantly 
improved recovery rates from 13% using standard protocols to 
70% overall for the new   workflow. 
Key words: melanoma  –  cell culture –  biobank –  fibroblast  overgrowth 
 





Fibroblasts can complicate the establishment of primary melanoma 
cell cultures from native biopsies (1,2). Thus, highly proliferative 
melanoma cells that grow well in vitro may be over-represented in 
biobanks using standard culturing procedures and may not recapit- 
ulate the full range of in vivo tumor heterogeneity (3–5). Various 
cellular features that differ between fibroblasts and melanoma cells 
can be used to retrieve melanoma cells from mixed cultures. To 
avoid the loss of valuable patient samples, we have tested different 
methods to enrich for melanoma cell cultures out of fibroblast-rich 
biopsies. 
We tested two different methods that induce fibroblast senes- 
cence while preserving melanoma cell  proliferation: 
1. Fibroblasts stop proliferating when they reach a certain 
density directly related to the confluency of the cell culture 
and inversely related to the foetal calf serum (FCS) concen- 
tration of the culture medium (6). FCS contains growth 
factors that are essential for fibroblast proliferation but not 
for metastatic melanoma proliferation (6,7). In addition, fi- 
broblasts secrete factors that stimulate melanoma cell prolif- 
eration (8,9). Combining these findings, we cultured 
fibroblast-rich biopsies for an extended time without split- 
ting and changed the medium only once every 2 weeks. In 
this way, fibroblasts stopped proliferating due to contact 
inhibition and serum deprivation, whereas melanoma cells 
could  continue proliferating. 
2. In a second approach, we cultured cells on ultra-low-bind- 
ing plates. Fibroblasts that cannot adhere arrest in the G0/ 
G1 phase of the cell cycle (10,11), whereas melanoma cells 
do not undergo adhesion induced apoptosis (anoikis) and 
can even proliferate under non-adhesive conditions (12). 
Finally, to generate pure melanoma cell cultures, we combined 
two  different   techniques  based  on  the  difference   in    adhesive 
properties between the two cell types. Fibroblasts  are  adherent 
cells that are relatively difficult to trypsinize, especially when they 
have been cultured for an extended time  without  splitting  and 
have generated extracellular matrix (13). Melanoma cells on  the 
other hand detach relatively easily upon  trypsinization,  even  when 
they grow in a layer on top of the fibroblasts. A further selection 
can be made using the difference of adhesion time between fibro- 
blasts and melanoma cells. Fibroblasts adhere more quickly to the 
culture dish’s surface (i.e. around 30 min after seeding) than mel- 
anoma cells, which  may  require  more  than  an  hour  after  seeding 
to  properly  adhere  (data  not  shown). 
Finally, our simple mixing experiments of melanoma and fibro- 
blast cells demonstrated the efficacy of the new protocols in 
retrieving slow-growing melanoma cells. Applying our protocols 
to 20 cultures that had failed to grow by conventional methods, 
we could retrieve 12 (60%) validated melanoma cell cultures. Fur- 
ther standardization  of the protocols  in the live-cell  biobank  of 
124 early passage cultures significantly improved recovery rates 
from an initial 13% to a 70% overall success rate with the new 
methods. 
Material and methods 
Standard cell culture 
Cell cultures were obtained from patient biopsies of cutaneous 
melanoma and distant melanoma metastases after informed con- 
sent according to ethical approval numbers 647 and 800 and fol- 
lowing the Declaration of Helsinki on human  rights.  Tumor 
material was processed as described in Widmer et al. (3). Briefly, 
tumor  material  was  divided  into  small  pieces  and  digested with 
2.4 U/ml dispase (Roche, Basel, Switzerland), followed by a diges- 
tion with 62.5 U/ml collagenase (Sigma, St. Louis, MO, USA), so 
that the final suspension consisted of separated cells. This suspen- 
sion was cultured in RPMI1640 (Invitrogen, Carlsbad, CA, USA) 











Germany), 1 mM sodium pyruvate (Gibco,  Carlsbad,  CA,  USA) 
and 10% FCS (Gibco) at 37°C and 5% CO2. Cultures were split 
when they were approximately 90% confluent, and medium was 
refreshed twice per week. 
No splitting, limited culture medium  change 
Cell cultures were handled as in the standard protocol above, but 
without  splitting  and  with  medium  changes  only  once      every 
2 weeks at 37°C in 5% CO2    atmosphere. 
Short trypsinization and selective adherence  method 
If nests of melanoma cells grew visibly on top of fibroblasts, the 
cell cultures were rinsed two times with PBS and trypsinized long 
enough for only the cells on the top layer to detach, which is 
approximately 1 min at room temperature. The detached cells 
were collected and seeded in supplemented RPMI1640 with 10% 
FCS and incubated for 30 min at 37°C in 5% CO2 atmosphere. 
After 30 min, the supernatant was transferred to another dish and 
cultivated further at 37°C in 5% CO2. The protocol was repeated 
if there were still some fibroblasts left at the end of the procedure. 
Ultra-low-binding plates 
Cells were plated in 6-well low-binding plates (catalogue number 
3471, Falcon, Corning, NY, USA) for 5 weeks. Medium was care- 
fully replaced every week to prevent damage of the cellular aggre- 
gates. After 5 weeks, aggregates were plated in uncoated and 
untreated polystyrene 6-well culture plates (Falcon), in  order for 
cells to attach and grow out of the   aggregates. 
Spiking experiment 
Independent cultures of 3^105  fibroblasts, derived from biopsies of 
normal skin,  were  spiked with six melanoma cells  from any  of the 
fast-growing cell lines M000921, M130429 or M130427, which carry 
the BRAFV600E, the NRASQ61R  and the NRASQ61R  mutations, respec- 
tively. Six melanoma cells from the slow-growing cell line M130219, 
which carries the NRASQ61R  mutation, were also added to a separate 
culture  of  3 105  fibroblasts.  An  average  of  four  counts  with  the 
Neubauer chamber was used to prepare the appropriate cell concen- 
trations. For each culture, four different methods to retrieve the mel- 
anoma   cells   were   compared   in   parallel:   the   ‘standard   culture’ 
protocol, the ‘no splitting, limited culture medium change’ approach, 
the  ‘short  trypsinization  and  selective  adherence  method’  and  the 
ultra-low-binding  plates.  After  3–6 weeks,  cultures  were  tested  for 
BRAFV600E or the NRASQ61R mutation by Sanger sequencing. 
Retrieval of melanoma cells from previously identified 
fibroblast cultures 
Cultures were isolated from melanoma biopsies with known  onco- 
genic driver mutations (based on  Sanger  sequencing  of  the  tumor) 
but from which only non-mutated, likely fibroblast cultures grew 
(based on morphology and Sanger sequencing) with the standard 
protocol. To retrieve the melanoma cells, these cultures were  sub- 
jected to the ‘no splitting, limited culture medium change’ approach 
followed by the ‘short trypsinization and selective adherence’ 
method. 
Mutation analysis melanoma cell  cultures 
DNA was isolated using a buccal swab (Raucotupf, Lohmann & 
Rauscher, Rengsdorf, Germany), in combination with the QiAmp 
DNA blood mini kit (Qiagen, Hilden, Germany). The DNA was 
sequenced by Sanger sequencing. 
Primer     sequences     were     as     follows:     BRAF:     forward 
50CTAAGAGGAAAGATGAAGTACTATG and reverse 50CTAGTAA 




Figure 1. Schematic view of spike experiment results. (a) 3 9 105 fibroblasts were 
spiked with six melanoma cells either from the fast-growing cell lines M000921 
(representative pictures shown), M130429 (not shown) or M130427 (not shown), 
or from the slow-growing cell line M130219. Each spiked culture was applied to 
four different conditions for parallel comparison of methods. For the cultures 
spiked with M000921 cells, all methods resulted in retrieval of the melanoma cells, 
as observed by Sanger sequencing of the BRAF
V600E 
mutation. However, the  
M130219 cells were only retrieved with the ‘no splitting, limited culture medium 
change’ protocol for the first weeks and a subsequent ‘short trypsinization and 
selective adherence’ method. Arrows indicate melanoma cells that grow in a layer 
on top of the fibroblasts. (b) BrdU assay showing that M000921 is a proliferative 
cell line and M130219 grows relatively slowly. P-values were calculated by 












TGGGCTTGA  and  reverse  50ATCATCCTTTCAGAGAAAATAAT 
GC. 
BrdU assay 
The BrdU assay was performed using the BrdU cell proliferation 
assay kit (Millipore, Billerica, MA, USA) according to the manu- 
facturer’s protocol. 
Statistics 
Data were analysed for statistical  significance  with  a chi-square 
test and a Z-test using a P-value of <0.01 at http://www.socscista- 
tistics.com/. The BrdU assay was analysed using a  T-test. 
Results 
Slow-growing melanoma cells require alternative culturing 
methods 
When the fast-growing BRAF- or NRAS-mutated melanoma cell 
lines were mixed with fibroblasts, cells with the oncogenic driver 
mutation could be retrieved with all methods tested, notably also 
with the standard culture protocol (Fig. 1). This was repeated with 
three different cell lines. However, slow-growing NRAS-mutated 
melanoma cells could only be retrieved with the ‘no splitting, lim- 
ited culture medium change’ method, followed by the ‘short tryps- 
inization and selective adherence’ method. 
Alternative methods improve the recovery of melanoma cells 
from  impure cultures 
Twenty   cultures   from   BRAF-   or   NRAS-mutated    melanoma 















Figure 2. A new protocol for isolating melanoma cells from native material. (a) A 
conditional workflow based on cell morphology and oncogenic driver mutation 
status. It uses the principles of no splitting, limited medium refreshment, short 
trypsinization times and selective adherence to enrich for melanoma cells. (b) The 
amount of successful melanoma cell cultures  in  2012,  2013 and  2014,  when  the 
new culture protocol was applied to the biobank collection, followed by Sanger 
sequencing  of  the  patient’s  known  BRAF  or  NRAS  mutation status. 
 
fibroblasts based on the recovery of only  the  WT  oncogene  allele 
upon Sanger sequencing of the cultures, were subjected to the ‘no 
splitting, limited culture medium change’  method,  followed  by 
one or more rounds of the ‘short trypsinization and selective 
adherence’ method. In this way, we were able to retrieve 11 (55%) 
of 20 melanoma cultures that had previously failed the standard 
culturing procedures (Table 1). A subset of the 9 WT cultures that 
had failed the standard protocols  as  well  as  our  alternative  meth- 
ods was subsequently seeded on low-binding plates. With this 
method, we were able to retrieve 1 additional cell line of 7 (14%), 
 
A new melanoma cell- culture workflow 
(a) 
(b) Table 1.  Isolation of melanoma cells from previously wild-type cultures 
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Twenty  cultures  from  BRAF-  or  NRAS-mutated  tumors  that  had  been  over- 
grown  by  fibroblasts  in  standard  culturing  conditions  (as  shown  by  their  WT 
mutation  status)  were  subjected  to  the  ‘no  splitting,  limited  culture  medium 
change’  method,  followed  by  the  ‘short  trypsinization  and  selective  adherence’ 
method.  A  subset  of  seven  cultures  that  still  tested  WT  after  this  method  was 
seeded   onto   low-binding   plates.   The   BRAF   or   NRAS   mutation   status   was 







resulting in a recovery rate of 60% overall for the combined pro- 
tocols. 
Conditional treatment protocols increase the success rate   of 
large-scale biobanking programmes 
Since the beginning of 2014, we applied a new cell culture work- 
flow (Fig. 2a) that included the different methods for retrieving 
melanoma cells out of fibroblast-rich cultures. This resulted in a 
significant improvement from  13%  using  the  standard  protocols 
to 70% with our optimized workflow in establishing melanoma 
cultures (Fig. 2b), compared with the previous year when the 
standard protocol was still  used. 
Discussion 
Currently, most in vitro research is carried out on fast-growing, 
adherent and robust cell cultures or cell lines, because these are 
the easiest to isolate and maintain. This is readily seen in our 
spike experiment in which fast-growing melanoma cells rapidly 
overtake the fibroblasts in culture. However, the slow-growing 
melanoma cells that are much more difficult to retrieve are largely 
underrepresented by most biobanking efforts (14). However, these 
cells may have important consequences for tumor progression or 
treatment response. Here we present an optimized protocol for 
establishing heterogeneous melanoma cell cultures out of patient 
biopsies, which reduces the chance of fibroblast overgrowth. Our 
method improves the basic in vitro tools available to study mela- 
noma biology by better representing the heterogeneous cell types 
present in melanoma tumors. 
Our proposed workflow starts with a 4-week  culture  period 
using the standard protocol. It  may  not  always  be  necessary to 
use special techniques to  obtain  slow-growing  melanoma  cells. 
For instance, from  tissues  with  little  fibroblast  contamination 
such as in brain metastases, we successfully obtained  slower 
growing melanoma cells  with  the  standard  protocol.  However, 
for some samples, this standard protocol does  not  suffice,  and 
then, the optimized methods could be used to retrieve the mela- 
noma cells from these samples as well. Application of our com- 
bined methods to 20 cultures  that  had  failed  the  standard 
culturing protocols resulted in the retrieval of 11 additional cul- 
tures using the ‘no splitting’ and ‘selective adherence’ methods 
and 1 culture using the ‘low-binding plate’ method, for a total 
success rate of  60%.  While  no  method  was  able  to  retrieve 
mutated melanoma cells from 8 of  the  20  cultures,  it  is  possible that  
these  early  cultures  never  contained  melanoma  cells,   or some 
other method would be necessary to  enrich  for  melanomas from  
these  cultures. 
By applying this optimized workflow to our live-cell biobanking 
programme, we improved our recovery rates from 13% to 70% in 
establishing melanoma cell cultures from native material. In addi- 
tion to confirming the oncogenic mutation status or morphology 
of over 250 early passage melanoma cultures, we also have a bio- 
bank of more than 1000 different unconfirmed early passage mela- 
noma cell cultures from consenting patients with diverse clinical 
features and treatment histories. As we have shown that it is pos- 
sible to recover melanoma cells from impure  cultures  that may 
have failed quality control steps from standard protocols, our col- 
lection represents an immense resource for investigating how mel- 
anoma heterogeneity contributes to tumor progression and 
therapeutic resistance. 
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ABSTRACT 
Acquired chemotherapeutic resistance of cancer cells can result from a 
Darwinistic evolution process in which heterogeneity plays an important role. In 
order to understand the impact of genetic heterogeneity on acquired resistance and 
second line therapy selection in metastatic melanoma, we sequenced the exomes 
of 27 lesions which were collected from 3 metastatic melanoma patients treated 
with targeted or non-targeted inhibitors. Furthermore, we tested the impact of a 
second NRAS mutation in 7 BRAF inhibitor resistant early passage cell cultures on 
the selection of second line therapies. 
We observed a rapid monophyletic evolution of melanoma subpopulations in 
response to targeted therapy that was not observed in non-targeted therapy. We 
observed the acquisition of NRAS mutations in the BRAF mutated patient treated with 
a BRAF inhibitor in 1 of 5 of his post-resistant samples. In an additional cohort of 5 
BRAF-inhibitor treated patients we detected 7 NRAS mutations in 18 post-resistant 
samples. No NRAS mutations were detected in pre-resistant samples. By sequencing 
65 single cell clones we prove that NRAS mutations co-occur with BRAF mutations 
in single cells. The double mutated cells revealed a heterogeneous response to MEK, 
ERK, PI3K, AKT and multi RTK - inhibitors. 
We conclude that BRAF and NRAS co-mutations are not mutually exclusive. 
However, the sole finding of double mutated cells in a resistant tumor is not sufficient 
to determine follow-up therapy. In order to target the large pool of heterogeneous 






The MAPK pathway, consisting of RAS-RAF- 
MEK-ERK, is a highly conserved signaling cascade in 
eukaryotic cells conserved from yeast to humans with 
many vital cellular functions, such as proliferation, 
differentiation, migration, and apoptosis [1]. About one- 
third  of  cancers  have  a  deregulated   MAPK   pathway, 
either due to overexpression of receptor tyrosine kinases 
(RTKs), increased production of activating ligands, 
activating mutations in RTKs, RAS or RAF or to failure of 
pathway control mechanisms [1]. In cutaneous melanoma, 
deregulation of the MAPK pathway is mainly caused by 
a hyperactive mutation in BRAF (50% of cases) or NRAS 
(15% of cases), highlighting the important role of controlled 
MAPK signaling for melanocyte homeostasis [1, 2]. 
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Targeting a hyperactivated MAPK pathway driven 
by mutated NRAS or BRAF with specific BRAF- and 
MEK inhibitors, increases the median overall survival 
from metastasized melanoma patients from 9 months with 
no therapy to approximately 14 months with successful 
inhibitor treatment [3]. Unfortunately, resistance to 
MAPK inhibition almost invariably develops [4]. Several 
resistance mechanisms have been described so far, which 
can roughly be divided into those that reactivate the 
MAPK pathway by circumventing the inhibitory effects 
of the MAPK inhibitors, or ones that activate alternative 
signaling pathways [5]. 
In the case of BRAF inhibitors, Shi et al identified 
reactivation of the MAPK pathway (70% of cases), mostly 
in the form of additional NRAS or KRAS mutation (18% 
and 7% of cases, respectively), CDKN2A loss (7% of 
cases), mutant BRAF amplification (19% of cases) or 
BRAF alternative splicing (13% of cases) as the most 
common resistance mechanisms. They  also  identified 
the PI3K-PTEN-AKT pathway as the second important 
resistance pathway (22% of their post-treatment samples 
contained mutations in PI3K-AKT regulatory genes) [5]. 
One of the more prevalent mechanisms is an 
additional mutation  in  NRAS,  leading  to  reactivation 
of the MAPK pathway [6]. However, it has been 
published that NRAS and BRAF mutations are mutually 
exclusive in single cells due to self-induced apoptosis 
by sustained hyper-activation  of  the  MAPK  pathway 
[7, 8]. Consequently, resistant tumors of patients that 
contain both mutations concurrently may be comprised 
of several mutually-exclusive subclones with either the 
activating BRAF or NRAS mutations [7]. A recent paper 
showed that both mutations can co-occur  in  a  small 
area (of approximately 10,000 cells) selected by laser 
microdissection [9], although this does  not  prove that 
the mutations can co-occur within single cells. Likewise, 
although double-mutated NRAS/BRAF melanoma cultures 
have been previously reported, these may still represent 
heterogeneous mixtures of singly-mutated melanoma 
cells [10, 11, 12], or may have arisen artificially through 
in vitro drug treatment and selection experiments [13]. 
Within a patient, various small populations of tumor 
cells (i.e., subclones) evolve during disease progression, 
which exhibit different genotypes and/or phenotypes 
([14, 15, 16]). Due to these different tumor subclones 
within a patient (intra-patient heterogeneity), it is believed 
that diverse resistance mechanisms can co-exist within 
one patient [17, 5]. However, where these resistance 
mechanisms originate from and how they evolve under 
treatment remains poorly understood [6, 11]. 
To better characterize the evolution of intra-patient 
heterogeneity under different treatment regimens, we 
performed exome sequencing on multiple samples   from 
3 stage IV melanoma patients (cohort 1) who each 
received a different therapy (BRAF inhibitor (patient 1), 
MEK  inhibitor  (patient  3)  or  multi-receptor    tyrosine 
kinase (patient 2)) but progressed quickly under treatment. 
We used formal phylogenetic  methods  on  tumor DNA 
to model the evolution of intra-patient heterogeneity 
from primary tumors to each individual metastasis for 
the targeted and non-targeted therapies. In addition, we 
could detect the presence of an NRAS mutated subclone 
in 1 of 5 treatment-resistant tumors from the BRAF 
inhibitor resistant patient (patient 1). Single cell clone 
sequencing from the cell culture generated from this 
treatment resistant tumor revealed the co-occurrence of 
a BRAF and NRAS mutation in a single cell. This was 
confirmed in an additional group of 5 patients (patient 4, 
5, 6, 7 and 8, cohort 2) from whom tumors after BRAF 
inhibitor treatment were collected and where cell cultures 
were generated from these tumors and showed secondary 
NRAS mutations. Sequencing of 65 clonal populations 
derived from 4 of these cell cultures showed the presence 
of both activating MAPK mutations in all but one 
subclone. Further in vitro work with these double-mutated 
cell cultures demonstrated sensitivity to BRAF inhibition, 
but heterogeneous responses to downstream MAPK 
inhibition, as well as to PI3K pathway inhibitors and the 




Tumor-type dependent, intra-patient heterogeneity 
 
We sequenced whole exomes of 27 samples from 
three metastatic melanoma patients (cohort 1) with 
different mutational statuses and different treatments 
(Table 1 and Figure 1A–1F). For all patients we 
performed exome sequencing on all of their samples and 
confirmed their mutational status (BRAFV600E mutated, 
BRAFWT/NRASWT or NRASQ61K mutated for patient 1, 2 
and 3, respectively) (Table 1, Figure 1, Supplementary. 
Table S1). In addition to these driver mutations, we looked 
for  other  mutated  onco-  and  tumorsuppressor  genes: 
in patient 2 we identified a nonsynonymous germline 
mutation in  the  Melanocortin  receptor  MC1RV92M  and 
in patient 3 a nonsynonymous germline mutation in the 
Microphthalmia-associated transcription factor MITFE318K 
(data not shown). By using EXCAVATOR and CONTRA 
algorithms we detected a high number of copy number 
variations (CNVs) in many chromosomes, with some 
samples exhibiting large losses throughout the genome 
(Figure 1G–1I). 
 
Whole-exome phylogenetic analysis identifies 
monophyletic evolution of therapeutic resistance 
In order to investigate the evolutionary relationship 
between tumor sites within individual patients, we used 
phylogenetic algorithms to group tumor samples  based 
on their total single nucleotide variants (SNVs) and copy 
number  variations  (CNVs)  (Figure  2,    Supplementary 
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Table S2). As opposed to  the  phylogenetic  tree of 
patient 2 biopsies, the evolutionary trees from patient 1 
and 3 showed monophyletic clades for the post-resistance 
samples (i.e. late metastases), meaning that these 
originated from only one node (Figure 2). However, no 
known and shared mechanism of resistance to BRAF- 
inhibitor or MEK-inhibitor treatment could be identified 
(Supplementary Table S2). Confidence is shown by 
bootstrap supports (arrow) which reflects the percentage 
of bootstrap trees also placing the clade at the endpoints 
of that branch. The tree of patient 2 (BRAFWT and NRASWT, 
patient received non-targeted therapy) did not show this 
strong monophyletic clade of late tumor metastases, 
instead the post-resistant samples originated from multiple 
nodes (Figure 2, arrows). Since there might be multiple 
different resistance mechanisms present in one patient, 
we also sought to identify explanatory protein-coding 
changes in any of the post-treatment samples. However, 
no known mechanisms of resistance were identified in 
the exome data of any tumor in the three patients   except 
for the NRASQ61K mutation that was present in a cell line 
(MM121224) derived from a resistant metastasis from 
patient 1 (Figure 2). 
 
Resistant subclones are present heterogeneously 
and at low frequencies 
In order to determine the origin of this NRASQ61K 
mutation from patient 1 we performed digital PCR as 
well as ultra-deep sequencing on all  tumor  samples 
(data not shown, and Figure 2D). Only one cell culture 
(MM121224) and one biopsy where the cell culture was 
derived from had an activating mutation in exon 2 of the 
NRAS gene (NRASQ61K), with a range from 5,473× coverage 
of the NRAS exon to 26,416× coverage by next generation 
sequencing (Figure 2D, and Supplementary Table S3). 
No other sample from this patient had this activating 
mutation, suggesting other resistance mechanisms to be 
involved in the metastases of  the  same  patient. Using 
the program deepSNV, a diverse series of other NRAS 
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coding mutations in  exon  2  was  present  significantly 
in all samples  at  low  subclonal  frequencies compared 
to the germline blood reference from the same patient 
(Figure 2D and 2E, Supplementary Table S3). Interestingly, 
the allele carrying the NRASQ61K mutation was only present 
at a frequency of about 6% in early passage cultures of 
the MM121224 cell line from this patient (Figure 2D–2F). 
 
Two activating MAPK mutations are present in 
single melanoma cells 
To determine the frequency of double mutations in 
early passage cultures in general in a larger patient cohort, 
we Sanger sequenced the NRAS locus in all BRAF-mutated 
cell  cultures  generated  from  2013—2015  archived   in 
our melanoma biobank [18]. In this way,  we identified     an 
additional 8  double-mutated  cell  cultures,  derived  from 
7 different patients, bringing the total to 9 out of 122 cell 
cultures (7.4%). Of these 9 cell cultures, 7 had an activating 
BRAF mutation at position 600 and a co-occurring activating 
NRAS mutation at position 61 or 12 (Table 1). Two of these 
cell cultures had a BRAF mutation at another position, 
namely one culture contained the double mutation BRAFD594H/ 
NRASQ61R and one culture had the double mutation BRAFL597R/ 
NRASQ61R (Data not shown). The BRAFD594H is an inactivating 
mutation, and a double mutation of this sort is already 
described elsewhere [19]. The BRAFL597R is a less prevalent 
activating mutation for which less information is available. 
We therefore decided to focus on the six patients (patients 
in cohort 2, and patient 1 from cohort 1, see Table 1) with 
cell cultures that had a BRAF mutation at position 600 and a 




Figure 1: Patient cohort (A, D) Patient 1 had a BRAFV600E mutated melanoma, samples were collected pre- and post 
LGX818 (encorafenib) treatment and included the primary tumor (green), two dysplastic nevi (black), two early 
metastases (orange) and 4 late metastases after tumor relapse (red). (B, E) Patient 2 had a melanoma WT for BRAF and NRAS. 
Samples were collected pre- and post non targeted multi RTK inhibitor (pazopanib), and included the primary tumor (green) and five late 
metastases (red). (C, F) Patient 3 had a NRASQ61R mutated melanoma, samples were collected pre-and post MEK162 (binimetinib) treatment 
and included the primary tumor (green), one early metastasis (orange) and three late metastases (red). (G, H, K) Every ring shows the CNVs 
detected of one biopsy, The enlarged regions show a commonly lost region in chromosome 9 which is coding for the tumor suppressor 
CDKN2A. (G) Patient 1, rings from outside to the center represent two nevi in the two outermost circles followed by the primary tumor, the 
two early metastases and finally the late metastases 1 to 4. (H) Patient 2, rings from outside to the center represent primary tumor samples 
1 to 3 and the late metastases 1 to 5. (I) Patient 3, rings from outsided to the center represent the primary tumor samples 1 and 2, one early 
metastases and the late metastases 1 to 3. 
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We asked if the double-mutated cell cultures consisted 
of two exclusive populations of cells (one with BRAF and 
another with NRAS mutations), or if both mutations were 
present in single melanoma cells. To distinguish between 
these possibilities,  we  generated  single-cell  clones  of 
4 double mutated cell cultures (from  patients  1,  5, 7 
and 8) and confirmed by Sanger sequencing the presence 
of both BRAFV600E/K and NRASQ61K/H/R or G12A mutations in 65 
independently derived colonies (Table 1). 
Both alleles (mutated and WT) from BRAF and 
NRAS were found to be expressed with Sanger sequencing 
of cDNA and RNA-seq (data not shown). 
 
Double mutations occur heterogeneously within 
patients after targeted therapy 
In order to investigate the evolution of the NRAS/ 
BRAF double mutated cancer cells within a patient, we 
analyzed tumor DNA for the presence of double mutations 
in all available histological and frozen material from 
patients 4, 5, 6, 7 and 8 before and after BRAF    inhibitor 
treatment (Table 1). For patients 4, 5 and 6 we could 
confirm the presence of the additional NRAS mutation  in 
the post-treatment samples from which the cell culture 
was derived. In patient 8, we had generated cell cultures 
from Late met 1 and Late met 2. In Late met 1 we could 
detect the BRAFV600E NRASQ61R double mutation, however 
in Late met 2 we could not detect the additional NRASQ61K 
mutation. For patient 7, the histology block corresponding 
to the tumor from which the cell culture was derived was 
no longer available. In patient 4 and patient 8, we could 
also detect the NRAS/BRAF double mutation in additional 
post-treatment metastasese. Interestingly, the NRAS 
mutation could not be detected in any of the pre-treatment 
biopsy samples. 
 
Double-mutant cells have heterogeneous MAPK 
pathway inhibitor and alternative pathway 
responses 
In order to gain more insight into the biology of NRAS/ 
BRAF double mutated cells, we performed viability assays 
with (control) single and double mutated cell cultures under 
MAPK inhibitor treatment. Double-mutated cell cultures 
from all 6 identified patients were resistant to three different 





Figure 2: Whole-exome phylogenetic trees of patient biopsies. Branch-lengths represent relative distances based on SNVs and 
indels, and the branches are colored according to biopsy type. Maximum likelihood phylogenetic trees are rooted by the blood sample 
for patient 1 (A), patient 2 (B), and patient 3 (C). Node supports are given as bootstra p values, with greater than 50% considered to be 
strong support. (D, E) deep sequencing results of the NRAS exon 2 locus in multiple samples from patient 1. (F) the double BRAFV600E and 
NRASQ61K  mutation is present in colonies derived from single cells. 
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A + indicates synergism of combination treatment, with ++ and +++ being a stronger effect. A – indicates no synergy. 
and ERK inhibitors was heterogeneous. The cell cultures 
MM140906 and MM150850 were resistant to MEK and 
ERK inhibitors, whereas other cell cultures were sensitive 
or partially resistant for one or for both of the inhibitors 
(Figure 3A, Table 2). We also tested the response for different 
inhibitors of the PI3K-AKT pathway, as this pathway is 
often involved in MAPK pathway inhibitor resistance [5], 
and for the multi-RTK inhibitor Pazopanib. Here the cells 
also showed a heterogeneous response, except for the multi- 
RTK inhibitor, for which all cell cultures were resistant 
(Figure 3A, Table 2). Therapies combining a MEK 
inhibitor with different PI3K pathway inhibitors worked 
synergistically in all cell cultures, albeit with different 
strengths (Table 2). As it was previously thought that 
BRAF and NRAS mutations are mutually exclusive due to 
the growth disadvantage of double mutated cells [8], we 
analyzed the proliferation  rate  of  double-mutated  cells 
in vitro, compared to single mutated control cell cultures 
(Figure 3B). Although the cell cultures MM121224 and 
MM140307 showed a higher proliferation rate compared to 
the control cell cultures, the other double-mutated cells had 
reduced proliferation rates. 
As   a   downstream    read-out    for    BRAF and/ 
or MEK activation, western blot analysis for  total 
ERK and phosphorylated ERK was performed in the 
presence   of   BRAF,   MEK,   or   ERK   inhibition. This 
showed that basal pERK levels were mostly higher in 
the double mutated cells compared to the single NRAS 
mutated control cell cultures (but not in MM150423) 
(Figure 3C). Upon treatment with the BRAF inhibitor 
LGX818 (encorafenib), the pERK levels of MM121224, 
MM150423, MM150849 and MM140906 stayed the same 
compared to the untreated control, whereas the levels 
of MM140307, MM150850 and M130903 decreased 
(Figure 3C). Levels of pERK expression upon MEK162 
(binimetinib) treatment decreased in all cell cultures 
except for MM140906. Upon ERK inhibition, pERK 
levels were reduced in all cell cultures. 
When we compared pERK  levels  and pAKT 
levels between the different double mutated  cell 
cultures without treatment, we found that MM140307, 
MM140906, MM150849 and MM150850 expressed 
relatively high levels of pERK, whereas M130903, 
MM150423 and MM121224 express relatively low levels 
(Figure 3D). pAKT expression is relatively constant 
between the different cell cultures, except MM150849, 




Genetic or transcriptional heterogeneity in tumors 
is  a  major  obstacle  to  obtaining  durable  responses  to 
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targeted therapy for metastatic melanoma. In order to 
better understand how individual cancer patients respond 
to standard therapies, we conducted multiple-sample, 
whole-exome sequencing from multiple time-points in 3 
patients receiving different therapeutic regimens. 
The sequencing results were used to infer the 
evolutionary relationships between the tumors within 
each patient, and to determine how each therapeutic 
regimen affected the evolution of genetic heterogeneity. 
Unlike previous studies that showed a branching 
evolution of clones subsequent to  targeted  therapy, 
we could see a strong, well-supported monophyletic 
evolution of metastases  following  both  BRAF  and 
MEK inhibitor treatment and relapse with phylogenetic 
analysis [5]. In contrast, patient 2, who received a multi-
kinase inhibitor (i.e. pazopanib), did not have a 
monophyletic topology of late tumor metastases, which 
is suggestive of genetic drift between the late metastases. 
Despite the monophyletic segregation of late   metastases 
in the patient who received the BRAF inhibitor, no known 
genetic mechanism of resistance  was  shared  between 
all sequenced biopsies accounting for the inter-patient 
heterogeneity  and  subsequent  treatment   difficulties. 
In fact, the additional activating mutation in NRASQ61K 
found in patient 1 with a BRAF mutation background 
was only present in a single metastasis of patient 1 and 
absent in all other resistant tumor samples from that 
patient. This is consistent with previously published data 
showing heterogeneity in resistance mechanisms within 
individual patients [5]. 
We went on to check if the double mutation could 
also be found in the cell culture obtained from this 
resistant metastasis, and if these mutations occurred in the 
same cell. By isolating and sequencing colonies derived 
from 23 single-cell clones of the resistant late metastasis 6 
from patient 1, we could show for the first time that both 
activating MAPK mutations (NRAS and BRAF) were 





Figure 3: Viability and proliferation assays of double mutated cells. (A) Viability assays of double mutated cells for 
different MAPK inhibitors and inhibitors from the PI3K-AKT pathway as well as a multi-RTK inhibitor. Single mutated control cell 
cultures are M000921 (BRAFV600E) and M010817 (NRASQ61R), indicated in dotted lines. The double mutated cell cultures are indicated 
in solid lines. MM121224 (BRAFV600E, NRASQ61K) derives from patient 1, MM140307  (BRAFV600K,  NRASG12A)  derives  from 
patient 5, MM140906 (BRAFV600E, NRASQ61R) derives from patient 6, MM150423 (BRAFV600E, NRASQ61R) derives from patient 4, M130903 
(BRAFV600E, NRASQ61H) derives from patient 7, MM150849 (BRAFV600E, NRASQ61R) and MM150850 (BRAFV600E, NRASQ61K) are both derived 
from patient 8. (B) Doubling time of double mutated cells under standard culturing conditions. Single mutated control cell cultures are 
indicated with stars. (C) Western blots showing pERK and ERK levels under MAPK inhibitor treatment in double mutated cell cultures. 
Single mutated control cell cultures are indicated with stars. (D) Westernblot showing pERK and pAKT levels under basic conditions 
(no treatment) in the different double mutated cells. 
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In order to confirm our finding, we identified a 
second cohort of BRAF inhibitor resistant patients from 
whom we had obtained a double mutated cell culture. 
In screening 121 cells from our live-cell biobank, we 
could identify an additional 8 cell cultures with double 
BRAF/NRAS activating mutations, bringing the total to 9 
out of 122 cell cultures. By sequencing colonies derived 
from single-cell clones, we confirmed  the  presence of 
the double mutation in 64 out of 65 colonies.  However, 
in our standard biobank protocol we establish cell 
cultures without additional treatment, also  when  they 
are derived from a therapy resistant patient. Therefore, 
due to selection, this  could  be  an underrepresentation 
of the  actual  number  of  double  mutated  subclones in 
a typical MAPK-inhibitor resistant tumor. Sequencing 
of colonies  derived  from  single  cell  clones  of  three 
of these double-mutated cultures confirmed that all 
except for one colony contained both BRAF and NRAS 
mutations, thus confirming the presence of both activation 
mutations in the same cells. Sequencing of the additional 
immunohistochemistry blocks from these patients only 
identified double mutations in the post-treatment samples, 
confirming the finding in patient 1 from cohort 1. 
To understand the general resistance mechanisms of 
the double-mutated cells, we conducted viability assays 
with different MAPK inhibitors. The double-mutated cells 
grew in normal culturing conditions, notably without any 
MAPK inhibition, were all resistant to BRAF-inhibitors, 
but showed heterogeneity in their response to MEK or 
ERK inhibition, possibly because of co-existing mutations 
in other pathways. Combination treatment with MEK and 
BRAF inhibitors, as it is now clinical practice, showed 
synergism in MM121224 and M130903, but no synergistic 
or additional effect in the other cell cultures,Suggesting 
that simultaneous or second-line treatment with other 
MAPK-pathway inhibitors might still be effective in 
controlling progression in selected patients,  but  not in 
all. However, a MEK inhibitor combined with a PI3K, 
AKT or mTOR inhibitor was synergistic in all of the cell 
cultures, albeit with different strength. It has to be kept 
in mind however, as the double-mutated genotype was 
only present in one or two metastases from each patient, 
it is likely not the most important resistance mechanism 
in these patients and  the  efficacy  of  these second-line 
or combination treatments in controlling overall tumor 
burden is questionable. Since no common mechanism of 
resistance was found in any patient, it is possible that the 
other resistant tumors activated different pathways. 
Except for 1 cell line (MM150423), all double 
mutated cell lines showed higher expression of pERK at 
the basal level compared to the single NRAS mutated cell 
line M010817. However, the basal level of pERK among 
the double mutated cells varied, with relatively high 
expression in MM140307 and MM140906 and relatively 
low expression in MM150423. It has been argued that 
BRAF and NRAS mutations are mutually exclusive     due 
to a growth deficit of double mutated cells, because of 
senescence-inducing high levels of pERK [8]. In our 
experiment, MM121224 and MM140307 grew faster 
than the single mutated control cell lines and MM140906, 
MM150423 and M130903 grew slower, not supporting 
the view the cells with high pERK level grow slower. 
However, in vitro growth behavior might not   represent 
in vivo growth, for instance depending on how well the 
cells have adapted to a 2D culture system, what growth 
factors are present or missing in the cell culture medium 
compared to the in vivo situation and how well the immune 
system can control metastasis formation. 
The pERK levels in the cell lines under treatment 
of various MAPK pathway inhibitors showed some 
discrepancy with the proliferation assay. Most profound 
was the strong reduction in pERK upon treatment with 
the BRAF inhibitor and MEK inhibitor in MM140307, 
although the cell line was resistant to these two inhibitors. 
We hypothesize that this is due to the very high pERK 
levels in this cell line at baseline, in such a way that even 
a strong reduction compared to baseline does not suffice to 
block the pathway. This would also be true for MM140906 
under ERK inhibitor treatment, although the cell line is 
resistant to ERK inhibition, levels of pERK show a 
decrease compaired to the baseline, but the levels are still 
high. MM150423 pERK levels are relatively low in MEK 
and ERK treated cells, although the cell line is partially 
resistant to these inhibitors. However, the pERK levels in 
the MEK and ERK treated cells do not differ considerably 
from the untreated cells. 
In this study, we show that known-resistance 
mechanisms are present at low frequencies and 
heterogeneously within individual patients. Furthermore, 
we show that finding an additional NRAS mutation in a 
tumor sample following BRAF inhibitor treatment could 
indicate the presence of a double mutated subpopulation 
that is not necessarily sensitive to MEK inhibition or ERK 
inhibition, rendering the MEK inhibitor therapy in all 
such cases suboptimal. This study indicates that genetic 
analysis of one tumor biopsy does not fully define the 
resistance mechanism for the whole patient, which has 
important implications for secondary therapy strategies in 
case of primary resistance. 
 
MATERIALS AND METHODS 
 
Patients and sample preparation 
 
Patients were selected after written consent from 
the patient, given through the university biobank program 
according to ethical approval  numbers  647  and  800. 
We collected surplus  material  before  and  after therapy 
at autopsy. Samples were processed immediately after 
collection to ensure best possible DNA and RNA quality. 
Primary cell cultures were established as described in [18]. 
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Notably, upon generation of cell cultures, all cultures 
were kept under standard conditions without additional 
treatment, even if they were derived from a therapy 
resistant patient. 
DNA was isolated from paraffin embedded tissue, 
fresh frozen tissue, cultured cells and PMCs stored in the 
biobank of the institute of Dermatology of the University 
Hospital of Zürich. Germline DNA from PBMCs was 
sequenced for all patients if available as a reference [20]. 
DNA from paraffin blocks was isolated using    the 
FFPE DNA isolation kit from Qiagen (QIAamp DNA FFPE 
Tissue Kit #56404) and optimized protocols developed by 
Ultan McDermott at the Sanger institute. Prior to DNA 
isolation, each block was evaluated by a trained dermato- 
histopathologist, and punches were made in tumor regions 
to ensure reduced contamination with stromal tissue. 
For DNA isolation from non-paraffin embedded 
samples we followed standard DNA isolation protocols 
published earlier. 
 
Library preparation and sequencing 
 
DNA quality was measured by an Agilent 2100 
Bioanalyzer  or  Agilent  2200  Tapestation.  One   to 
three ug of high quality DNA was used to prepare the 
whole exome library using the Agilent SureSelect V4 or V5 
kit. Sequencing was performed on an Illumina Hiseq 2000 
machine in the Functional Genomics Center at University 
of Zürich. For the whole exome sequencing we sequenced 
0.25 lanes per sample, paired-end, with 100 bp reads. 
 
Whole exome sequencing analysis 
 
Bioinformatics analysis was conducted with a 
modified GATK pipeline [21–23]. Quality control was 
done with „FASTQC” [24]. Alignment of the FASTQ 
file to the reference genome “hg19” [25] Lander, Linton 
et al. 2001) and transformation from  SAM  to  BAM 
was done with “BWA” [26]. PCR duplicates were 
marked by MarkDuplicates from “Picard” [22], Local 
realignment around indels with RealignerTargetCreator 
(GATK), realigning with IndelRealigner (GATK), fix 
mate information with FixMateInformation (Picard), 
base quality score recalibration with Baserecalibrator 
(GATK) and PrintReads (GATK). Variant calling was 
done with UnifiedGenotyper (GATK). For annotation of 
the VCF files we used Annovar [27], Samtools [28] and 
Bedtools [29]. For data interpretation we used Microsoft 
Access, Microsoft Excel, Venny [30], ConSet [31] and 
IGV [32, 33]. 
For copy number analysis we used Excavator [34] 
and Contra [35], results were visualized with Circos [36]. 
SNVs were filtered according to the following read 
count criteria: A base must have at least four mutant reads 
and at least 10 total reads, if less than 10 total reads, at 
least half of them must be mutated. Also all SNVs with 
a  phred-scaled  quality  score  of  <  50  were    excluded 
from further analysis. A SNV was called somatic if the 
unfiltered blood sample from the same patient did not 
show any mutant read for this position. 
Mutant allele ratios (MAR) were calculated by 
dividing mutant read counts by total read counts for each 
called SNV. Frequencies for these ratios were calculated 
and trendlines were plotted in Excel with the Moving 
Average method (period: 3). To reduce the number of 
false positive SNVs we applied more strict filtering on 
the private SNVs. Quality threshold was raised to a phred 
score of 100, and the SNV needed to have at least 10 total 
reads. Genes that had more than 8 SNVs were excluded. 
 
Deep sequencing of PCR amplicons containing 
NRAS exon 2 
DNA of 7 tumor samples (EMG P5 cell culture, 
M121224, 401/II, 404/II, 403, H12.684, H12.12640/1/B) 
were amplified with primers containing  a  NRAS 
specific sequence (see chapter sanger sequencing), 
adaptor sequences and a unique multiplex-identifier 
(MID) sequence (according to eurofins protocol). Each 
tumor sample analyzed is carrying therefore the adaptor 
sequence and a unique MID sequence. The PCR product 
was gel purified and 200 ng of each amplicon was sending 
for deep sequencing. Amplicons were subjected to Roche 
454 sequencing using emulsions-PCR. Data were analyzed 




After DNA amplification of NRAS and 
BRAF with the following primers: BRAF forward: 
5ʹCTAAGAGGAAAGATG     AAGTACTATG     reverse: 
5ʹCTAGTAACTCAGCAGCATCTCAG  NRAS forward: 
5ʹGATAGGCAGAAATGGGCTTGA reverse: 5ʹATCAT 
CCTTTCAGAGAAAATAATGC using a touchdown 
program going from 60 C to 55 C in 10 cycles, followed 
by 40 cycles at 55 C, the PCR product was diluted 100× 
and send to Microsynth for sequencing. 
 
Generation of single cell clones and single cell 
clone sequencing 
Cells were distributed over 96-well plate, containing 
1 cell per well, via FACS cell sorting or serial dilutions. 
Cells were grown for several weeks under standard 
conditions [18] until visible colonies had formed. Then, 
medium was removed and wells  were  washed  with 
PBS. Colonies  were  directly  lysed  in  the  well,  with 
10 ul lysis buffer (2.5% 1 M Tris pH 8.0 (Ambion), 0.1% 
1.5 M EDTA (Sigma-Alderich), 0.25% Tween 20 (Sigma- 
Alderich), 1% proteinase K (Qiagen), Aqua dest.), and 
incubated at 55°C for 1 hour, followed by 5 min at 95°C. 
Afterwards, 10 ul 25 mM MgCl2 was added and the total 
volume was devided over 2 PCR reactions for NRAS and 





Around 1 × 107 melanoma cells were resuspended in 
100 µl FACS buffer (1% FBS, 5 mM EDTA pH 8, 0.01% 
NaN /ddH O in PBS). Cells were incubated for 20 minutes 
available at http://www.combosyn.com/index.html. We 
have taken the mean of the raw CI values for the different 
concentration combinations,  in  order  to  determine  it 
as overall synergistic (CI value < 0.9) or overall not 
synergistic (CI value > 0.9). 
3 2 
at 4°C with the following photosensitive antibodies: Anti- 
human MCSP-FITC (1:20 dilution) (Miltenyi Biotec 130- 
098-794, Bergisch Gladbach Germany) and Anti-human 
Fibroblasts/Epithelial-PE (1:200 dilution) (ABIN319868, 
Aachen Germany). After washing, cells were resuspended 
in 200 µl FACS buffer and sorted using the Aria IIb (BD 




Maximum Parsimony, Bayesian and Maximum 
likelihood (ML) phylogenies were constructed with the 
POSIX-threads version of RAxML v8.0.19 (7). To correct 
for among-site rate heterogeneity using the Γ distribution, 
we used an ascertainment bias correction and a general 
time reversible (GTR) substitution model. Four rate 
categories (ASC_GTRGAMMA model) were used to 
calculate the optimal tree. Node support was evaluated 
with 100 nonparametric bootstrap pseudoreplicates, they 
therefore indicate the percentage of bootstrap trees that 
contained a given internode branch. 
Variants  diagnostic for a given clade are  defined 
as existing solely in that clade  and  nowhere  else  for 
that position. All leaves emanating from the node in 
question must share a variant and all other leaves must 
contain a different character for a variant to be diagnostic. 
Diagnostic variants can therefore also be termed an 
apomorphy. 
 
Cell viability assay 
 
1   ×   104   cells   were   seeded   and   treated   for 
72 hours with different concentrations of either a BRAF 
inhibitor (PLX4032, LGX818 or GSK2118436), a MEK 
inhibitor (MEK162), an ERK inhibitor (SCH772984). 
DMSO   treatment   was   used    as    a    control. After 
72 hours, the medium was removed and fresh RPMI1640 
supplemented with 10% FCS and 8% MTT reagent 
(Sigma, 5 mg/ml in PBS) was added, and  the  cells 
were incubated at 37°C. After 1 hour, the RPMI1640 
with MTT reagent was removed and 10% SDS (Sigma) 
and 95% isopropanol/ 5% Formic Acid (Sigma) (ratio 
1:1) were added. After 5 min of incubation at 37°C, 
absorbance was measured at 595 nm (reference 620 nm) 




Combination treatments and subsequent calculation 
of synergy were carried out according to the  method 




5 × 104 cells/ml were seeded per T75 flask. After 
24 hours, 72 hours, 144 hours and 240 hours the cells 
were counted. From the linear growth fase, the doubling 





Total protein was collected by washing cells twice 
with ice cold PBS and subsequent lysis in RIPA buffer 
(20 mM Tris-HCl (pH 7.5), 1% Triton X-100 (Sigma), 
137 mM NaCl, 10% glycerol and protease inhibitors 
(Roche)). Concentration of the protein was measured 
with the Bio-Rad Dc Protein Assay (Bio-Rad, Hercules, 
CA, USA) according to the manufacturer’s protocol. 
SDS-Page was used to separate the proteins, after which 
they were transferred onto a nitrocellulose membrane. 
Membranes were probed with a rabbit anti-pERK 
antibody (Cell Signaling, product nr #4376S), a rabbit 
anti-ERK antibody (Cell Signalling, product nr#9102) 
and a rabbit anti-GAPDH antibody (Abcam, Cambridge, 
UK, product nr ab9385), followed by horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz, 
product nr sc-2030)Bound antibodies were detected using 
chemiluminescence (ECL, GE Healthcare, Chalfont St. 
Giles, UK). Afterwards, band intensity was measured 
using ImageJ software (imagej.nih.gov/ij/) and pERK 
band intensity was corrected for corresponding GAPDH 
band intensity. 
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IRS1 is not a general mechanism of MEK inhibitor resistance in NRAS mutated melanoma 
Abstract 
NRAS mutated melanoma patients quickly develop resistance to MEK inhibitor therapy, which is the 
only targeted therapy that is available for this patient group. Few other therapeutic options, besides 
immunotherapy, are available for these patients. As IRS1 was found to be a mechanism of BRAF 
inhibitor resistance in BRAF mutated melanomas, and inhibition of IRS1 resulted in cell death in 
these tumors, we wondered if IRS1 inhibition would also be a good option for NRAS mutated 
tumors. Therefore, we identified 18   NRAS-mutated melanoma cell cultures from our biobank, 
performed RNA-sequencing, and confirmed that 9 were resistant to MEK inhibition. High IRS1 
expression was associated with MEK inhibitor resistance, although it was not a direct cause of 
resistance. This set included multiple paired cell culture, in which inhibition of IRS1 through  siRNA 
knockdown or a small molecule targeting  IRS1 of the top 5 high IRS1 expressing cells resulted in 
reduced viability in 1 cell culture, but not in a paired low-IRS1 expressing MEKi-sensitive cell culture 
from the same patient.  We found that this reduced viability was independent of the PI3K-AKT 
pathway. Furthermore, this resistant cell culture had an MEKi dependent upregulation of pAKT, 
however, inhibition of pAKT via PI3K or AKT inhibitors did not reduce viability.   
 
Introduction 
Around 15-20% of melanoma patients have activating NRAS mutations. RAS is a GDP/GTP regulated 
kinase, which switches from an inactive, GDP bound state to an active, GTP bound state. In mutated 
forms of RAS, the protein is kept in a GTP-bound active state [1-5]. Other RAS isoforms besides NRAS 
are HRAS,KRAS4A, and KRAS4B,  with each being expressed in different tissues and in various stages 
of development, while NRAS is the most frequent RAS isoform in melanoma [6].  
Unlike the successful targeting of BRAF mutated tumors with BRAF inhibitors, efforts over the past 
30 years to generate specific RAS inhibitors have failed. The only way to target RAS mutated tumors 
to date, is by inhibiting downstream effectors, which in the case of NRAS mutated melanoma is 
inhibiting the MAPK pathway by MEK inhibitors (MEKi). Unfortunately, NRAS mutated melanoma 
patients treated with MEKi rapidly develop therapeutic resistance. Resistance mechanisms to MEKi 
therapy have not been as extensively investigated as resistance to BRAF inhibitor therapy, but a 
likely possibility is that mutated NRAS can signal through effector pathways other than the MAPK 
kinase pathway.    
Downstream signaling effectors of RAS, which play a role in the oncogenesis induced by 
constitutively active RAS, include RAF in the MAPK pathway [7], PI3K in the PI3K-AKT pathway [8] 
and RalGEFs in the RalGEF-Ral cascade [9-11]. Other effectors with less well studied roles in 
oncogenesis are the RacGEF Tiam1 [12], PLCε [13] and members of the RASSF family, which have a 
role in RAS mediated apoptosis [14]. 
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. IRS1 is a signaling adapter molecule that transmits signals from IGFR to downstream signaling 
pathways, mainly the PI3K-AKT pathway and the MAPK pathway. Upregulation of IRS1 was found to 
be a mechanism of resistance for BRAF mutated tumors treated with BRAF inhibitors, and targeting 
IRS1 in these cell lines with small molecules resulted in significant cell death [15].We wondered if 
IRS1 inhibition could be a potential target for NRAS mutated melanoma and therefore we identified 
18 NRAS mutated cell cultures from our biobank, which included patients who had been treated and 
those who had not been treated with a MEK inhibitor. We performed RNA-sequencing of these cells 
and tested their sensitivity to MEK162 treatment. We found that high IRS1 expression was 
associated with MEK162 resistance in vitro. However, in general siRNA mediated knockdown of IRS1 
in the resistant cell cultures and transient overexpression of IRS1 in the sensitive cultures did not 
induce sensitivity or resistance, respectively, for MEK162 treatment, indicating that high IRS1 
expression is not a direct cause of resistance in most of these cells. However, in the cell culture with 
the highest expression of IRS1, and independent of MEK162 treatment, siRNA mediated knockdown 
of IRS1 decreased viability. We therefore tested the drug NT157, which has been published to inhibit 
IRS1, and we found that this high-IRS1 expressing cell culture was also sensitive to NT157.  We found 
that NT157 targets IRS1 through phosphorylation of S1101 and S612, but this does not result in 
inhibition of the  PI3K-AKT pathway, which is the best studied downstream effector pathway of IRS1. 
In order to investigate the role of IRS1 in MEKi resistance, we examined other NRAS-mutated, low-
IRS1 expressing melanoma cells derived from the same patient as the high-expressing cultures. We 
found that all of these cell cultures were sensitive to MEKi therapy, had low levels of IRS1 
expression, and were resistant to NT157 treatment. Co-treatment of NT157 with MEK162 was 
antagonistic, which underscored the fact that a thorough understanding of the action of each drug 
and the interaction of different drugs is vital in order to make rational combinations that might 
ultimately benefit a patient.   
 
Results 
High IRS1 expressing melanoma cells are resistant to MEK-inhibitor treatment 
We generated and analyzed 18 NRAS-mutated cell cultures from consenting patients treated or not 
treated with MEK inhibitor therapy. We found that 9 cell cultures were sensitive (i.e. IC50 < 100 nM 
MEK162) and 9 cultures were resistant (i.e. IC50>100 nM MEK162), as determined by in vitro cell 
viability assays. We performed RNA sequencing of these cultures and clustered them for in vitro 
MEKi sensitivity or resistance (Figure 1).  We found high IRS1 expression was associated with in vitro 
MEK162 resistance and that the cell cultures with the highest IRS1 expression were resistant to 
MEK162 (Figure 2A).  
siRNA mediated knockdown of IRS1 or treatment with NT157 decreases viability in one of the five 
highest IRS1 expressing cells 
We went on to check the dependency of IRS1 in the 5 cell cultures with the highest IRS1 expression, 
as well as to test if high IRS1 expression was a direct cause of MEK162 resistance, by siRNA mediated 
knockdown of IRS1. We found that knockdown of IRS1 does decrease viability in the cell culture with 
the highest IRS1 expression (Figure 2B), but not in the other 4 cell cultures. For none of the cell 
cultures did IRS1 knock-down sensitize the cells to MEK162 treatment (Figure 2C). We next tested if 
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introducing IRS1 in a MEK162 sensitive cell culture with low expression of IRS1 can induce resistance 
to MEK162 treatment. We transfected M130429 (a MEK162 sensitive cell culture obtained from the 
same patient as M130219) with a transient GFP tagged IRS1 overexpression construct. We found 
that overexpression of IRS1 does not lead to MEK162 resistance in this cell culture (data not shown). 
We went on to test if the cell cultures with high IRS1 expression are sensitive to treatment with 
NT157, which is an IRS1 inhibitor that works by ERK dependent degradation of IRS1 following 
increased inhibitory Serine phosphorylation of IRS1. Consistent with the siRNA results, we found that 
the cell culture with the highest IRS1 expression, M130219, was sensitive to NT157, whereas the 
other 4 cell cultures were resistant (Figure 2D).  
IRS1-mediated MEKi resistance in M130219 melanoma cells is independent of PI3K-AKT signaling 
We next tested if high IRS1 expression led to increased PI3K-AKT signaling in the 5 high IRS1 
expressing cells compared to a cell culture with low IRS1 expression. IRS1 expression was not 
associated with AKT pathway activity (Figure 3A). We next evaluated the phosphorylation of IRS1 
Tyr612 in the cell cultures, as this phosphorylation site resembles active IRS1, which signals through 
PI3K-AKT. We only found this site to be phosphorylated in cell culture MM070221; however, this cell 
culture did not have high phosphorylation of AKT (Figure 3A and 3B). Furthermore, we found that 
the cell culture M130219, which was sensitive to NT157 treatment, was resistant for AKT inhibition 
and intermediately resistant to PI3K inhibition (Figure 5C). In addition, we noticed that 
administration of a PI3K inhibitor to M130219 completely prevented phosphorylation of AKT, 
whereas inhibition of IRS1 with NT157, which would be upstream of PI3K, does not prevent the 
phosphorylation of AKT (Figure 3C). Similarly, administration of Rapamycin led to increased 
phosphorylation of AKT through a positive feedback loop by which inhibition of mTOR by rapamycin 
leads to an inhibition of S6K, which results in activation of IRS1 and PI3K (by a reduction of the 
normal inhibitory effect of S6K on IRS) [16]. Combination treatment of Rapamycin and a PI3K 
inhibitor could prevent the phosphorylation of AKT, however, combination treatment of Rapamycin 
with NT157 was not able to block the phosphorylation of AKT (Figure 3C). As a final proof that NT157 
did not interfere with PI3K-AKT signaling, we treated M130219 cells with soluble IGF1, which is a 
substrate for the IGFR, and we observed an increase in phosphorylated AKT at 20 min and 1 hour 
after IGF1 addition. This was seen to the same extent in the control and in the NT157 treated cells, 
whereas in the IRS1 siRNA knockdown cells this increase in AKT phosphorylation was inhibited 
(Figure 3D).    
IRS1 blockade increases inhibitory Ser phosphorylation of IRS1 in M130219 melanoma cells and 
not STAT3 inhibition 
We next analyzed the effect of NT157 on IRS1 and observed a dose dependent increase in inhibitory 
Ser phosphorylation of IRS1 upon NT157 treatment as previously described [15]; however, we did 
not observe a subsequent degradation of IRS1 protein (Figure 4A).  
In a recent publication, it was shown that STAT3 is also a target of NT157, in which NT157 decreases 
phosphorylation of STAT3. When we compared STAT3 expression in our cohort of RNA sequenced 
cell lines, the NT157-sensitive culture M130219 had an average expression of STAT3. Furthermore, 
there was no difference in STAT3 expression between the cohort of NRAS-mutated, high-IRS1 
expressing cells that were resistant to NT157 treatment and the cell line M130219 which was 
sensitive to NT157. When we treated M130219 with NT157, we could not see a reduction in STAT3 
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phosphorylation (Figure 4B), nor did treating M130219 with a STAT3 inhibitor result in decreased 
viability, as compared to cell cultures that were resistant to NT157 treatment (Figure 4C). Thus, we 
concluded that the sensitivity of M130219 to NT157 was not dependent on STAT3 inhibition. 
Different cell cultures retrieved from different tumor sites from the same MEK162 resistant 
patient showed different responses on MAPK pathway inhibitor therapy and PI3K pathway 
inhibitor therapyFrom the same MEK inhibitor resistant patient where M130219 was derived from, 
we had generated 9 cell cultures from 9 different biopsies from multiple tumor locations during 
MEK162 treatment (M130219) and at autopsy post-resistance (M130420, M140404, M130421, 
M130428, M130425, M130429, M130427 and M130426) (Figure 5 A and B). We decided to study 
those in more detail in order to find a possible mechanism for MEK162 resistance as well as to see 
whether NT157 treatment would have likely benefitted this patient. We found that, in vitro, all the 
other cell cultures obtained at autopsy were sensitive for MEK and ERK inhibition. The different cell 
cultures also showed heterogeneity in their response on inhibitors of the PI3K pathway (Figure 5C). 
Notably, all samples were resistant for NT157, apart from M130219 (Figure 5D). When we treated 
the cell cultures with a combination of NT157 and MEK162, we found that these drugs antagonize 
each other, which is unwanted. Triple therapy with NT157, MEK162 and a PI3K inhibitor could 
prevent this antagonistic effect (Figure 5E). 
Whole exome sequencing and RNA sequencing does not identify known genetic resistance 
mechanisms or substantial differences between the different cell lines 
We next analyzed the genomic mutations in M130219 and the other cell cultures from the same 
patient by whole exome sequencing. In all cell cultures we found the following melanoma driver 
mutations: NRAS Q61R, MITF E318K and a CDKN2A loss. In total, 152 mutations were identified, 
which had more than 10x coverage for that coordinate across all samples including the germline, for 
which two or more variant callers supported it (of mutect, varscan, multiSNV and indelgenotyper), 
that didn’t overlap with repetitive regions and that were not present in the 1000 genome project or 
EVS databases. Of these 152 mutations, only two genes were found to be mutated in M130219 and 
not in the other cell cultures: SOS2 and GCOM1. However, these mutations we could not find in the 
RNA sequencing, suggesting that the mutant allele was not expressed. 
The resistant cell culture M130219 has a mesenchymal transcription profile and an upregulation of 
multiple RTKs compared to the sensitive cell cultures 
In addition to the difference of IRS1 expression in M130219 compared to the others (Figure), we 
looked for other transcriptional differences between the cell cultures that could explain the 
resistance to MAPK pathway inhibitors of M130219. By geneset enrichment analysis, we found that 
M130219 has a more mesenchymal signature compared to the sensitive cell cultures, which are 
more melanocytic (suppl. Table 1). Furthermore, we found that M130219 has multiple RTKs 
upregulated, however, M130219 was resistant to inhibitors targeting those RTKs (Suppl figure 1).  
 
Discussion 
We have shown that high IRS1 expression is associated with MEK162 resistance in the 18 NRAS 
mutated melanoma cell cultures we have tested. However, based on experiments with siRNA 
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mediated knockdown of IRS1, and unlike in BRAF-inhibitor resistant cells, we conclude that IRS1 is 
not generally sufficient for MEK162 resistance. Nevertheless, in the cell culture with the highest IRS1 
expression, knockdown of IRS1 independent of MEK162 treatment caused a decrease in cell viability, 
suggesting that this cell culture is dependent on IRS1 expression and/or the pathway through which 
IRS1 is signaling. However, this pathway is not the usual IRS1 target PI3K-AKT pathway, as the basal 
phosphorylation of AKT was very low in this cell culture, as well as IRS1 pTyr612, suggesting a low 
activity of the PI3K pathway. Treatment with a PI3K or AKT inhibitor did not decrease viability. 
Consistent with the siRNA data, treatment with NT157, an IRS1 inhibitor, decreased viability in the 
high-IRS1 expressing cell culture which also was responsive to siRNA mediated knockdown, but not 
in the other melanoma cultures. Furthermore, NT157 acts on IRS1, as indicated by the increased 
Serine phosphorylation upon treatment. NT157 did not act via the PI3K-AKT pathway, as stimulation 
with IGF1 during NT157 treatment still increased phosphorylation of AKT. These findings are 
consistent with Song et al, who showed that IRS1 phosphorylation at Serine 1101 does not interfere 
with IRS1 signaling via the PI3K-AKT pathway [17].      
Although both the knockdown and inhibitor experiments suggest that IRS1 is playing an important 
role in MEKi-resistance in M130219 cells, the pathway or mechanism in which IRS1 exerts is effect 
needs further investigation. Known IRS1 targets other than PI3K include SHP-2 [18], Grb-2 [19, 20], 
Fyn [21], Nck [22] and Crk [23], but, these downstream effectors are typically recruited by IRS1 
phosphorylation on tyrosine residues. On the contrary, increased phosphorylation of serine residues 
on IRS1 has been associated with facilitation of interaction with integrins [24, 25]. In neurons, 
increased serine phosphorylation of IRS1 upon TNFa treatment leads to increased binding of integrin 
b1 to IRS1, which results in reduced development and stability of neuronal processes and reduced 
attachment to collagen IV [25]. From the 18 NRAS mutated cell cultures that were analyzed by RNA-
seq, M130219 had the highest expression of ITGA1, ITGA11, ITGA8 and ITGB2. However, a scenario 
where increased IRS1 Serine phosphorylation upon NT157 treatment leads to increased integrin 
binding, thereby reducing cell viability, cannot explain why reduced cell viability is also observed in 
siRNA mediated knockdown of IRS1. Nevertheless, it would be interesting to test the effect of TNFa 
on M130219 as well as perform 3D spheroid cultures and invasion assays under NT157 treatment, to 
see if integrins play a role in M130219.  
Especially Serine 1101 is hyper-phosphorylated upon NT157 treatment, Song et al has shown that 
Pim-kinase is responsible for the phosphorylation of IRS1 Serine 1101 and that a pan-PIM inhibitor 
inhibits this phosphorylation [17]. It would be interesting to see if treatment with NT157 leads to an 
increased expression of Pim, which could explain the increased phosphorylation at Serine 1101 upon 
NT157 treatment. Furthermore, in order to test whether this phosphorylation is the mode of action 
of NT157, one could do combination treatment with NT157 and a pan-PIM inhibitor.   
Serine 1101 is positioned in the SHP2 domain of IRS1 [26]. SHP2 is a tyrosine phosphatase and Luo et 
al has shown that phosphorylation of IRS1 on S1223, which is also in the SHP2 domain, interferes 
with the recruitment of SHP2, leading to increased tyrosine phosphorylation of IRS1 [27]. We have 
evaluated the phosphorylation of Tyrosine 612, located in the PI3K domain, which was low at 
baseline and unaltered upon NT157 treatment. However, other tyrosine phosphorylation sites 





Material and Methods 
Patient and sample preparation 
Surplus material, collected during or after therapy and at autopsy, was used from patients who had 
given written consent according to ethical approval numbers 647 and 800.  Primary cell cultures 
were generated and kept under standard conditions (i.e. without drug treatment) as described in 
[28].  
Cell viability 
Cell viability was measured with the assay described in [29]. Drugs tested in different doses were 
those targeting the MAPK pathway (MEK (MEK162) and ERK (SCH772984) inhibitors) and the PI3K 
pathway (PI3K (GDC-0941), AKT (GSK690693) and mTOR (Rapamycin) inhibitors), as well as the IRS1 
inhibitor NT157. 
DNA preparation and Exome sequencing 
From all cell cultures, DNA was prepared using QiAmp DNA blood mini kit (Qiagen), according to the 
manufacturers’ instructions. Library preparation, sequencing and subsequent analysis were done as 
described in [29]. 
RNA preparation and RNA sequencing 
RNA was isolated with the QIAGEN RNeasy Mini kit (74104, QIAGEN, Venlo, Netherlands). RNA-seq 
libraries were prepared using poly(A) enrichment and sequenced on a HiSeq4000. Raw reads were 
aligned to hg38 and gene counts with gencode v22 using STAR [30] aligner. Gene counts were 
normalized with edgeR [31] and differential expression performed with limma voom [32].  
Westernblot 
Protein isolation, sample preparation and westernblot was done as described in (cite reference 2). 
Membranes were probed with a rabbit total IRS1 antibody (Sigma Alderich), a rabbit anti-pERK 
antibody (Cell signaling, product #4376), a rabbit anti-pAKT Ser473 antibody (Cell signaling, product 
#9271), different rabbit IRS1 antibodies (from the IRS-1 inhibition antibody sampler kit, cell signaling, 
product #12879) , a rabbit pSTAT3 Tyr705 antibody (cell signaling, product #9131) and a rabbit anti-
GAPDH antibody (Cell signaling, product #2118), followed by horseradish peroxidase-conjugated 
goat anti-rabbit IgG (Santa Cruz, product sc-2030). As a detection reagent ECL (..) was used and blots 
were developed using .   
siRNA of IRS1 
Cells were seeded at 90% confluency in T25 cell culture flasks (Falcon). The following day, the 
medium in the flasks was changed to DMEM with 10% FCS and cells were transfected with a mixture 
of DMEM, interferrin and a final concentration of 20 nM siRNA IRS1 or siRNA allstars negative 
control. After 24 hours, the transfection medium was removed and cells were trypsinized and 
seeded for the subsequent experiments. 
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Transient overexpression of IRS1 
Cells were seeded in 90% confluency in T75 cell culture flask (Falcon). The following day, medium 
was refreshed to DMEM with 10% FCS and cells were transfected using a mixture of . After 6 hours 
of transfection, medium was refreshed to standard culture medium (reference 1). 48 hours post 
transfection, cells were sorted, using the FACS… sorter on GFP positive and GFP negative cells. These 
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Figure 1: Heatmap clustered for MEK inhibitor sensitive and resistant cells 




Figure 2: high IRS1 expression correlates with MEK162 resistance in NRAS mutated melanoma but is not a direct cause of 
resistance 
A: Viability under MEK162 resistance of the top 5 high IRS1 expressing NRAS mutated melanoma cells compared to a MEK162 
sensitive cell culture with low IRS1 expression (M130429) 
B: Viability of high IRS1 expressing cells with siRNA mediated IRS1 knockdown 
C: Viability of high IRS1 expressing cells with siRNA mediated IRS1 knockdown under MEK162 treatment 
D: Viability of high IRS1 expressing cells under NT157 (IRS1 inhibitor) treatment 
50
Figure 3: The dependency of M13019 on IRS1 is not mediated by signaling through the PI3K-AKT pathway 
A: Westernblot showing the expression of pAKT and pERK under standard conditions and under MEK162 treatment in high IRS1 
expressing NRAS mutated melanoma cells 
B: Westernblot showing the expression of total IRS1 and of active IRS1 Tyr612 in high IRS1 expressing NRAS mutated melanoma 
cells 
C: Westernblot showing pAKT and pERK under various treatment conditions in M130219 
D: Westernblot showing total IRS1 and pAKT under IGF1 treatment in NT157 treated compared to siRNA mediated IRS1 
knockdown treated M130219 
51
Figure 4: NT157 increases Ser phosphorylation of IRS1 and does not have an effect on pSTAT3 in M130219 
A: Westernblot showing Ser1101, Ser612 and Ser636/696 phosphorylation of IRS1 under various dosages and timepoints of 
NT157 treatment 
B: Westernblot showing pSTAT3 under NT157 treatment in M130219 
C: Viability of M130219 compared to two low IRS1 expressing, NT157 resistant cell cultures (M130421 and M130425) under 
STAT3 inhibitor treatment 
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Figure 5: Different cell cultures retrieved from different tumor sites from the same MEK162 resistant patient showed different 
responses on MAPK pathway inhibitor therapy and PI3K pathway inhibitor therapy 
A and B: Multiple cell cultures were generated from different tumor sites from the same MEK162 resistant, NRAS mutated 
patient 
C: Viability assays of different MAPK and PI3K-AKT pathway inhibitors on different cell cultures from the same patient 
D: Viability assay of different cells cultures treated with NT157 
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Melanoma immunotherapy: historical precedents, 




The idea of cancer immunotherapy has been around for more than a century; however, the first 
immunotherapeutic ipilimumab, an anti-CTLA-4 antibody, has only recently been approved by the US 
FDA for melanoma. With an increasing understanding of the immune response, it is expected that more 
therapies will follow. This review aims to provide a general overview of immunotherapy in melanoma. 
We first explain the development of cancer immunotherapy more than a century ago and the general 
opinions about it over time. This is followed by a general overview of the immune reaction in order to 
give insight into the possible targets for therapy. Finally, we will discuss the current therapies for melanoma, 
their shortcomings and why it is important to develop patient stratification criteria. We conclude with an 
overview of recent discoveries and possible future therapies. 
 
KEYWORDS: cancer immunotherapy n cancer testis antigens n Canvaxin™ n CTLA‑ 4 
n immunotherapy n interferon n melanoma n PD ‑ 1 n T‑ cell therapy n vaccines 
 
 
History of cancer immunotherapy 
In 1890, a surgeon in New York City, named 
William Coley, directly injected streptococcal 
bacteria into the inoperable tumors of cancer 
patients in order to induce an immune response 
to combat tumors. He had some notable successes 
in regressing tumors, which were published in 
1893 [1–3]. This was the first demonstration in 
medical literature that the immune system could 
be used to kill cancer cells and was subsequently 
applied to hundreds of cancer patients by Coley 
for the rest of his career. 
However, during this time, immunotherapy 
was not considered to be a serious cancer therapy, 
as  Coley’s  successes  were  sporadic,  difficult 
to  reproduce  and  lacked  a  solid  theoretical 
foundation. In a major review published in 1929, 
WH Woglom even wrote that “it would be as 
difficult to reject the right ear and leave the left 
ear intact as it is to immunize against cancer” 
[4]. Further rejection of cancer immunotherapy 
came following the discovery that, during the 
development of the immune system in prenatal 
life, lymphocytes that react to self-tissues are 
destroyed  [5] .  Therefore,  the  combination 
of  unconvincing  clinical  data  and  a  general 
paradigm in which immune cells were incapable 
of recognizing any self-tissue prevented progress 
in cancer immunotherapy for several decades. 
A few exceptions to this trend occurred in 
the 1950s, when tumors were discovered to be 
recognized by the immune system [6–9] and in the 
1960s, when Burnet proposed that lymphocytes 
continuously checked tissues for transformed cells 
to destroy, probably through the recognition of 
tumor-associated antigens [10]. A similar theory 
had already been proposed in 1909 by Ehrlich [11]; 
however, the theory did not receive much support, 
as several experiments (of which later the validity 
was questioned) showed contradictory evidence. 
Thus, until the 1980s, cancer immunotherapy 
was considered to be ineffective and irreproducible. 
However, three discoveries in the mid-1990s 
changed the prospects of cancer immunotherapy. 
First, it became clear that some autoreactive T cells 
can be found in the blood, which theoretically 
could be directed against transformed self-cells 
[12–14]. Second, immunogenic cancer antigens 
were discovered [15–19], suggesting that they may 
be recognized and cleared by the immune system. 
Finally, malignant cells were shown to be highly 
genetically unstable [20,21]. This genetic instability 
could produce cancer-specific epitopes on the cell 
surface  that  might  distinguish  cancerous from 
normal cells. 
Most convincingly, in 1995 it was demonstrated 
that dendritic cells can induce tumor-specific 
T-cell immunity and regression of melanoma 
metastases when appropriately activated and 
reinjected [22–25]. Lastly, immunocompromised 
mice were observed to have a higher incidence 
of carcinogen-induced tumors [26]. This, together 
with further proof that both the adaptive and 
innate immune systems play a role in eliminating 
tumors [27], has put immunotherapy back on the 
list of potential anticancer therapies. 
Since  the  early  1990s,  researchers  have 
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immune system, some of which were successful 
and some less so, depending on the cancer type 
(for a historical overview see [28]). Melanoma in 
particular is a highly immunogenic tumor, as was 
confirmed in 1999 after a study identified cir- 
culating T cells that could specifically recognize 
tumor-associated antigens on melanoma cells 
[29]. Therefore, many attempts to induce an 
immune response against cancer have been 
tested in melanoma. An extensive overview of 
these studies can be found in the review from 
Zeiser et al. [30]. 
 
 
The immune reaction 
In  order  to  induce  an  antitumor  immune 
response,  specialized  APCs,  called  dendritic 
cells (DCs), have to process antigens from the 
tumor and present them to naive T cells (Figure 1). 
Products  of  mutated  or  nonmutated  genes 
expressed specifically by tumors (e.g., cancer- 
testis antigens [CT-antigens]), as well as differen- 
tiation antigens specific for the cancer’s tissue of 
origin (e.g., melanocytic differentiation antigens) 
can all serve as tumor antigens [31]. Each type 
of antigen has advantages and disadvantages. 
Products of mutated genes will be exclusively 
expressed by tumor cells, therefore reducing the 
risk of autoimmunity; however, as they are also 
patient specific, they cannot be translated to a 
broader group and may exhibit a high degree of 
heterogeneity within each patient. CT-antigens, 
on the other hand, are normally only expressed in 
the testis, where the blood–testis barrier prevents 
the entrance of immunologic cells [32] and are re- 
expressed in many cancers. Hence, the presence 
of T cells directed against CT-antigens will not 
induce autoimmunity, since these genes are not 
normally expressed in adult somatic tissues. One 
example of CT-antigens used in cancer therapy 
for melanoma and ovarian cancer showed that 
vaccination for NY-ESO-1 resulted in the gen- 
eration of T cells directed against NY-ESO-1, 
with  a  favorable  clinical  response  in  some 
patients [33]. Melanocytic differentiation anti- 
gens are also expressed by normal melanocytes; 
therefore vaccination with these antigens could 
lead to autoimmune-induced pigmentation loss 
(vitiligo) [34]. DCs can directly obtain and pro- 
cess antigens from the tumor as demonstrated by 
the discovery of tumor-infiltrating T cells (TILs) 
in some cancer patients (i.e., those with a better 
prognosis) [35]. The antigens could also be deliv- 
ered via a therapeutic vaccine. These antigens can 
be in the form of synthetic peptides or proteins, 
tumor-cell lysates, or antigen-encoding DNA or 
RNA in viral vectors. 
In order to be activated upon capture and 
antigen presentation, DCs must receive an 
immunogenic maturation stimulus, such as 
microbial peptides or proinflammatory cytokines; 
without such a stimulus, an opposite reaction 
will induce tolerance by T-cell deletion and/or 
the production of Tregs [36–39]. Immunogenic 
maturation signals not only can be derived 
from necrotic tumor cells, but also can be 
therapeutically administered. DC maturation is 
induced by activated pattern recognition receptors 
such as Toll-like receptors, therefore, Toll-like 
receptor ligands or agonist antibodies may be 
used to stimulate the DCs. Such stimulated DCs 
will process the captured antigen and present it 
on MHC class II molecules, at which point they 
are transported to the draining lymph node, 
interact with T cells and induce an immune 
response. 
Effective  interaction  of  the  MHC/antigen 
molecule with the T-cell receptor (TCR) requires 
a costimulatory signal in the form of either plasma 
membrane ligands on the DC that interacts with 
stimulatory or inhibitory receptors on the T cell, 
or in the form of secreted cytokines [40]. Several 
costimulatory  and  inhibitory  molecules  have 
been  identified,  of  which  CD28  has  received 
the most attention. CD28 encodes the primary 
costimulatory receptor expressed on T cells that 
is required for a rapid T-cell response. Recent 
research on the therapeutic potential of this protein 
is a cautionary tale of how direct modulation of 
the immune response can have dramatic and 
unexpected consequences in human patients. A 
CD28 superagonist immunomodulatory drug 
(TGN1412) that was developed to activate the 
immune response in B-cell chronic lymphocytic 
leukemia  patients  resulted  in  a  massive  and 
potentially   lethal   cytokine   storm   within 
12–16  h  after  administration  of  the  drug  in 
human volunteers and the trial was immediately 
terminated  [41].  The  unexpected  and  severe 
reaction  to  this  CD28  agonist  suggests  that 
therapeutics designed to harness the immune 
response  to  fight  cancer  must  proceed  with 
extreme caution in order to ensure controlled and 
specific targeting of cancer cells. 
Not only must effective cancer immuno- 
therapies be predicated on a thorough under- 
standing of normal immune functions, but the 
mechanisms that cancer cells employ to evade 
immunoregulation may also provide clues as to 
how to better modulate the immune response. 
In cancer, after the T cells have been activated 
they enter the tumor bed to destroy the antigen- 
expressing cancer cells. Tumors,  however, 
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possess a large battery of defense mechanisms 
[42] and the tumor microenvironment may also 
have a suppressive effect on tumor-infiltrating 
lymphocytes. This is demonstrated by the fact 
that these cells are unable to destroy tumor cells 
in  vivo;  however  they  do  have 
immunologic 
Figure 1. Tumor evasion mechanisms and immune reaction against tumors. The immune reaction that leads to tumor 
elimination is shown on the right. In the activation phase (upper-right corner), tumor antigens expressed by the tumor are taken up 
by DCs (step 1). The DCs will be activated by an immune maturation signal and travel to the lymph node. Here they present the 
antigen on MHC class II molecules to naive T cells (step 2). These T cells will become activated if a costimulatory signal is received. 
This costimulatory signal can  be in the form of interaction with plasma membrane ligands of the TNF family or the B7 family on the 
dendritic cell with activating receptors on the T cells. Both the TNF and the B7 family of ligands interact with activating receptors, 
whereas only B7 family ligands interact with inhibitory receptors. When the activated T cell travels to the tumor (lower-right corner; 
effector phase) it will recognize the antigens and eliminate the tumor (step 3). However, the tumor possesses some defense 
mechanisms (shown on the left). In the activation phase, tumors can downregulate their antigen expression by downregulation of 
MHC class I molecules. Also, the immune maturation signal can be absent, which will lead to tolerance to the antigen, as interaction 
of the unactivated DC with the naive T cell in the lymph node will induce the formation of Tregs (step 4). In the effector phase, 
tumors can overexpress inhibitory ligands, such as PD-1 ligand, which will interact with inhibitory receptors on T cells. Furthermore, 
tumors can secrete immunosuppressive molecules such as PGE2, arginase, IDO and VEGF, which will prevent the T cells from 
eliminating the tumor (step 5). 
DC: Dendritic cell; TCR: T-cell receptor; TNFR: TNF receptor. 
Tumor antigen Activating TCR
MHC class I TCR
Immune maturation signal Immunosuppressive molecule
B7 family PD-1 
TNFR family Immunoregulatory steps 
Inhibitory TCR T cell 




























































properties  when  they  are  removed  from  the 
tumor  environment  [43].  The  tumor  defense 
mechanisms  include  the  presence  of  Tregs 
and myeloid-derived suppressor cells in tumor 
tissue,  secretion  of  T-cell-suppressive  factors 
such as IL-6, IL-10, VEGF and TGF, as well 
as the (over)expression of ligands for inhibitory 
receptors  on  T  cells.  In  general,  an  immune 
response  can  be  divided  into  an  activation 
phase, consisting of the activation of DCs and 
their interaction with T cells in the lymph node, 
and an effector phase, consisting of the actual 
invasion of activated and selected T cells in the 
tissue, and the elimination of cells expressing the 
antigen (Figure 1). In both phases, 
immunological checkpoints prevent the 
reaction against ‘self ’ cells. Tumor cells can 
use these checkpoints as a defense mechanism 
by not letting the immune reaction pass the 
checkpoint. Many checkpoints work via 
receptor–ligand interactions that are either  
stimulatory  or  inhibitory.  Tumors  can 
activate  the  inhibitory  interaction  by  (over) 
expression of ligands for inhibitory receptors on 
T cells, for example PD-1 ligand [44]. 
 
 
Targets for therapy 
Aside from strategies that directly regulate the 
immune  system,  the  identification  of  tumor- 
specific antigenic targets has been challenging. 
Owing to cells within a tumor being genetically 
and behaviorally heterogeneous [45], a specific 
therapeutic target may not be expressed in all 
cancer  cells.  CT-antigens,  for  example,  are 
only expressed in 5–50% of the tumor cells; 
therefore, it is unlikely that vaccination against 
these antigens will target all cancer cells [46]. 
Even  if  certain  antigens  such  as  melanocytic 
differentiation  antigens  are  homogeneously 
expressed in tumor tissue [47], some cells may 
develop  additional  strategies  to  overcome  the 
therapy,  such  as  downregulating  the  targeted 
proteins. In addition, it is likely that immune 
tolerance  mechanisms  of  the  tumor  work  in 
combination  with  each  other  and,  therefore, 
combination therapy allows for the simultaneous 




Current treatment options 
Despite some setbacks, cancer immunotherapy 
for melanoma has shown early moderate success 
with IL-2 and interferon, and more recent signif- 
icant results through targeting the inhibitory 
receptor CTLA-4. In addition,  inhibiting 
the interaction of PD-1 ligand with the PD-1 
receptor,  either  by  anti-PD-1-receptor  or 
anti-PD-1-ligand antibodies, is a promising 




More than three decades ago, IL-2 was shown to 
expand T cells with antitumor activity in vitro 
and in vivo [50]. Subsequently, treatment with 
high-dose (HD), single-agent IL-2 in metastatic 
melanoma and renal cell carcinoma patients was 
investigated, which demonstrated 7% complete 
remission (CR) and 10% partial remission in 134 
melanoma patients [51]. A subsequent publication 
including 270 melanoma patients from multiple 
clinical studies reported CR in 17 patients (6%) 
and partial remission in 26 (10%)[52]. In the 
follow-up report in 2000, the authors estimated 
a CR median duration of at least 59 months, 
although this had not been reached in their 
patient population. 
Based  on  available  evidence,  but without 
a randomized controlled trial, HD IL-2 was 
approved by the US FDA for the treatment of 
metastatic melanoma in 1998. However, the 
moderate results, as well as the drawbacks of 
IL-2, such as its toxicity profile and quality 
of life impairment, diminished its general 
applicability. Studies with low-dose IL-2 failed 
to show improvement over HD treatment [53]. 
Reviewing all clinical data available on IL-2 
treatment in melanoma, there seems to be a 
mild benefit without improvement of overall 
survival (OS) [53]. Arguably, these outcomes are 
still comparable with dacarbazine (DTIC) or 
other chemotherapies. Fortunately, the toxicities 
caused by IL-2 therapy have become more 
predictable and manageable as experience with 
IL-2 has increased over the years. Moreover, the 
durable long-term disease-free survival recorded 
in selected patients still suggests IL-2 therapy 
as a possible treatment option for metastatic 
melanoma. 
In order to improve the outcome with IL-2, 
many studies were conducted that investigated 
combinations of IL-2-based immunotherapy 
and chemotherapy, termed biochemotherapy [54]. 
The initial results of combined cisplatin-based 
chemotherapy and IL-2 versus single arms were 
promising [55,56]; however, two Phase III trials were 
unable to produce statistically significant response 
improvements and failed to show an OS benefit 
[57,58]. In another Phase II study, Tarhini et al. 
investigated sequential temozolomide followed by 
HD IL-2 in 38 patients [59]. Their results indicated 
that although this combination had lower toxicity 
than previous biochemotherapies, the overall 
response rate and durability of responses did not 
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exceed those of single-agent HD IL-2. High levels 
of VEGF and fibronectin were shown to correlate 
with lack of clinical response to IL-2 therapy and 




Interferons  (IFNs)  are  pleiotropic  cytokines 
that were first described in 1957 as proteins that 
interfere with viral replication [61]. IFNs induce 
synthesis of hundreds of different proteins by 
activating the JAK–STAT pathway, which is a 
major signaling system that cells use to transmit 
extracellular information from many cytokines 
and growth factors to the nucleus [62,63]. Seven 
IFNs have been described in humans and based 
on the type of receptor they bind to, all these 
IFNs fall into two main types produced by dif- 
ferent cell populations [64]. Type I IFNs (IFN-, 
IFN- and IFN-) bind to IFN- receptors, 
whereas type II IFNs (IFN-) bind to IFN- 
receptors. Although the different types of IFN 
have little structural similarity and may signal 
through distinct receptors and pathways, they 
also  exhibit  overlapping  effects,  particularly 
through their antiproliferative activities [62]. 
IFN treatment is the most studied and 
only approved adjuvant therapy for melanoma 
patients. IFN-2b was f irst shown to be 
beneficial in stage II/III melanoma without 
sentinel node microstaging [64]. Other studies 
conducted in the 1990s also demonstrated that 
adjuvant IFN can significantly increase disease- 
free survival [65–68] and in some studies, overall 
survival [64,68,69,70]. Hence, IFN was the first 
agent to show a significant benefit in relapse- 
free survival and OS of high-risk melanoma 
patients in a randomized controlled trial [64]. 
These results finally led to FDA approval of HD 
IFN-2b adjuvant therapy for intermediate- 
and high-risk melanoma patients. Low-dose 
conventional IFN-, three milli-international 
units administered three-times weekly, is 
approved as the standard dosing for adjuvant 
IFN therapy by most European countries [71]. 
Currently, IFN is applied either in standard 
or pegylated form (PEG) and, until recently, 
the  latter  was  only  used  for  treatment  of 
chronic hepatitis C. The pegylation of IFN- 
by  covalent  binding  of  polyethylene  glycol 
increases its half-life from 3–8 h to 22–60 h 
(PegIntron®,   Schering-Plough,   NJ,   USA; 
IFN- 2b  with  12-kDa  PEG-chain)  or  even 
to 60–80 h (Pegasys®, F Hoffmann-La Roche, 
Basel, Switzerland; IFN-2a with 40-kDa PEG- 
chain) without changing its tertiary structure or 
spectrum of activity [62]. The advantage of this 
is that it can be injected only once per week, 
whereas the standard IFN needs to be injected 
three-times per week. However, the use of IFN, 
both in its standard and pegylated form, is 
associated with an extensive range of side effects 
and must be carefully monitored [72]. 
Based on these results, the largest IFN adjuvant 
trial to date was initiated (i.e., the EORTC18991 
trial), which included detailed information on 
microstaging and ulceration [73]. A total of 
1256 patients with resected stage III melanoma 
were randomly assigned to observation (n = 629) 
or pegylated IFN-2b (n = 627) 6 µg/kg per week 
for 8 weeks (induction), followed by 3 µg/kg per 
week (maintenance) for an intended duration 
of 5 years. The authors of this study concluded 
that patients with sentinel node involvement and 
ulcerated melanoma benefited the most, in terms 
of relapse-free survival, distant metastasis-free 
survival and OS [73]. 
 
 
Anti CTLA4 antibody 
Activated T cells play an important role in medi- 
ating host immune response against tumors. 
Nevertheless, tumors are able to evade detection 
and destruction by the immune system through 
local and regional immunosuppressive mecha- 
nisms. Ipilimumab (Yervoy™, Bristol-Meyers 
Squibb, NY, USA) is a fully human monoclo- 
nal antibody that binds to and blocks CTLA-4. 
CTLA-4 is one of the inhibitory receptors on 
T cells that will inhibit T-cell activation when 
it binds to the B7-family proteins on the cell 
membrane of DCs (Figure 1) . 
Subsequently, blocking CTLA-4 with anti-
CTLA-4 antibod- ies enhances T-cell responses 
in vitro and in vivo, and activates proliferation 
of tumor-specific T cells. The efficacy of 
ipilimumab was investi- gated in a large, 
randomized, Phase III clinical trial involving 
676 patients with unresectable stage III or IV 
melanoma, whose disease had progressed 
during therapy for metastatic disease [74]. 
Patients were treated with ipilimumab plus the 
peptide vaccine gp100 (n = 403), ipilim- 
umab alone (n = 137) or gp100 alone (n = 136). 
The aim of the study was to demonstrate the 
benefit of the combination of antibody and vac- 
cination. Surprisingly, the results showed that 
the median OS was increased in all patients 
receiving ipilimumab from 6.4 months in the 
gp100 alone group to 10 months in the ipi- 
limumab plus gp100 group and 10.1 months 
in the ipilimumab alone group. This posi- 
tive impact on OS in patients with advanced 
melanoma has led to the approval by the FDA, 
EMA, SwissMedic, Health Canada and most 
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recently, by the National Institute for Health 
and Clinical Excellence for use in England and 
Wales. However, cost concerns and contradic- 
tory follow-up results have led to some concerns 
regarding the overall efficacy of this new treat- 
ment. For instance, in a recently published study 
of 82 patients, no association between the status 
of the well-known BRAF V600E mutation of 
melanoma and disease control after treatment 
with ipilimumab was detected [75]. Currently, 
no biomarkers are available to identify patients 
who will benefit from ipilimumab treatment. 
Another Phase III study investigating the use 
of ipilimumab in combination with DTIC in 
patients with previously untreated metastatic 
melanoma also reported prolonged OS com- 
pared with DTIC plus placebo treatment [76]. 
The combination of ipilimumab with DTIC 
leads to an increased hepatotoxicity [76]. Magolin 
et al. showed that the activity of ipilimumab in 
patients with melanoma brain metastasis is simi- 
lar to patients with advanced melanoma with- 
out brain metastases [77]. Ipilimumab is associ- 
ated with immune-related adverse events [74,78], 
requiring specific management. Autoimmunity 
and the appearance of thyroid dysfunction have 
already been reported with IL-2 and IFN- [79], 
indicating a correlation between autoimmunity 
and antitumor response. The mode of action of 
immune-potentiating agents such as ipilimumab 
led to the formulation of novel radiologic tumor 
response criteria (immune-related response cri- 
teria) [80], since these agents can result in an 
initial increase in the size of a tumor followed by 
a regression. Using the common response evalu- 
ation criteria in solid tumors, a size increase or 
new tumor lesions correspond to ‘progressive 
disease’. However, this initial increase in tumor 
size might be due to local inflammation, sub- 
sequent to recruitment of activated T cells at 
tumor sites [77,81]. 
Combination therapies of ipilimumab with 
the specific BRAF kinase inhibitor or with 
radiotherapy and other molecular  targets 
are currently under investigation [201,202]. In 
addition, the results of a clinical trial analyzing 
the efficacy of ipilimumab as an adjuvant 
treatment in melanoma patients, along with 
another comparing two different dosages will 
give more information concerning the dosage 




Most people are familiar with the global 
success of vaccines in eradicating or controlling 
important diseases. However, with only a    few 
notable successes, cancer vaccination has had 
little clinical benefit overall, especially for 
the treatment of metastatic melanoma [82,83]. 
Numerous clinical vaccination trials have 
been conducted, in particular with irradiated 
whole-tumor cells mixed with bacterial 
adjuvants such as Bacillus Calmette-Guérin or 
Corynebacterium parvum, showing small but 
significant effects in melanoma treatment [83,84] 
One of the most ambitious whole-cell 
melanoma vaccines (Canvaxin™, CancerVax, 
DE, USA) is another cautionary tale on the road 
to developing a melanoma vaccination. This 
vaccine (developed from multiple melanoma cell 
lines) initially showed some promise in matched- 
pair analyses of patients receiving the vaccine 
after surgery; however, subsequent data showed 
the median survival of the placebo group to be 
longer than the vaccine arm [85–87]. A similar 
approach was taken by the manufacturers of 
Melacine® (Corixa, WA, USA), which also 
reached Phase III studies [88]. Once again, an 
initially auspicious outlook from Phase I and II 
trials led to optimism for the clinical application 
of Melacine, but Phase III trials failed to   show 
any benefit in the total study group [89]. 
The development of a more comprehensive 
molecular understanding of melanoma 
progression and immune recognition in  the 
last decade has led to more focused attention 
on specific melanoma antigens. A variety of 
tumor-associated antigens such as differentiation 
antigens, CT-antigens and viral antigens (as 
listed in the T-cell defined tumor antigen 
database at [204]) have been studied to augment 
antitumor immune responses in animal models 
and partly in clinical trials. The antigen-based 
vaccine therapies can be divided into: 
▪  Plasmid DNA-based vaccines that deliver the 
gene encoding the antigen 
▪  Recombinant viral and bacterial vaccines 
▪  Peptide- or protein-based vaccines that deliver 
the antigen mixed with adjuvants 
▪  Antigen-pulsed DC vaccines 
DNA vaccines provide the opportunity to 
express the immunizing antigen over time as they 
are based on the ability of the cell to transcribe 
encoded genes from DNA episomes delivered to 
the host. The exact mechanism by which DNA 
vaccines induce antitumor immunity is yet to be 
determined; however, several studies suggest that 
immunity is generated by DNA transfection of 
muscle cells and keratinocytes [90]. One example 
is Allovectin-7®  (Vical, CA, USA), a bicistronic 
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plasmid encoding human leukocyte antigen-B7 
and -2 microglobulin, an immunotherapeutic 
agent designed to express allogeneic MHC class I 
antigen upon intralesional administration. This 
vaccine seems to be an active, well-tolerated 
treatment for selected stage III/IV metastatic 
melanoma patients with injectable cutaneous, 
subcutaneous or nodal lesions [91], and is 
currently being studied in a Phase III clinical 
trial [205]. 
Several recombinant viral vectors are also 
under investigation to augment antitumor 
immune responses against model tumor antigens. 
Of particular interest are vaccinia and other 
pox viruses, as well as Listeria 
monocytogenes. These vaccines are difficult 
to use in a clinical setting owing to the 
formation of neutralizing antibodies. Protein- 
and peptide-based vaccines can be modified to 
increase their binding to MHC molecules, 
stimulating stronger T-cell responses. This has 
been performed with the peptide gp100 and 
the MART-1 analog peptide [92,93]. A major new 
advance was the introduction of Toll-like 
receptor ligands, which can activate APCs in 
vivo [94]. 
MelQbG10 is a vaccine that contains an 
immunogenic virus-like nanoparticle to which 
the antigenic peptide (melan-A/MART-1) is 
covalently coupled, as well as immunostimulatory 
oligonucleotides that trigger Toll-like receptor 9. 
The virus-like nanoparticle is a protein shell 
derived from the bacteriophage Q-, which 
efficiently drains into local lymph nodes for 
uptake and processing by DCs and macrophages 
[95]. In a Phase II clinical trial, MelQbG10 was 
combined with additional adjuvants and/or 
the administration route was varied showing 
quantitatively and qualitatively different T-cell 
responses [96]. Prospective randomized clinical 
studies comparing vaccinated with unvaccinated 
patients are needed to determine whether the 
responses seen in Phase I and II testing are due to 
the vaccine or the natural biology of malignant 
melanoma. 
Work on cancer immunotherapies for prostate 
cancer has proceeded furthest, in that the 2010 
FDA approval of sipuleucel-T (Provenge®, 
Dendreon, WA, USA) has led the way for 
other similar approaches involving autologous 
vaccination regimens [2,97]. In this procedure, 
the peripheral blood mononuclear cells are 
collected from castration-resistant prostate 
cancer patients and cultured with a prostate 
antigen (i.e., prostatic acid phosphatase) and 
then coupled to GM-CSF. Patients are then 
given  three  infusions  over  several  weeks. 
Although the approval of this treatment was seen 
as a great success for cancer immunotherapy, its 
high cost (about US$93,000 for the full course) 
has diminished its widespread use. 
 
 
Adoptive T cell therapy 
Over the last few years, there has been great focus 
on personalized medicine, although recent critics 
argue that a tumor is too heterogeneous and, 
therefore, a combination of ‘mass’ medication is 
probably more effective. However, personalized 
medicine  in  melanoma  has  demonstrated 
some success; melanoma patients who received 
lymphodepleting therapy and are subsequently 
transfused with self-derived and ex vivo expanded 
tumor-reactive lymphocytes have response rates 
of approximately 50% [98]. 
Adoptive T-cell therapy was developed by the 
Rosenberg lab in 1988 [99] and currently there 
are three strategies: 
▪  TILs are obtained from a melanoma biopsy 
and amplified ex vivo. The lymphocytes 
are then transfused back into the patient; 
▪  Lymphocytes are obtained from the patient’s 
peripheral blood and modified so that they 
express a chimeric antigen receptor (CAR). 
They are then amplified ex vivo and 
transfused back into the patient. A CAR is 
composed of an extracellular single chain 
antibody and an intracellular TCR signaling 
domain [100]; 
▪  Lymphocytes are obtained from the patient’s 
peripheral blood and modified so that they 
express a recombinant TCR, which recognizes 
a melanoma-associated antigen. They are then 
amplified ex vivo and transfused back into 
the patient. 
In all strategies, the patient is lymphodepleted 
in order to gain a stronger clinical response 
[101,102]. The different strategies all have advant- 
ages and disadvantages. Strategy one has less risk 
for autoimmunity, as in a recent study it was 
found that most TILs are not directed against 
known tumor antigens, but in fact are directed 
to unknown antigens, probably mutated self- 
proteins that are not expressed in other tissues 
[103]. In the last 10 years, TIL therapy has shown 
impressive results and according to the National 
Cancer Institute group, which summarized its 
10 year experience with Phase II clinical trials, 
the clinical response rate is 51% and continuing 
complete regression over 5 years is 13% [104,105]. 
However, a disadvantage is that in a large number 
of cases it is impossible to isolate enough TILs 
from a melanoma sample. Furthermore, as this 
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technique is individualized and, therefore, time- 
consuming and expensive, it prevents its wider 
use. Recent developments to make the technique 
applicable on a larger scale include strategies 
two and three. Strategy two is independent 
from the functioning of the antigen-presenting 
machinery in melanoma. As a tumor-escape 
mechanism, melanomas often downregulate the 
expression of MHC molecules [106] while also 
deregulating the antigen-presenting machinery, 
which makes them unrecognizable by T cells. 
By using a CAR, the antigen is still recognized 
by the antibody and via the intracellular TCR 
signaling domain the T cell becomes activated. 
The method is still preclinical for melanoma; 
however, clinical trials in hematologic cancers 
show promising results [107,108]. 
The rationale for the third strategy is the 
possibility to acquire sufficient amounts of 
tumor antigen-specific T cells, which is often 
not possible with TIL therapy. However, the 
technique has some disadvantages, such as that 
the TCR is specific for one antigen presented 
on a specific MHC molecule. This means that 
immunoselection occurs where tumor cells that 
do not express the antigen will not be recognized. 
Furthermore, to date, only the MHC molecule 
HLA-A0201 is targeted and only patients who 
express at least one of these HLA molecules can 
benefit from the therapy, which is about 35% 
of the patients. There are also concerns about 
autoimmunity, as many tumor antigens are also 
expressed in normal tissue. In the last clinical 
trial, which had a clinical response rate of 30%, 
many patients experienced autoimmune effects 
[109]. Currently, further clinical trials are being 
developed and conducted to determine the 




Anti PD1 therapy 
The inhibition of PD-1 targets a different 
immunoregulatory mechanism as compared 
with other immune-activating therapies, in that 
its function focuses on the effector phase instead 
of the activation phase of the immune response 
(Figure 1). PD-1 is an inhibitory receptor on the 
T cell that, upon interaction with PD-1 ligand on 
the tumor cells, prevents the T cell from 
becoming active. Tumor cells can overexpress 
PD-1 ligand to escape immunological 
surveillance. Normal tissues, except for cells 
of the macrophage lineage, express little to no 
PD-1 ligand on their surface [110]. This tissue- 
specific expression suggests that abrogating the 
interaction of PD-1 with PD-1 ligand will have 
fewer side effects in the form of autoimmunity 
than, for example, blocking CTLA-4, which 
has  autoimmune  toxic  effects  in  20–30%  of 
patients [111]. Inhibiting the interaction between 
PD-1  and  PD-1  ligand  can  be  achieved  by 
using either anti-PD-1 antibodies or anti-PD-1 
ligand antibodies. Both antibodies have been 
tested in Phase I trials; anti-PD-1 antibodies 
had  an  objective  response  rate  of  41%  with 
the optimal dose in melanoma, with 6% of all 
the treated patients (also patients with other 
tumors  than  melanoma)  experiencing  grade 
3 or 4 drug-related adverse events  [49], while 
anti-PD1-ligand 1 antibodies had an objective 
response rate of 29% with the optimal dose in 
melanoma, with 5% of the treated melanoma 
patients experiencing grade 3 or 4 drug-related 
side effects [48]. Phase II trials with anti-PD-1 
antibodies  will  soon  be  started  [206,207]   and 
Phase III trials are planned. 
As PD-1–PD-1 ligand interaction is playing 
a  role  in  the  effector  phase  of  the  immune 
response, combining anti-PD-1 therapy with 
a therapy that has its effect in the activation 
phase  could  be  promising.  Anti-CTLA-4 
antibodies,  which  act  in  the  effector  phase, 
were the first immunotherapeutics to show a 
clinically important and statistically significant 
impact on patient survival [112]. Clinical trials 
combining anti-PD-1 and anti-CTLA-4 therapy 
are underway. 
Furthermore, combining anti-PD-1 with a 
cancer vaccine that also works in the activation 
phase may provide some benefit. Cancer vaccines 
have been shown to induce the production of 
systemic antitumor-specific T cells [93,113,114]; 
however, these T cells are mostly ineffective in 
the clinic, since the immunologic inhibition in 
the tumor environment seems to be too strong. 
Overcoming this by simultaneously inhibiting 
PD-1–PD-1 ligand interaction in mice showed 
a tumor-eliminating response [115]. 
In another study using mice, combining 
anti-PD-1 with a therapy that stimulated DC 
maturation through activation of Toll-like 
receptor pathways (i.e., CpG therapy) showed a 
synergistic effect [116]. The same holds true for 
GM-CSF-secreting tumor-cell immunotherapy, 
which is based on the intradermal injection of 
tumor cells that are genetically modified to 
secrete GM-CSF [117]. Local GM-CSF secretion 
activates DCs, which will be targeted against 
tumor-associated antigens that are also present 
in the injected tumor cells. Both CpG and 
GM-CSF therapies work in the activation phase 
of the immune response. 
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Patient stratification criteria 
Given the large number of uncharacterized 
genetic, epigenetic and probably environmental 
variables, not all patients respond to a given 
immunotherapy in the same way. For example, 
only 30% of the patients receiving CTLA-4- 
antibodies show a response [74]. However, almost 
all patients experience some side effects and 
stratification criteria such as better biomarkers 
are therefore needed to predict which patients 
will benefit from any particular treatment. To 
this end, most of the current research in the 
field is concentrated on the expression of certain 
immunologic factors that have an effect on 
tumor immunotherapy. These predictive markers 
could be the targets themselves; for example, 
PD-1 ligand. In a preliminary study, Topalian 
and coworkers found that 36% of the patients 
that were positive for PD-1 ligand expression 
had an objective response to anti-PD-1 therapy 
compared with none of the 17 patients with PD-1 
negative tumors [49]. 
Other predictive biomarkers, aside from the 
molecular target itself, may be proteins that have 
an important role in either tumor progression or 
immune response; for example, the expression of 
MHC class I molecules. Tumor cells can evade 
immune recognition and elimination through the 
downregulation of MHC class I molecules on the 
tumor cells [118,119]. By downregulation of MHC 
class I molecules on tumor cells, they will be 
less recognizable to T cells. When the difference 
in MHC class I expression between regressing 
and progressing metastases from patients 
receiving immunotherapy was compared, only 
the progressing metastases downregulate MHC 
class I expression [120]. Furthermore, in another 
study where the HLA types in patients treated 
with IFN-and IL-2 were checked, certain 
HLA types corresponded with a better response 
to treatment [121]. 
In addition to these immunologic factors, the 
predictive value of more general physiological 
markers have also been investigated, such as 
normal lactate dehydrogenase levels, a good 
performance status (e.g., Eastern Cooperative 
Oncology Group 0 or 1)  [56],  metastasis  to 
less than three organs and cutaneous and/or 
subcutaneous metastasis [122], which were all 





The difficulty in successfully using immuno- 
therapy to cure cancer, despite intensive att- 
empts, may be the result of an overly  simplistic 
understanding of how the immune system 
functions. More intelligent combination ther- 
apies are needed that influence multiple stages of 
the immune reaction to elicit a synergistic 
effect. For example, vaccination with mRNA- 
encoding tumor antigens is a new strategy where 
antigen presentation and immune  stimulation 
are combined [123]. In contrast to normal RNA, 
which is degraded in a few minutes and cannot 
act as an immune stimulus, stabilized RNA can 
act as pathogen-associated molecular patterns, 
which are recognized by the immune system 
[124]. On the other hand, stabilized RNA is 
hard to translate by a cell, which is required for 
antigen presentation. Recently, a new vaccine 
combining stabilized and unstabilized  RNA 
has been developed with promising preclinical 
results [98,123,125,126]. 
It is likely that in the future, more basic research 
on the immune system and tumor immune 
evasion mechanisms may reveal additional targets 
for pharmaceutical or biologic intervention 
through better antigen identification and targeted 
immunoregulation. For instance, in addition to 
the demonstrated success of CTLA-4 and PD-1, 
blocking TIM-3 and LAG-3 (i.e., two additional 
inhibitory receptors expressed on T cells) shows 
promising results. A recent study in mice with 
solid tumors showed that combining Tim-3 
blockade with PD-1 blockade is more effective 
than blocking either receptor alone [127]. Another 
study suggested that LAG-3 and PD-1 also work 
synergistically [128]. 
Finally, the way drugs are delivered is likely 
to influence their effectiveness. With localized 
therapy, higher doses can be reached and 
combinations that previously were not possible 
owing to systemic side effects become feasible. 
The recent example of nanolipogels demonstrates 
this well. These very small (i.e., nanoscale), 
hollow and biodegradable spheres are able to 
carry the drugs through the bloodstream to the 
tumors, where they ultimately get trapped in the 
tumor vasculature [3] and release their drugs. 
In a recent study, nanolipogels with a TGF-- 
inhibitor and IL-2 were injected into mice with 
melanoma [3]. The results showed that the tumors 
went into remission, their growth was delayed 
and the survival of the mice was prolonged. By 
combining these two drugs, the mouse immune 
response was boosted with IL-2 and the secretion 
of tumor defense molecules was inhibited with 
anti-TGF-. This combination treatment  had 
not been possible previously owing to systemic 
side effects [3]. However, with this technique, 
the combination therapy was localized and  side 
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effects were greatly reduced. A Phase I/II clinical 
trial analyzing the safety, tolerability and OS 
combining the specific BRAF kinase inhibitor 
vemurafenib with ipilimumab in BRAF-mutated 
melanoma patients is ongoing [208]. 
These and other combinatorial approaches 
may start a new wave of therapeutic strategies that 
use immunoregulatory agents to target different 
aspects of tumor growth, metastasis and immune 
evasion. From the dramatic increase in interest 
regarding cancer immunotherapy and many 
recent successes, it is clear that immunotherapy 
is back on the list of antimelanoma therapies and 
likely to yield greater results in cancer patients 
as our understanding of the immune system 
and tumor-evasion mechanisms improves  in 
the coming years. 
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Executive summary 
▪  Cancer immunotherapy has a long history, and recent successful application suggests a promising future in various cancer types. 
▪  Past failures in cancer immunotherapy such as the CD28 superagonist are a cautionary tale in immunomodulatory treatment. 
▪  The administration of the CD28 superagonist in healthy human volunteers elicited a massive cytokine storm within 12–16 h 
postadministration. 
▪  An alternative to direct modulation of the immune system is the identification of tumor-specific antigens that could be used for 
immune therapy. Cancer testes antigens (CT-antigens) and melanocytic differentiation antigens are examples of such targets. 
▪  Current cancer immunotherapy for melanoma consists of regimens involving IL-2, interferon, targeting of the inhibitory receptor 
CTLA-4, or inhibiting the interaction of PD-1 ligand with its receptor. 
▪  IL-2 therapy has shown little improvement in overall patient survival; although interferon was shown to improve relapse-free and overall 
survival, it is also associated with an extensive set of side effects; CTLA-4 targeting (ipilimumab) has resulted in a significant increase 
in median overall survival. 
▪  Melanoma vaccines, although showing great promise, have so far failed to demonstrate a significant therapeutic effect. 
▪  Adoptive T-cell therapy, although quite complex, has shown strong clinical response rates. But this treatment is both cost-
prohibitive and time-consuming, thus limiting its general applicability. 
▪  Treatment of the effector phase of the immune response, through PD-1 inhibition, has resulted in high objective response rates 
in clinical trials and shows great promise for more general use. 
▪  The identification of patient stratification criteria for melanoma immunotherapy will be critical to determining which patients might 
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Abstract Progress in understanding and treating metastatic 
melanoma is the result of decades of basic and translational 
research as well as the development of better in vitro tools for 
modeling the disease. Here, we review the latest therapeutic 
options for metastatic melanoma and the known genetic and 
non-genetic mechanisms of resistance to these therapies, as 
well as the in vitro toolbox that has provided the greatest 
insights into melanoma progression. These include next- 
generation sequencing technologies and more complex 2D 
and 3D cell culture models to functionally test the data gener- 
ated by genomics approaches. The combination of hypothesis 
generating and hypothesis testing paradigms reviewed here 
will be the foundation for the next phase of metastatic mela- 
noma therapies in the coming years. 
 
Keywords Melanoma . 3D culture . Translational research . 
Bioengineered skin . Skin reconstructs . Melanoma treatment 
 
Great discoveries often lag far behind technological innova- 
tions; real-world, transformative applications are even slower 
to materialize. It took 100–150 years to adapt the Breading 
stone^ lenses of the twelfth century into spectacles to correct 
hyperopia and myopia, and another two centuries to   build 
telescopes out of lenses that allowed Galileo to support the 
Copernican model of a heliocentric solar system. 
Although the pace of translational science has greatly ac- 
celerated since the Middle Ages, the journey from theory, 
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been slow for most cancer therapies. This has been especially 
true for metastatic melanoma, which has only recently benefit- 
ed from decades of basic research. However, within the last 
10 years, metastatic melanoma has gone from being almost 
untreatable to one of the most promising examples of evi- 
dence-based, personalized medicine today. It was not until 
the publication of some landmark papers in 1996 and 2002 
that the foundation was set for two of the most disruptive 
technologies in the treatment of metastatic melanoma: 
targeted therapy and checkpoint inhibition [1–3]. These dis- 
coveries themselves were the results of decades of technolog- 
ical advances and basic research in next-generation sequenc- 
ing technologies and immune biology, to name a few [4, 5]. 
While the recent successes of single-agent and combination 
therapies have been encouraging, there is still a great deal of 
work to be done to better stratify patients for the appropriate 
treatment, to understand and circumvent therapeutic resis- 
tance, and to identify new targets for therapy. Below, we re- 
view the latest technological developments in these areas, the 
scientific results that will inform the next generation of thera- 
pies, and the challenges we still face in translating basic dis- 
coveries to treatments that will ultimately benefit patients. The 
selection of papers is focused on the technologies that have 
yielded the most clinically relevant results in recent years re- 
garding metastatic melanoma progression: next-generation se- 
quencing tools and in vitro functional assays. 
 
 
1 Melanoma treatment 
 
The majority of malignant melanoma cases are detected at an 
early stage where surgical excision is curative. However, once 
melanoma has spread to a distant site, disease control becomes 
difficult. After decades of disappointing clinical studies in meta- 
static melanoma patients, the last 10 years have shown some
  





exciting successes with clear clinical benefit. The current treat- 
ment paradigm for our metastatic melanoma patients follows the 
recently published treatment guidelines (Fig. 1) [6]. 
Early studies in B-rapidly accelerated fibrosarcoma 
(BRAF)-mutated patients investigated small molecules that 
blocked a range of kinases including RAF (sorafenib, 
RAF265), but more potent and selective inhibitors that 
targeted mutated BRAF (particularly at amino acid 600) were 
more recently tested. These revolutionized the treatment of 
BRAF-mutant melanoma [7–11]. Phase III trials of both 
vemurafenib and dabrafenib demonstrated superiority over 
chemotherapy, as did the mitogen-activated protein kinase ki- 
nase (MEK1/2) inhibitor trametinib. However, within   5– 
7 months, disease progression was observed with single- 
agent BRAF and MEK inhibitors [12–14]. In three random- 
ized trials (COMBI-d, COMBI-v, co-BRIM), combined 
targeting of BRAF/MEK (i.e., encorafenib and binimetinib, 
dabrafenib and trametinib, or vemurafenib and cobimetinib) 
also showed improved response rates, progression-free sur- 
vival, and overall survival than either therapy alone [15–20]. 
But resistance (innate or primary, and acquired or secondary) 
is still a major challenge in the targeted-therapy paradigm. 
To date, immunotherapy with high-dose IL2 or checkpoint 
inhibitor antibodies against cytotoxic T-lymphocyte associat- 
ed protein (CTLA-4) and/or programmed cell death protein 
(PD-1), and targeted therapies (BRAF and MEK inhibitors) in 
patients with a BRAF V600 mutation. Also in NRAS mutated 
patients (the MEK inhibitor), have shown clinical benefit [6]. 
The use of BRAF inhibitors has significantly improved over- 
all and progression-free survival in BRAF V600-mutated pa- 
tients [21]. Unfortunately, most patients develop resistance 
after some months. 
Several theoretical models have been developed to under- 
stand how resistance may arise. These include a subclonal evo- 
lution model, phenotype switching, or cancer stem cells [5]. 
Like most models, each of these has some relevance and strong 
supportive data, but also major caveats. Understanding this 
complexity outside of the dogma associated with any particular 
model will facilitate a more accurate representation of how 
therapeutic resistance exists in a real-world clinical setting. 
 
 
1.1 Genetic mechanisms of therapeutic resistance 
(subclonal evolution) 
 
There is some evidence that resistance may follow aspects of a 
Darwinistic evolution model in which selection and adapta- 
tion play vital roles. Small populations of resistant melanoma 
cells might already exist before treatment, either by genetic or 
epigenetic means, which are then selected during treatment 
due to the advantage they have over non-resistant cells [22]. 
Resistance could also develop during the course of treatment 
when the cells adapt to the new stressor. This too could happen 
via alterations in the genotype or epigenome resulting in phe- 
notypic changes. 
Immunohistochemical analysis of post-resistant samples 
fromthephase IIBRIM-2 vemurafenibtrialrevealedthatnearly 
all resistant samples had a reactivation of the MAPK pathway 
[23]. Since then, several genetic as well as non-genetic adaptive 
mechanisms for MAPK therapy have been described. A metic- 
ulousanalysisofpre-treatment, on-treatment, andpost-resistant 
biopsies has shown elevated pERK1/2 levels in progressive 
tumors and gain-of-function mutations in MEK and NRAS that 
reactivate MAPK signaling [24]. 
The first paper describing this reactivation demonstrated a 
de novo MEK1 mutation (P124L) in a treatment-resistant me- 
tastasis from a BRAF-mutated patient who was successfully 
treated with a MEK inhibitor (selumetinib) [25]. This muta- 
tion conferred substantial resistance to MEK inhibitor therapy 
and only moderate resistance to a BRAF inhibitor. MEK mu- 
tations can also occasionally confer resistance to both BRAF 
and MEK inhibitors [26]. More commonly, concomitant 
NRAS mutations have been observed with persistent BRAF 
mutation [26–29]. This is especially interesting because of the 
paradoxical activation caused by BRAF inhibitors, which has 
been demonstrated for cutaneous epithelial malignancies [30, 
31]. It may be that the presence of an NRAS mutation under 
BRAF inhibitor therapy may result in a detrimental effect 
because of this paradoxical activation. 
In a large sequencing study that is described further in the 
genomics section below, Shi et al. analyzed the genomes of 
100 tumor samples derived from 44 patients, which consisted 
of 29 pre-treatment samples and 71 resistant post-treatment 
samples [28]. All post-treatment samples still contained the 
BRAF
V600E/K 
mutations, indicating that non-mutated 
subclones were not being selected during treatment. In line 
with the BRIM-2 analysis, the most common resistance mech- 
anism they identified was MAPK reactivation (in 70% of the 
cases), either by an additional NRAS or KRAS mutation, 
mutant BRAF amplification or BRAF alternative splicing, or 
by CDKN2A loss. BRAF amplifications and truncated BRAF 
variants have also been reported elsewhere [32]. BRAF splic- 
ing variants result in a truncated BRAF protein, which lacks a 
RAS-binding domain, thereby conferring BRAF inhibitor re- 
sistance through dimerization and pathway activation [33]. 
They also identified the PI3K-PTEN-AKT pathway as a 
second important resistance pathway (22% of their post- 
treatment samples contained mutations in PI3K-AKT regula- 
tory genes). By in vitro overexpression and knockdown stud- 
















were more re- 
sistant to BRAF inhibition compared to cells overexpressing 
the WT variant of AKT1, AKT3, PIK3CA, and PIK3R2, re- 
spectively. In addition, PTEN knockdown in a PTEN WT cell 
line introduced vemurafenib resistance. When they analyzed 








Fig. 1  Current treatment guidelines for metastatic melanoma [6] 
 
nine different resistant post-treatment samples from one pa- 
tient, they identified at least five different resistance mecha- 
nisms, indicating that a single biopsy from one sample is not 
sufficient to determine follow-up inhibitor treatment after 
BRAF inhibitor resistance. 
 
1.2 Non-genetic mechanisms of therapeutic resistance 
(phenotype switching) 
 
Disease progression occurs in most patients after successful 
tumor control with mono- or combination therapy for months 
or even years. The response duration is generally quite broad 
(i.e., from weeks to years), and the causal mutations driving 
treatment failure are described above. In the context of the 
phenotype switching model, the transcriptional response to 
MAPK pathway inhibition can be considered to be prolifera- 
tive cells activating mesenchymal (i.e., invasive or stem-like) 
expression modules that are associated with reduced glucose 
metabolism [34]. The melanoma cells may thereby buy time 
to activate alternative signaling pathways and enable 
subclones with additional activating mutations to flourish in 
the new microenvironment. 
Besides MAPK pathway reactivation, activation of parallel 
signalling pathways such as the phosphoinoside-3-kinase 
(PI3K) pathway can also occur, for instance through the acti- 
vation of the kinase COT [35–37]. This can occur, for in- 
stance, through the activation of the kinase COT [38]. The 
tumor stroma can also play an important role in bypass 
signaling.  Stroma cells from  resistant tumors can   secrete 
growth and viability factors that protect melanoma cells from 
BRAF inhibition. These include the hepatocyte growth factor 
(HGF), which can facilitate tumor cell growth through the 
paracrine activation of the HGF receptor MET, which leads 
to PI3K pathway activation [39, 40]. Other receptor-tyrosine 
kinases (RTKs) may enable proliferation in the presence of a 
BRAF inhibitor. While melanoma cells can express the epi- 
dermal growth factor receptor (EGFR), the levels are quite 
low compared to colon or squamous cell carcinomas. 
However, upon innate or acquired resistance, melanoma cells 
can upregulate the autocrine secretion of EGF and EGFR [41, 
42]. This suggests that, indeed, the tumor stroma is an active 
participant in the response to targeted therapies and may play a 
crucial role in the attenuation of therapeutic success. 
Other avenues for intervention strategies may arise from a 
more complete understanding of the biochemical and meta- 
bolic events that are associated with MAPK reactivation, such 
as the maintenance of eIF4F complexes and the persistent 
ERK-independent phosphorylation of 4EBP1 or the enrich- 
ment of pro-apoptotic BCL-2-modifying factor-dependent 
degradation of eIF4G [43]. Interestingly, interferon beta secre- 
tion was also observed to occur with tumor regression in the 
presence of BRAF inhibitor therapy. In addition, PKCε- 
phosphorylated ATF2 downregulates IFNβ1, which elicits 
therapeutic resistance (Lau et al. Oncogene in press). 
Genetic mutations may confer permanent drug resistance. 
However, it has been observed that before the drug resistant 
stage, an adaptive and transient stage of reversible drug resis- 
tance  exists. Upon stress, such  as  inhibitor treatment, 





melanoma cells undergo an innate response which allows 
them to better tolerate drugs [44]. This response is character- 
ized by de-differentiation (reduced expression of melanocytic 
lineage-specific markers), increased expression of stemness 
and EMT markers, and increased expression of genes in- 
volved in epigenetic remodeling. Of the latter group, the en- 
zyme KDM5B is a marker for a slow-cycling phenotype with 
increased drug tolerance [45, 46]. This enzyme was upregu- 
lated in the stress response, as well as other markers, pointing 
to a downregulation of transcription and replication pathways, 
suggesting a slow cycling semi-quiescent state. In this station- 
ary phase, cells change morphology to a flattened and en- 
larged phenotype and increased senescence associated 
SA-β-Gal activity, H3K9me3-positive heterochromatic foci, 
and promyelocytic bodies (PML) bodies [47]. Other stressors, 
such as hypoxia or low glucose, can induce a similar stress 
response [48]. Interestingly, when these stressed hypoxic or 
low glucose cells are exposed to various drugs, they are more 
resistant than their non-stressed equivalents. 
In the previously mentioned study from Shi et al., the au- 
thors further investigated the genomes from 13 tumor samples 
derived from 1 patient [28]. Two samples were prior to treat- 
ment, two samples were taken during treatment, and nine 
samples were disease-progressive tumors taken after treat- 
ment. The tumors taken during treatment expressed little to 
no Ki-67 staining in immunohistochemistry compared to pre- 
treatment samples, indicating a senescent-like state with no 
proliferation. To the contrary, the post-treatment samples 
showed the highest level of Ki-67 staining; moreover, the 
two tumors from the post-treatment samples with the most 
extensive genetic divergence displayed the highest prolifera- 
tive activity, suggesting increased tumor fitness with decreas- 
ing C > T transitions, suggesting the presence of non-UV- 
related mutagenic processes upon progression. 
Early adaptive signaling upon BRAF inhibitor therapy can 
occur as soon as 24 h after initiation of therapy [49]. Responses 
described include activation of the PI3K pathway [50], an al- 
tered oxidative metabolism [51], and upregulation of ERBB3 
expression [52]. This rapid response, as well as the observation 
that melanoma primary tumors and metastases are very hetero- 
geneous at multiple levels (i.e., genetic, epigenetic, transcrip- 
tional, proteomic, metabolomic, etc.), suggests that subclonal 
evolution or the stem cell model does not play much of a role in 
the acute phase of treatment response. This observation and 
some compelling publications over the last few years have gen- 
erated a widely accepted opinion in the melanoma community 
that these models alone fail to adequately account for heteroge- 
neity and the early phases of resistance [5]. These subpopula- 
tions can contribute to tumor progression by exhibiting expres- 
sion-driven, treatment-resistant slow-cycling behavior (such as 
JARID1B expressing cells) and tumor cells with features of 
epithelial to mesenchymal transition or mesenchymal pheno- 
types and expression patterns. This plasticity may enable  a 
dynamic response to external stressors such as therapies and 
may further generate a non-hierarchical organization of the tu- 
mor, which allows for a more rapid adaptation to the sudden 
reduction of MAPK signaling [53]. Interestingly, the limited 
cell death observed in vitro and in vivo during targeted therapy 
may be the result of proliferative tumor cells switching their 
epigenetic and transcriptional states to allow for a more slow- 
cycling mesenchymal phenotype that can better tolerate the 
therapeutic intervention. Resistance to BRAF inhibitors has 
also been associated with high, pre-treatment expression of 
anti-apoptotic BCL2 proteins (i.e., BCL2 and BCL2A1) [54, 
55]. This may explain the limited apoptosis that has been ob- 
served upon BRAFi treatment. 
The role of MITF in resistance is conflicting, as roughly 
50% of resistant tumors have an increased expression of 
MITF, whereas the other 50% show a decreased expression 
as an early response to BRAF inhibitors. Even within a pa- 
tient, different relapsing tumors can have enhanced or absent 
MITF expression [56]. An interesting observation is that in 
(vemurafenib) resistant cell lines, the presence of MITF indi- 
cated resistance to BRAF inhibition but retained responsive- 
ness to MEK or ERK inhibition, whereas absence of MITF 
was observed in cells that were also resistant to other MAPK 
pathway inhibitors [56]. The authors also noted that cells with- 
out MITF expression can better tolerate higher drug doses. In 
addition, when they checked for intrinsic resistance in 
treatment-naive melanoma cell lines, they found that if a 
BRAF- or NRAS-mutated melanoma cell line was intrinsical- 
ly resistant to BRAF or MEK inhibitors, it had low MITF 
expression, which is probably due to the higher expression 
of RTKs such as AXL, EGFR, and PDGFRb in MITF-low 
cells, as the inhibition of those receptors, especially AXL, 
sensitized the cell lines to MAPK inhibitors [56]. 
In cases of BRAF inhibitor resistant cells with elevated 
MITF expression, Nelfinavir (an HIV1-protease inhibitor) 
might be an interesting therapy [57]. Inhibition of BRAF or 
MEK reduces the expression of SKI, which leads to an upreg- 
ulation of PAX3, and this in turn increases the expression of 
MITF [57]. In mice, combination treatment with Nelfinavir 
prevented the MAPK inhibitor-induced upregulation of 
PAX3 and MITF levels, thereby sensitizing the melanoma 
cells to MAPK pathway inhibition. However, whether elevat- 




2 Non-cell autonomous resistance 
 
Interestingly, the classical theoretical models of melanoma 
progression tend to be cell-autonomous and do not leave much 
of a role for the interplay of external factors such as the tumor 
microenvironment. Darwin also postulated that species that 
learn to collaborate have a better chance to prevail. In a non- 





treated tumor, sensitive cells will generally have a growth 
advantage over resistant cells. However, upon treatment, re- 
sistant cells will have the upper hand, and it might even be so 
that sensitive cells support the resistant cells in this situation 
[58]. Upon treatment, sensitive cells secrete a therapy induced 
secretome (TIS), which was found to contain many mediators 
directly or indirectly activating the AKT pathway in resistant 
cells, who therefore became more proliferative upon treatment 
[58]. Treating mice with a combination of MAPK pathway 
and AKT pathway inhibitors could prevent this TIS-induced 
accelerated expansion of resistant cells in tumors [58]. 
Resistant cells in turn can help sensitive cells by preventing 
dendritic cell maturation and activation. When treated with 
BRAF inhibitors, sensitive melanoma cells express danger 
signals that incite an immune response, and the presence of 
resistant cells has a dampening effect on that response [59]. 
Collaboration can also take place with other cells in the 
tumor microenvironment. In a sophisticated in vivo mouse 
model where intravital imaging was combined with a biosen- 
sor construct that could monitor ERK/MAPK activity in live 
tissue, Hirata et al. observed that melanoma cells respond to 
BRAF inhibition by reducing pERK; however, in tumor areas 
with high stromal density, cells rapidly recovered pERK ex- 
pression to normal levels as soon as 1 day after the initial dose 
[60]. In mice, these tumors were resistant; however, when 
cultured as pure melanoma cultures in vitro, the cells were 
sensitive to BRAF inhibition, suggesting that the microenvi- 
ronment aids melanoma cells to withstand inhibitor treatment. 
Indeed, when they co-cultured the melanoma cells with the 
tumor-associated fibroblasts, the melanoma cells conferred 
resistance to BRAF inhibition. It appeared that fibroblasts, 
upon treatment with BRAF inhibitors, paradoxically activate 
the MAPK pathway via PDGFRa upregulation which let them 
remodel the extracellular matrix in a denser collagen fibril 
matrix. This stiff matrix has changes in integrin organization 
and FAK signaling and directly provides a safe haven for 
melanoma cells. Adding FAK inhibitors to the BRAF inhibi- 
tor resensitized the melanoma cells to BRAF inhibition [60]. 
Lastly, next to tumor cell mutations and adaptations and 
microenvironmental factors, patient factors possibly also play 
an important role in resistance. How well the drug is absorbed 
in the intestine (e.g., receptors on intestinal cells, intestinal 
flora drug metabolism), how much of the drug is cleared in 
the liver (enzyme activity), how much of the drug is bound to 
albumin (starvation/feeding status), and how well the drug can 
reach the tumor (vasculature, location of the tumor) all may 
have an influence on the drug concentration that effectively 
reaches the tumor cells. However, as every patient is unique, 
this is very complicated to investigate in an evidence-based 
medicine approach. 
One of the factors that can be investigated and maybe com- 
pensated, however, is age. In a small cohort of 79 patients, 
those younger than 65 years had almost a double reduction in 
tumor burden upon MAPK inhibitor therapy than older pa- 
tients due to more resistance in the latter [61]. 
The authors found that sFRP2 levels are increased in the 
serum of patients older than 55 years compared to younger 
patients, probably due to an increased secretion by aged se- 
nescent fibroblasts. This increased sFRP2 expression caused a 
reduction in β-catenin, MITF, and APE1 expression. A loss of 
APE1 leads to more cellular damage by ROS. Indeed, mela- 
noma cells exposed to aged fibroblasts or aged fibroblast con- 
ditioned medium in vitro have greater DNA damage. This 
damage could be reversed by inhibiting ROS activity. 
Decreases in β-catenin and MITF and increases in ROS have 
been linked to BRAF inhibitor resistance. The authors could 
show that in vitro and in vivo melanoma cells treated with 
conditioned medium from young fibroblasts or implanted in 
young mice were more sensitive to BRAF inhibition than 
those treated with the conditioned medium from old fibro- 
blasts or implanted in old mice, respectively. 
 
 
3 Melanoma genomics 
 
Undoubtedly, one of the major transformative technologies driv- 
ing translational research today is next-generation sequencing 
(NGS). Although genetics has been known to contribute to mel- 
anoma progression for decades, the first pivotal study identifying 
BRAF as the most important driver gene revealed that melanoma 
is a genetic disease and highlighted the importance of the MAPK 
pathway [2]. It was the discovery of BRAF V600 that was mutated 
in 50% of the melanoma samples with V600E comprising 80% of 
the mutations. Another observation from this study was that 
NRAS mutations, mutated in 15% of the melanoma samples, 
were mutually exclusive to BRAF mutations [2]. The scope of 
this study was just focused on the MAPK pathway (i.e., RAS- 
RAF-MEK-ERK), but revealed crucial information about the ge- 
netics of melanoma. Many subsequent NGS studies used whole 
exome (WES) or whole genome sequencing (WGS) on melano- 
ma tumors, melanoma short-term cultures, or melanoma cell lines. 
In this section, we will focus on the large cohort studies for a 
comprehensive review of genomic analyses in melanoma [62]. 
The first genomic characterization of melanoma was a WGS 
study performed on the melanoma cell line COLO-829 [63]. An 
ultra-violet radiation (UVR) signature, defined by C > T substi- 
tutions [64], was detected in this cell line. This finding supported 
the notion that UVR is an environmental risk factor for melano- 
ma. Two of the largest (WES) studies looking at 121 melanoma 
tumors and 147 melanoma tumors confirmed the UVR signature 
for sun-exposed melanomas and uncovered that non-sun- 
exposed melanomas exhibited a lower mutation rateand different 
mutation signature, thus highlighting the differences in melano- 
ma subtypes, such as acral, mucosal, and uveal melanomas [65, 
66]. These two studies together detected known melanoma on- 
cogenes such as BRAF and NRAS and in addition  uncovered 





new oncogenes like RAC1, PPP6C, and STK19 and new tumor 
suppressors like ARID2, DCC, TACC1, SNX31, NF1, ZNF560, 
FAM58A, and ME1. Copy-number analysis revealed losses in 
known tumor suppressors like PTEN and CDKN2A and gains in 
known melanoma oncogenes like MITF, CCDN1, CDK4, and 
TERT. These two studies provided a great insight into the geno- 
mic landscape of melanoma and also highlighted the fact that 
driver mutations in BRAF and NRAS do not likely occur from 
UVR. This suggests that the initial oncogenic transformation is 
UVindependent. Exome sequencing of BRAF
V600E 
mice treated 
with UVR revealed a typical UVR mutation signature across the 
exome and inactivating mutations in Trp53 [67], thus demon- 
strating the direct link of UVR to melanomagenesis. 
WGS of 25 metastatic melanomas revealed frequent 
PREX2 mutations and TERT promoter mutations [68, 69]. 
WGS also confirmed the UVR signature and as well revealed 
many structural rearrangements in the genome of known on- 
cogenes like ETV1. TERT promoter mutations were also seen 
in an independent study looking at families with a history of 
melanoma and were also validated in sporadic melanoma sam- 
ples [70]. WES has also been used for phylogenetic analysis of 
metastatic progression of melanoma [71, 72]. Each study had 
eight patients where the primary tumor and multiple metasta- 
ses were subjected to WES. Both studies found that metastasis 
formation is not a simple linear progression of mutation accu- 
mulation, but exhibits a quite complex evolution from the 
primary tumor. The metastases can be founded from multiple 
subgroups of the primary lesion. These findings have great 
implications for therapy as inter-tumoral and intra-tumoral 
heterogeneity can play a large role in response to treatment. 
Thenextlargestomicsstudycamefrom The Cancer Genome 
Atlas melanoma working group [73]. In this study, 67 primary 
tumors and 266 metastatic tumors were analyzed by WES, 
RNAseq, copy number, and reverse phase protein array. Two 
new molecular subtypes were defined in this study. Tumors that 
were both BRAF and NRAS wild-type often had a mutation in 
NF1 (45%). Since no high-frequency hotspot mutations oc- 
curredin NF1, itwas assumed that NF1 was a tumor suppressor. 
NF1 is known as a negative regulator of RAS, thus loss of 
function mutations would lead to activation of the MAPK path- 
way. Tumors that were triple wild-type for BRAF, NRAS, and 
NF1 weretypicallylesslikelytohavea UVRsignatureandwere 
morelikelytohavecopy-numberalterationsandcomplexstruc- 
tural rearrangements. Interestingly, there were no significant 
mutations associated with metastasis suggesting progression 
to metastasis may be patient specific. 
Thenexttwo WESstudiesanalyzed 501 and 213 melanomas 
and confirmed the NF1 molecular subtype. Inaddition, RASA2 
mutations were discovered to significantly co-occur with NF1 
mutations [74, 75]. It was observed that the NF1-mutated mel- 
anomas had a higher mutation rate than BRAF or NRAS mu- 
tated melanomas suggesting that NF1 alone is not sufficient to 
drive melanomagenesis and additional mutations are needed 
such as mutations in RASopathy genes. RASopathies are de- 
velopmental disorders caused by mutations in genes in the 
RAS/MAPK pathway. For instance, germline mutations in 
NF1 cause neurofibromatosis. Many melanoma mutations 
share known RASopathy gene mutations, reviewed in [76], 
suggesting that patients with a RASopathy could have a higher 
chance of developing melanoma. 
One large WES study interrogated the mutation progression 
of melanocytic nevi to melanoma [77]. This study sequenced 
37 FFPE melanomas with histologically distinct precursors. 
The authors sequenced by WES 150 distinct areas. Benign nevi 
generally had one mutation, which was usually BRAF V600E. 
Intermediate lesions had at least two pathogenic mutations and 
had a higher mutation rate than benign lesions. BRAF V600E 
mutations occurred in intermittent sun-damaged skin and in 
younger patients, whereas BRAF V600K or K601E and 
NRAS mutations occurred in chronic sun-damaged skin and 
older patients. TERT promoter mutations were found in a sig- 
nificant portion of the intermediate lesions. Once a melanoma 
becomes invasive, inactivation of CDKN2A occurs. TP53 and 
PTEN mutations were observed to occur in late stages of inva- 
sion. This study elegantly dissected the stepwise genetic evo- 
lution from melanocytic nevi to invasive melanoma. 
 
 
4 Melanoma transcriptomics 
 
One of the first studies to apply RNAseq to melanoma sam- 
ples discovered 11 novel gene fusions and 12 novel chimeric 
transcripts and, in addition, validated 29 somatic mutations in 
10 melanoma samples [78]. The study did not detect any of 
the gene fusions in an additional 90 samples, suggesting gene 
fusions are private events. 
The TCGA has one of the largest collections of RNAseq 
data with 470 melanoma samples with supporting clinical da- 
ta. From the TCGA melanoma landmark study, RNAseq anal- 
ysis uncovered three signatures of gene expression across 
these melanoma tumors: a group with high immune gene ex- 
pression, a group with high keratin gene expression, and a 
group with low MITF gene expression. Survival analysis of 
these three groups revealed the keratin group to have the low- 
est survival rate and the immune group to have the highest 
survival rate, suggesting biological significance to these gene 
signatures. BRAF hotspot mutations were more likely to be 
found in the MITF-low group (66%), and the MITF-low 
group generally contained samples with a mutation in BRAF 
or NRAS or NF1 compared to the keratin and immune group 
(3% vs. 21% and 14%, respectively). 
Before NGS, microarrays were a popular tool to dissect the 
molecular characteristics of melanoma. Microarray analysis of 
218 melanoma cell cultures across 6 different studies revealed 
two gene expression patterns, a Bproliferative^ signature and 
an Binvasive^ signature [79]. The Bproliferative^ signature 





was defined by high expression of typical melanocytic genes 
like MITF, TYR, LEF1, and SOX10, and the Binvasive^ sig- 
nature was defined by high expression of WNT5A, SOX9, 
TGFB, and TCF4. This signature was found to be independent 
of primary or metastatic lesions and of mutated BRAF V600E. 
These two signatures had phenotypic consequences in vitro, 
with the Bproliferative^ signature melanoma cells having a fast 
doubling time  and  limited  invasive capacity, whereas 
Binvasive^ signature melanoma cells had a slow doubling time 
and high invasive capacity, and the melanomas were able to 
switch back and forth between the two phenotypes [80]. This 
has been termed phenotype switching. A recent study demon- 
strated that the TCGA RNAseq dataset also contained these 
two signatures [81]. No significant mutations were associated 
with either phenotype, suggesting these two cell states are 
driven by transcriptional reprogramming and not by genetic 
events. We have recently shown that DNA methylation of the 
SOX9 promoter is at least one of the mechanisms that regu- 
lates this phenotype by the mutually exclusive developmental 
transcription factors SOX10 and SOX9 that could control as- 
pects of each phenotypic state (Fig. 2) [82, 84]. 
Single-cell RNAseq has also dissected the heterogeneity of 
melanoma [85]. In this study, 4645 cells were isolated from 19 
melanoma tumors and subjected to single-cell RNAseq. One 
interesting finding from the study was the MITF high signature 
and an AXL high signature which resembled the proliferative 
and invasive signatures described before. At the bulk tumor 
level, the tumor could be classified as MITF high or AXL high, 
but at the single cell level, a spectrum could be found. The 
tumor also contained cells with high cycling capacity and low 
cycling capacity. Along with the tumor cells, stromal cells and 
lymphocytes were also sequenced. Cancer-associated fibro- 
blasts (CAFs) had a significant association with the AXL high 
signature and an anti-correlative association with the MITF 
high signature. CAFs and melanoma cells could both express 
an AXL signature suggesting tumor-stromal interactions where 
CAFs could influence the transcription profile of melanoma 
cells. CAFs expressing C3 also had a significant association 
with CD8
+ 
T cells. Briefly, the lymphocyte population could be 
distinguished by their specific identities and subsets by known 
gene markers and even identifying exhausted T cells. 
Exhausted T cells were linked to T-cell expansion, whereas 
non-exhausted T cells were not expanded. Overall, this study 
has provided great insight into the transcriptomic heterogeneity 
of melanoma and the interaction of melanoma cells with the 
environment of stromal and lymphocytic cells. 
 
 
5 Discovery of resistance mechanisms to therapy 
by genomics and transcriptomics 
 
NGS has also been a great boon for the study of drug resistance 
mechanisms in melanoma. One of the first studies using gene 
 
Fig. 2 Current model of melanoma heterogeneity (i.e., phenotype 
switching), whereby SOX9 and SOX10 represent mutually exclusive 
repressors of the alternative fate and switching of phenotypic states is 




expression profiling discovered that upregulation of PDGFRB 
leads to resistance to BRAF V600E inhibition [27]. In that same 
study, mutations and upregulation of NRAS also conferred re- 
sistance to BRAF V600E inhibition. Targeted sequencing of 
138 cancergenes uncovered a MEK1 mutation (C121S) to con- 
fer resistance to BRAF V600E inhibition [86]. WES of 20 pa- 
tients uncovered BRAF
V600E 
copy number gain [87]. WES of 
FFPE material from 45 patients revealed MEK2 mutations and 
some MEK1 mutations that confer resistance to vemurafenib 
[88]. MITF amplification was also detected in this study to 
confer resistance. Multiple resistance mechanisms were also 
seen to evolve in parallel within one tumor. One patient had 
two distinct NRAS mutations that were detected mutually ex- 
clusively on reads that spanned the same locus. The authors 
suggested that the two mutations occurred in trans in the same 
resistant tumor or represent separate subclonal resistant popu- 
lations in the tumor. 
Earlier, we described the WES treatment-resistance study 
of Shi et al. [28], which detected 22% of the resistant tumors 
had a perturbation in the PI3K-PTEN-AKT pathway, which 
included mutations in AKT1/3, PIK3CA, PIK3CG, PIK3R2, 
PTEN, and PHLPP1. The authors observed that 20% of the 
resistant tumors could have more than one resistance mecha- 
nism, suggesting tumor heterogeneity and/or collaborative 
mechanisms. Phylogenetic analysis of multiple resistant tu- 
mors from the same patient revealed branched evolution rather 
than linear evolution suggesting resistant mechanisms can 
evolve in parallel in different tumors. RNAseq analysis   of 





the same patient cohort revealed that transcriptional processes 
were highly consistent in the resistant tumors, which is in 
contrast to genetic events that were more heterogeneous 
[89]. cMET upregulation and LEF1 downregulation occurred 
in the majority of resistant tumor cells. These two genes were 
observed to have a strong anti-correlation with DNA methyl- 
ation, suggesting an epigenetic mechanism to BRAF inhibitor 
resistance. In addition, upregulation of M2 macrophage 
markers could be seen in a subset of the tumors which was 
also associated with reduced expression of T-cell markers. The 
authors suggest that the involvement of the immune system is 
also an important component to BRAF inhibitor resistance. It 
is interesting to note the importance of LEF1. It is a gene part 
of the proliferative signature in the phenotype switching mod- 
el. We have observed that cells with a proliferative phenotype 
are generally sensitive to BRAF inhibition and upon resis- 
tance the cells adopt an invasive signature, thus supporting 
the notion that downregulation of LEF1 leads to resistance 
[34]. In the single-cell RNAseq study by Tirosh, the authors 
also observed that cells adopt an invasive signature, AXL high 
MITF low, when resistance occurs [85]. These studies high- 
light the role that phenotype switching has in resistance to 
BRAF inhibitors (see Kemper et al. for a comprehensive re- 
view [90]). Again, based on our initial findings published in 
cancer research 2008 [80], these two profiles have been pre- 
dicted and coined proliferative (MITF high) and invasive 
(MITF low AXL positive) phenotypes [91]. Resistant tumors 
are characterized by a strong expression of gene sets that we 
have called invasive gene sets representing mesenchymal 
transition, cell adhesion, extracellular matrix remodeling, an- 
giogenesis, and stemness [80]. 
Immunotherapy with anti-PD-1 antibodies is a preferred 
first-line therapy for metastatic melanoma [92]. However, 
not all patients respond, which is also true for anti-CTLA4 
therapy. High mutational load, neoantigaen load and expres- 
sion of cytolytic markers are beneficial for anti-CTLA4 ther- 
apy [93]. In this study, 110 patients were subjected to WES 
and 40 of those with RNAseq; they observed that high muta- 
tional load, neoantigen load, and expression of cytolytic 
markers were beneficial for response. WES and RNAseq were 
performed on a set of 38 and 28 but do not have a role in anti- 
PD1 therapy in melanoma [94]. Mutational load did not have a 
significant association to response to anti-PD-1 therapy and 
neoantigen load was not significant for response either. 
BRCA2 mutations occurred in 30% of the responders to an- 
ti-PD-1. However, the frequency of BRCA2 mutations may 
differ between anti-PD-1 responders and non-responders. 
Previous studies have shown that tumor mutational and 
neoantigen load were correlated with response to anti-PD-1 
immunotherapy in NSCLC they do seem to have a role in anti- 
PD1 therapy [95, 96]. Interestingly, resistant tumors expressed 
a gene signature reminiscent of the invasive phenotype. AXL, 
ROR2, WNT5A, LOXL2, and TWIST2 were  significantly 
upregulated in the non-responding tumors. The authors also 
noted that this gene signature is also seen in BRAF inhibitor 
resistant tumors suggesting an innate biological response to 
anti-tumor therapy. In another study looking at PD-1 resis- 
tance mechanisms, JAK1 and JAK2 mutations were found 
in two patients who developed new lesions under anti PD-1 
treatment. B2M mutations were found in one other patient. 
JAK1 and JAK2 mutations cause loss of interferon gamma 
growth induced arrest [97]. 
During the evolution of a malignancy, there is an intensive 
interaction with immune cells described as immunoediting 
[98]. This process can besubdividedintothree phases: the elim- 
ination phase, the equilibrium, and the escapephase. Duringthe 
elimination phase, immune cells such as T lymphocytes recog- 
nizeneoantigensontumorcellsandareabletokillmostofthem. 
However, some tumor cells survive and manage to grow, but 
this growth is controlled by immune response mechanisms [4]. 
This is called the equilibrium phase. If the tumor cells gain 
additional mechanisms to suppress immune functions, the tu- 
mor cells can escape. We speculate that one of these escape 
mechanisms is the upregulation of immune suppression factors 
such as PDL-1 on the surface of tumor cells. 
For the immunoediting process, expression of HLA surface 
molecule is essential and is controlled by interferons. 
Interestingly, the genomic analysis of acquired resistant tu- 
mors during anti-PD-1 therapy showed in two of the four 
patients resistance-associated alterations of the interferon sig- 
nal (loss of function mutations in Janus kinase 1 or Janus 
kinase 2). In addition, a mutation of the Beta-2-microglobulin, 
which is an essential competent of HLA class 1, was found in 
another patient [99]. 
In summary, NGS has provided a wealth of information 
about the genomic and transcriptomic landscape of melanoma 
biology and resistance. These studies have shown the genetic 
and transcriptional events important for melanoma progres- 
sion as well as resistance to BRAF inhibitors and immuno- 
therapy. Of note is the phenotype switching model, which 
seems to have an important role in the fundamental behavior 
of melanoma and in one of the resistance mechanisms to 




6 In vitro tools of melanoma metastasis 
 
While the strength of NGS studies is an unprecedented profiling 
of large-scale molecular events, finding causal features from 
high-dimensional data remains a great challenge. Thus, in vitro 
tools such asdiverse cell line biobanks that better represent actual 
tumor diversity [100], more complex but scalable assays that 
serve as relevant tumor proxies, and in vivo models that are trans- 
latable to human biology are essential to test the hypotheses gen- 
erated by NGS projects. Here, we will summarize the latest 





in vitro developments that will facilitate the functionalization of 
genes identified in WES or RNA-seq experiments. 
As melanoma is the most aggressive form of skin cancer 
with a high predisposition to invade and metastasize [101], it 
is of fundamental importance to select the most appropriate 
in vitro model to study disease progression ex vivo [102, 103]. 
For many years, melanomas have been studied by using cell 
lines that grow under adherent conditions to form two- 
dimensional (2D) monolayers. However, 2D cultures do not 
fully reproduce the tumor three-dimensional (3D) organiza- 
tion, the cell–cell and cell–matrix interactions, and the patchy 
distribution of oxygen and nutrients. For this reason, 2D 
monolayers do not represent an adequate system to study the 
tumor biology and the acquired resistance to therapeutic treat- 
ments. In fact, the drug response observed in monolayers often 
fails to reflect the in vivo situation [104, 105]. To date, 3D 
models have been used in melanoma research for preclinical 
studies as a compromise between standard 2D cultures and 
xenografts of human tumors, taking advantage of their re- 
duced costs and time compared to animal models [106]. 
 
6.1 Three-dimensional melanoma spheroids 
 
Among 3D tools, melanoma spheroid models mirror the ar- 
chitecture of the tumor and recreate the oxygen/nutrient gra- 
dients observed in vivo [105]. Comparative gene expression 
profile studies revealed that genes associated with prolifera- 
tion, differentiation, resistance to therapy, and migration are 
differentially expressed in cells maintained as 3D spheroids in 
comparison with 2D cultures, suggesting the preferential ex- 
pression of specific constellations of genes in well-defined 
structures [107–109]. Moreover, the localization of the cells 
expressing specific markers can be affected by the model 
used. For example, ERK is mainly found in the growing pe- 
riphery of spheres, mirroring the sub-compartmental expres- 
sion of melanoma lesions. On the contrary, it is homogeneous- 
ly expressed in 2D cultures [110]. 
Similarly, the choice of in vitro models is also relevant in 
the context of targeted therapy. One of the best examples 
comes from BRAF inhibitors (BRFAi) such as vemurafenib 
and dabrafenib. The inhibition of growth and invasive abilities 
of 3D melanoma spheroids with these drugs recapitulates the 
results of phase II and III clinical trials. 
Melanoma spheroids can be classified into two different 
groups: (1) multicellular tumor spheroids (MCTSs) and (2) 
tumorospheres. Although these models share the same 3D 
structure, they are used for different applications according to 
their intrinsic features [111]. In contrast to tumorospheres that 
select a subpopulation of melanoma cells with stemness prop- 
erties, the multicellular spheroid model (MCTSs) preserves the 
cell heterogeneity of the tumor [103]. MCTSs can be generated 
with different protocols, all of them based on the anchorage- 
independent growth, such as the Bliquid overlay method,^ the 
Bhanging drop method,^ and the encapsulation in alginate- 
based membranes or with rotating systems [111]. In the liquid 
overlay method, cells are seeded on plates previously  coated 
with a thin layer of inert material (agarose or polyHEMA) to 
prevent cell adhesion and promote aggregation. Alternatively, 
cells can be placed in commercial ultra-low attachment plates. 
The Bhanging drop technique^ consists in depositing small 
drops of cell suspension on a lid to induce the cells to accu- 
mulate and give rise to spheroids [112]. MCTSs can also  be 
obtained after encapsulation in microparticles of well-defined 
and reproducible structure and size, which are compatible with 
high-throughput screening studies. Finally, MCTSs formation 
can be induced by using rotating systems (shakers and spinner 
flasks). Implanting multicellular spheroids into collagen I- 
coated surfaces allow the study of melanoma migration and 
invasion. This assay is frequently used to study the metastatic 
potential of melanoma as it mirrors the intercellular interac- 
tions with the tumor microenvironment [113–115]. To further 
investigate the role of stromal cells in the tumor behavior, 
MCTSs can be generated from a co-culture of melanoma and 
different cell types (fibroblasts, endothelial or immune cells). 
The second 3D tool to study melanoma biology is the 
tumorosphere. Unlike MCTSs, their main goal is not to fully 
replicate the in vivo tumor but rather to isolate melanoma cancer 
stemcells (CSCs). However, whetherthis modelreallyenriches 
CSCs is still a matter of debate [116]. The formation of 
tumorospheres spontaneously occurs when cells are plated at 
a low density in the presence of serum-free conditioned media 
(Bstem cell medium^) supplemented with basic fibroblast and 
epidermal growth factors. The resulting spherical aggregates 
derive from the clonal expansion of one single cell [117]. 
In the recent years, two new protocols have been developed 
to generate tumor spheroids such as the tissue-derived tumor 
spheres (TDTSs) and the organotypic multicellular spheroids 
(OMSs). While TDTSs are generated by partial dissociation of 
cancer tissues, OMSs are derived from tumor fragments main- 
tained in culture without any dissociation step [118]. To date, 
these models have been successfully generated only for glio- 
blastoma, lung, bladder, and colorectal cancer, but none of 
them has been established for melanoma [118]. 
 
6.2 Analysis of melanoma spheroids with imaging 
software and mathematical models 
 
Given the great complexity of the 3D structures and the pres- 
ence of cells on different focal planes, the analysis of 
melanospheres is not easy and obvious. For this reason, a huge 
number of software tools have been developed with the aim to 
analyze growth, invasion, and drug response. The majority of 
these protocols allow for the interpretation of the behavior of 
spheres through the calculation of a set of parameters (diameter, 
total area, area of invasion, factor shape, percentage of fragmen- 
tation, number of invading cells, distance reached in  collagen, 





etc.), thereby defining a complete picture of the model [119]. To 
this purpose, spheroids are followed up and pictures are taken at 
different time points to assess the changes in the tumor mor- 
phology and size. Pictures are then converted into binary im- 
ages and analyzed, manually or through an automated system, 
with an imaging software (ImageJ, CellProfiler, SpheroidSizer, 
AnaSp, Image-Pro Analyzer, etc.). In addition, some mathe- 
matical models can mirror the distribution and penetration of 
the drug within spheroids, contributing to highlighting the ki- 
netics and dynamics of the treatment [120]. Although it will be 
difficult to achieve a general protocol of analysis, its standard- 
ization could simplify the complexity of the available mathe- 
matical models and encourage industries to consider this as a 
standard step for the evaluation of drug efficacy. 
 
6.3 Three-dimensional melanoma skin equivalents 
 
One of the critical aspects of melanoma progression is the 
invasion of the dermal compartment after crossing the base- 
ment membrane. The 3D melanoma skin reconstructs repre- 
sent a better tool to study the mechanisms underlying this 
early stage of the tumor and to evaluate the toxicity of new 
therapeutic approaches on the healthy cells of the skin. 
Melanoma skin reconstructs are artificial skin consisting of a 
dermal equivalent, composed of fibroblasts embedded in colla- 
gen, and an epidermal compartment, composed of keratinocytes 
and melanoma cells [105]. This model is representative of the 
tumor microenvironment and architecture. In addition, melano- 
ma reconstructs accurately recapitulate the different stages of 
tumor development. It has been demonstrated that melanoma 
cells are located in the skin equivalents in a different position 
according to the progression stage from which these cells are 
derived [121]. In detail, cells from radial growth phase tumors 
are confined to the epidermis, while those derived from vertical 
growth phase melanomas are located at the dermal-epidermal 
junction. This model has been used in the past to evaluate the 
efficacy of BRAF inhibitors, revealing a decreased proliferation 
and the induction of apoptosis in melanoma cells [122]. Despite 
the great utility of skin reconstructs in testing the efficacy and 
toxicity of new compounds, this model is a time-consuming pro- 
cedure that requires constant monitoring and more than 15 days 
to obtain the skin. Moreover, it can be employed only to evaluate 
the early stages of the tumor, when melanoma cells are still in the 
dermis. On the other hand, it is the in vitro tool that closest resem- 
bles the tumor architecture and will undoubtedly play an impor- 
tant role in hypothesis testing from NGS studies prior to the 
application of even more difficult and costly in vivo models. 
 
 
7 Outlook: new therapeutic strategies 
 
If melanoma progression is thought of in a Darwinistic evo- 
lutionary model,  this  opens  the  possibility of adapted 
therapeutic dosage schemes with already available drugs 
[123]. This might suggest that the goal should be to find an 
equilibrium between the resistant and sensitive tumor cells to 
control tumor proliferation. Without therapy, sensitive cells 
have an advantage over resistant cells, whereas the opposite 
is true with therapy. By applying drug holiday schemes, in 
theory, the two populations could then be better controlled 
[124]. But therapeutic or microenvironmental phenotype 
switching of cells into slow-cycling, treatment-resistant 
subclones can add even more complexity to an already com- 
plicated phenomenon [48, 125]. Thus, future treatments will 
have to account for the large variety of resistance patterns that 
exist, which include innate, adaptive, fixed (i.e., genetic), and 
non-cell autonomous resistance. Targeting multiple pathways 
may not only make sense from a resistance perspective but 
also for controlling both phenotypic states of melanoma cells. 
Clinically, tumor regression after termination of MAPK 
pathway inhibitor treatment is sometimes seen, but overall 
disease regression or even clinical remission has not been 
described. Due to tumor heterogeneity and different resistance 
mechanisms (i.e., both genetic and adaptive) present in an 
individual patient, not all tumors within one patient will react 
in the same way upon treatment; hence, it will be very difficult 
to adjust therapy schemes accordingly. We think future efforts 
will need to focus on better sampling of tumor material, as one 
tumor biopsy may not represent a complete tumor or a com- 
plete patient. The collection of liquid biopsies (circulating 
tumor cells) might be an approach that gives a better picture 
of the heterogeneity within one patient [126]. Likely, combi- 
nation treatments targeting different pathways or hitting the 
same pathway twice, or combining therapies with different 
working mechanisms, will be necessary to induce overall dis- 
ease regression, after which new therapeutic dosage schemes 
and strategies can be applied. 
There have been unexpectedly great successes in the last 
decade of translating basic research results into treatment strat- 
egies with measureable clinical benefits. But we still need 
better tools to analyze molecular phenomenon with greater 
breadth and precision, and also to build better theoretical 
and in vitro models that will more accurately recapitulate the 
complexity inherent in actual patient tumors. The speed of 
discovery keeps accelerating, and our efforts to bring that 
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11. Results and Discussion 
 
During the work of this thesis over the past 5 years, research on melanoma worldwide followed on the 
success of newly FDA approved drugs, which for the first time in history showed an improvement in 
overall survival for melanoma patients with metastatic disease. However, during these years it 
became apparent that not all patients respond to the treatments, with immunotherapy especially 
showing relatively low response rates of approximately 10% for anti-CTLA4 and 33% for anti-PD1 
mono-therapy [1, 2], opening the search for biomarkers that could predict treatment benefit. For 
targeted therapies it became clear that, after an initial response of around 9 months, almost all 
patients develop resistance to these treatments, which initiated the search for resistance 
mechanisms. 
 
We also aimed to gain insights in the process of resistance development to targeted MAPK therapy in 
BRAF or NRAS mutated melanoma. As most experiments for this thesis were planned to be done 
with in vitro cell cultures, we started with the optimization of generating cell cultures from melanoma 
biopsy material that we obtained from patients treated in our institution. With standard culturing 
techniques, only melanoma cell cultures are generated that are proliferative in a cell culture setting 
and adherent to plastic; however, in order to acquire relevant insights into in vitro studies regarding 
therapeutic resistance, we reasoned that it is essential that the in vivo diversity is recapitulated in an 
in vitro setting, as heterogeneity is likely to be an important contributor to resistance development. 
This optimization resulted in a new protocol for cell culture generation which is successfully integrated 
in our clinic. At the moment we have a success rate of about 70% in generating cell cultures from 
native melanoma biopsies, whereas before our success rate was only about 15% [3]. This protocol 
enabled the establishment of many important cell cultures used in our lab, as well as in the work of 
our collaborators (Wellbrock et al, University of Manchester), such as the MEK162 resistant NRAS 
mutated cell culture M130219 and the BRAF inhibitor resistant BRAF mutated cell culture M121224.  
 
We showed that after BRAF inhibitor therapy NRAS mutated cells can be found in resistant tumors 
[4]. However, this mutation cannot be found in all resistant tumors from the same patients, indicating 
that different resistance mechanisms exist in one patient [4], which was also observed by other 
groups [5]. In total, we investigated 6 BRAF mutated patients with an NRAS mutation in their post- 
BRAF-inhibitor-treatment resistant tumors. None of these patients had an NRAS mutation in their pre-
treatment sensitive tumors, suggesting this mutation arose de novo during treatment. From the 
resistant tumors from these 6 patients we generated 7 cell cultures in total. These cell cultures also 
contained an NRAS mutation in addition to their BRAF mutation, and via single cell clones we could 
show that BRAF and NRAS mutations are not mutually exclusive, as previously thought, but that they 
can occur in the same cell. We went on to test the sensitivity of these cell cultures for different 
inhibitors of the MAPK and PI3K-AKT pathway, and found a different response for every cell culture. 
Hence we concluded that the presence of a double mutation cannot determine follow-up treatment.  
 
Finally, we focused our efforts on finding resistance mechanisms in NRAS mutated patients treated 
with a MEK inhibitor. To date, no specific RAS inhibitors are available, and RAS is targeted indirectly 
by inhibiting essential downstream pathways, such as the MAPK pathway which is the most 
frequently altered pathway in melanoma. However, the observation that these patients quickly 
develop resistance on MEK inhibitor treatment, may imply that mutated RAS can quickly adapt and 
signal through one of its other target pathways, such as the PI3K-AKT pathway and the RalGEF-Ral 
cascade, among others [6-10]. IRS1 overexpression was found to be a mechanism of BRAF inhibitor 
resistance in BRAF mutated melanoma and targeting IRS1 with small molecules induced cell death in 
those tumors [11]. IRS1 is an adapter protein signaling through PI3K and MAPK pathways, therefore 
we wondered if this would be a possible target for NRAS mutated melanomas as well. In total we 
tested 18 NRAS mutated cell cultures from our biobank and found that an upregulation of IRS1 
expression was associated with MEK162 resistance. However, siRNA mediated IRS1 knockdown in 
the top 5 high IRS1 expressing cells and IRS1 overexpression experiments in low IRS1 expressing 
MEK162 sensitive cells showed that IRS1 upregulation was not the cause of the MEK162 resistance. 
However, we found that the cell culture with the highest IRS1 expression was sensitive to NT157, an 
IRS1 inhibitor, independent of MEK162 treatment. The mechanism of action of this inhibitor is not by 
blocking the PI3K-AKT pathway, however, the exact mechanism of action will require further 




With the current therapies and treatment regimens almost all melanoma patients develop resistance 
to the treatment. To increase the efficacy of current therapies, several strategies can be proposed in 
order to postpone or avoid drug resistance. 
 
The recognition that the development of targeted therapy resistance follows some principles of 
Darwinistic evolution, including selection and competition, suggested that sensitive and resistance 
cancer cells can be seen as two populations that compete with each other for space and substrate 
[12]. In the absence of therapy, sensitive cells have an advantage over resistant cells and will 
populate the patient; whereas in the presence of therapy, resistant cells will become the dominant 
population. In order to create an equilibrium where the two populations oscillate and none of them will 
take the upper hand, much like in a well-functioning eco-system where prey and predator are in 
equilibrium, drugs would need to be administered intermittently; a few weeks in which the drug is 
given so that the resistant cells are the leading population, followed by a few weeks of drug-holiday in 
which the sensitive cells can take over. In this way melanoma may even become a chronic disease. 
For breast cancer, in an in vivo  murine study the authors used an evolutionary approach for 
administering paclitaxel; they let the tumors’ response on a previous dose determine the timing and 
amount of the next dose [12]. In this way, the authors were able to control tumor growth, even with no 
treatment intervals lasting several weeks. A similar result was found in an in vivo melanoma xenograft 
study, were it was found that the resistant tumors become BRAF inhibitor dependent for their growth, 
and that discontinuation of treatment leads to regression of the resistant population. By treating the 
mice intermittently with BRAF inhibitors, they were able to postpone development of resistance [13].  
 
In order to overcome resistance, one could also try to specifically target common cellular processes 
that are different in resistant cells compared to sensitive cells. Upon treatment with a MAPK pathway 
inhibitor, melanoma cells can enter a slow-cycling drug-tolerant state, characterized by a high 
expression of the histone demethylase JARID1B and resistance to a wide variety of drugs [14]. By 
analyzing differences in gene expression, it was found that this slow-cycling state has mitochondrial 
proteins responsible for oxidative phosphorylation that are upregulated, whereas genes responsible 
for glycolysis were downregulated. Accordingly, cells overexpressing JARID1B consumed 50% more 
oxygen than non-overexpressing cells. The authors found that these multi-drug resistant cells could 
still be targeted by drugs specifically targeting the mitochondrial respiratory chain [14]. Another study 
found that MAPK inhibitor resistant cell lines had a greater uptake and dependency on glutamine than 
the sensitive lines, and that these cells could be targeted by drugs targeting glutamine metabolism. 
Glutamine is an abundant amino-acid in the plasma, and tumors are high consumers of it, as it is an 
important metabolite for many tasks; it has a role in oxidative stress defense, participates in 
bioenergetics and it also participates in glucose metabolism.  
 
Another strategy of inhibiting the growth of a heterogeneous pool of melanoma cells with different 
mutational profiles, including the resistant population, is the creation of an amenable micro-
environment for tumor growth. Melanoma cells interact with cells in their micro-environment in order to 
alter and improve the conditions for tumor growth. Cancer associated fibroblasts have a different 
transcriptional profile and phenotype compared to normal fibroblasts. By remodeling the extracellular 
matrix and secreting factors, they aid in tumor growth, angiogenesis, inflammation, metastasis and 
drug resistance. Zhou et al found that inhibition of b-catenin in fibroblasts prevented them from 
supporting melanoma tumor growth. Accordingly, melanoma cells grown together with b-catenin 
knockdown fibroblasts in 3D spheroids had diminished tumor growth and a downregulation of the 
MAPK pathway [15]. In another study, where the authors pharmacologically inhibited fibroblasts 
activation protein (FAP) on fibroblasts in mice, they could show an attenuated growth of lung cancer 
and colon cancer cells in vivo [16]. In 2015, Jackson et al. published the development of specific 
inhibitors for FAP and prolyl oligopeptidase (POP) [17]. They could show that these inhibitors reduced 
growth of colon cancer xenografts on mice by more than 90%, and at immunohistochemistry, the 
treated tumors had fewer microvessels [17]. In an older study from 2005, the authors immunized mice 
against FAP and could show that they had diminished growth of implanted melanoma tumors [18]. 
The tumor micro-environment also harbors other cells such as immune cells and endothelial cells, 
which can be altered in order to become harmless (immune cells) or even supportive for melanoma 
growth. The successful anti-PD1 therapy works by blocking the immune-inhibitory signal on 




As resistance is often mediated by signaling through escape pathways, for example the PI3K pathway 
in MAPK inhibitor resistant melanoma, one could also think of combining drugs targeting different 
pathways at the same time. However, precaution is warranted with such an approach, as certain 
pathways may influence and antagonize each other. Another possibility may be to sequentially treat 
with different pathway inhibitors, depending on the resistance mechanism that patient develops, which 
is an approach termed precision medicine. However, as it has been shown by us and others that 
different metastasis in the same patient can have different resistance mechanisms, current trials need 
to show whether this approach will lead to major benefits. 
 
It is expected that targeted therapy will remain important in melanoma treatment, despite the lack of 
durable effects, such as seen in a small patient population treated with immunotherapy. However, 
targeted therapy has some important advantages over immunotherapy, such as a higher and faster 
response rate and fewer side-effects, which is especially important for patients who are in a bad 
condition due to their illness. Therefore, it is essential to try to improve this treatment modality of 
melanoma. Improvements have to be made to extend the time of treatment response before 
resistance develops and to develop more targeted therapies for prevalent melanoma 
mutations/pathway alterations, other than BRAF.  
 
We will continue to investigate MAPK pathway resistance mechanisms in NRAS and BRAF mutated 
melanoma, in order to anticipate on and thereby overcome or delay therapy resistance. NRAS 
mutated melanoma patients are especially in need of alternative treatment options, as these patients 
quickly develop resistance to MEK inhibitors, which are to date the only targeted therapy option for 
this patient group. In the last decade, research has mainly focused on the MAPK pathway, but as 
NRAS can also signal via alternative pathways, it will be interesting to look for other possible 
targetable pathways.  
 
Advances can also be made with new techniques for studying tumor biology such as in in vitro cell 
cultures, including the 3D culture systems such as growing melanoma cells in 3D spheroids, or 
culturing them together with fibroblasts and keratinocytes, for instance in an in vitro artificial skin 
construct. For certain research questions, including drug resistance, these systems are thought to 
better represent the in vivo situation and thus can give additional information about melanoma versus 
melanoma and melanoma versus micro-environment interactions. It would be interesting to check 
new possible therapies, including the IRS1 inhibitor NT157, in these culture systems. 
 
With the availability of next generation sequencing techniques, there is an increased interest in 
personalized targeted therapy selection based on RNA and DNA sequencing. So far however, results 
have been disappointing, probably due to limitations of only analyzing single biospies, whereas 
melanoma has high intra-patient heterogeneity. As we have, for some patients, material from multiple 
tumor sites available in our biobank, we have the possibility to first test this concept in an in vitro 
setting. Especially when combined with 3D in vitro techniques and/or co-cultures from different 
melanoma cells from the same patient, this might give valuable results whether such an approach of 
personalized medicine is beneficial. This also opens the possibility of identifying rational combinations 
of different inhibitors and examine their combined effect in vitro. 
 
A large amount of progress has been made over the last years in treating metastatic melanoma, 
however, a lot still needs to be done before it can be cured or kept under control for every patient. 
Continuing world-wide efforts to understand melanoma biology, its resistance mechanisms during 
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